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Abstract	  
Mesenchymal	  stromal	  cells	  (MSCs)	  are	  a	  multipotent	  cell	  population	  acquired	  most	  
prominently	  from	  bone	  marrow	  with	  the	  capacity	  to	  differentiate	  into	  osteoblasts,	  
chondrocytes,	  adipocytes,	  cardiomyoctes,	  fibroblasts	  and	  other	  cell	  types.	  The	  
immunoprivileged	  nature	  of	  these	  cells	  combined	  with	  their	  ability	  to	  home	  to	  sites	  
of	  injury	  enhances	  therapeutic	  interest	  in	  this	  stem	  cell	  population.	  Phase	  I-­‐III	  
clinical	  trials	  are	  being	  conducted	  evaluating	  the	  therapeutic	  potential	  of	  MSCs	  in	  
graft	  vs.	  host	  disease,	  following	  acute	  myocardial	  infarction,	  multiple	  sclerosis,	  and	  
bone	  and	  cartilage	  diseases.	  Sphingosine	  1-­‐phosphate	  (S1P)	  is	  a	  biologically	  active	  
sphingolipid	  impacting	  proliferation,	  apoptosis,	  inflammation,	  and	  angiogenesis.	  
Interactions	  with	  5	  G-­‐protein	  coupled	  S1P	  receptors	  (S1PR1-­‐5)	  mediate	  in	  part	  
these	  functions.	  Whereas	  S1PR1-­‐R3	  are	  ubiquitously	  expressed,	  S1PR4	  and	  S1PR5	  
have	  more	  limited	  expression.	  This	  project	  seeks	  to	  assess	  the	  role	  of	  the	  S1PRs	  in	  
the	  maintenance	  of	  a	  multipotent	  MSC	  population	  and	  the	  impact	  of	  modulation	  of	  
S1PR2	  on	  the	  progression	  of	  prostate	  cancer.	  Inhibition	  of	  S1PR2	  results	  in	  
increased	  MSC	  clonogenicity,	  migration,	  and	  proliferation.	  The	  increased	  Erk	  
phosphorylation	  observed	  with	  S1PR2	  inhibition	  is	  required	  for	  these	  increases	  in	  
migration	  and	  proliferation.	  Furthermore,	  decreased	  S1PR2	  expression	  decreases	  
the	  differentiation	  of	  MSCs	  into	  adipocytes	  and	  mature	  osteoblasts	  that	  may	  be	  the	  
result	  of	  increased	  expression	  of	  MSC	  pluripotency	  factors	  including	  Nanog,	  Sox9,	  
and	  Oct4.	  Inhibition	  of	  S1PR1	  and	  S1PR3	  in	  contrast	  does	  not	  impact	  MSC	  migration	  
or	  Erk	  activation	  although	  increased	  proliferation	  is	  observed.	  In	  the	  study,	  we	  
describe	  the	  essential	  role	  of	  S1PR2	  in	  MSC	  differentiation	  pathways	  through	  
modification	  of	  pluripotency	  factors.	  We	  propose	  a	  MAPK	  dependent	  mechanism	  
through	  S1PR2	  inhibition	  that	  promotes	  equally	  pluripotent	  MSC	  proliferation	  in	  a	  
way	  that	  can	  be	  exploited	  for	  better	  ex	  vivo	  MSC	  expansion	  in	  autologous	  MSC	  
transplant.	  	  	  When	  MSCs	  are	  co-­‐cultured	  with	  murine	  prostate	  cancer	  cells,	  an	  
increased	  stem	  cell	  population	  is	  observed	  with	  greater	  proliferation	  of	  cancer	  cells	  
following	  inhibition	  of	  S1PR2.	  We	  therefore	  proposed	  that	  S1PR2	  in	  MSCs	  within	  the	  
tumor	  microenvironment	  enhances	  the	  metastatic	  potential	  of	  tumors.	  	  
	  
	  





Mesenchymal	  stromal	  cells	  (MSCs)	  were	  first	  identified	  and	  preliminarily	  
characterized	  by	  Friedenstein	  et	  al	  in	  1966.	  The	  subset	  of	  the	  stromal	  bone	  marrow	  
fraction	  they	  identified	  was	  an	  adherent	  cell	  population	  capable	  both	  of	  self-­‐renewal	  
in	  vitro	  and	  differentiation	  into	  an	  osteogenic	  phenotype.	  Originally	  termed	  
osteogenic	  stem	  cells,	  the	  cell	  population	  was	  described	  as	  having	  a	  spindle-­‐like	  or	  
fibroblast	  like	  appearance	  ranging	  in	  size	  from	  10-­‐30	  μM	  (1-­‐6).	  	  At	  higher	  passages,	  
when	  the	  MSCs	  approach	  senescence,	  MSCs	  appear	  increasingly	  flatter	  and	  
multinucleated	  (7).	  	  The	  onset	  of	  senescence	  in	  MSCs	  with	  culture	  in	  vitro	  due	  to	  
limitations	  in	  the	  cell	  culture	  environment	  emphasizes	  the	  need	  to	  improve	  ex	  vivo	  
expansion	  for	  clinical	  usage	  and	  the	  necessity	  of	  using	  MSCs	  at	  a	  low	  passage	  
number	  for	  in	  vitro	  experimental	  evaluation.	  	  
	  
	  Further	  work	  published	  in	  1987,	  expanded	  on	  this	  initial	  characterization	  of	  MSCs	  
citing	  their	  capacity	  for	  colony	  formation	  and	  chondrogenic	  differentiation	  in	  
addition	  to	  the	  already	  recognized	  osteogenic	  differentiation	  potential.	  	  In	  1991,	  
Caplan	  et	  al.	  coined	  the	  term	  mesenchymal	  stem	  cells	  that	  has	  persisted	  through	  
subsequent	  literature	  despite	  the	  ongoing	  debate	  on	  whether	  mesenchymal	  stem	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cells	  are	  true	  stem	  cells	  or	  stromal	  progenitor	  cells	  (8,	  9).	  	  Throughout	  the	  literature	  
the	  terms	  mesenchymal	  stromal	  cells	  and	  bone	  marrow	  derived	  stromal	  cells	  have	  
been	  used	  to	  represent	  an	  MSC	  population	  although	  careful	  attention	  must	  be	  paid	  
to	  the	  isolation	  and	  characterization	  techniques	  employed.	  	  
	  
The	  heterogeneous	  nature	  of	  MSCs	  and	  the	  frequent	  contamination	  of	  adherent	  cell	  
cultures	  with	  macrophages	  and	  adherent	  hematopoietic	  cells	  prompted	  further	  
investigation	  on	  proper	  identification	  of	  MSCS.	  Positive	  and	  negative	  surface	  marker	  
expression,	  colony	  forming	  capacity,	  and	  multi-­‐lineage	  differentiation	  therefore	  
became	  essential	  to	  the	  proper	  characterization	  of	  MSCs.	  Kasseme	  et	  al.	  identified	  
CD44,	  CD63,	  CD105,	  and	  CD146	  as	  positive	  markers	  of	  MSCs	  in	  1993.	  Pittenger	  et	  al.	  
further	  expanded	  the	  gold	  standard	  for	  differentiation	  of	  MSCs	  by	  describing	  the	  
adipogenic	  capacity	  of	  MSCs	  (1).	  Despite	  ongoing	  work	  seeking	  to	  better	  
characterize	  and	  define	  a	  uniform	  MSC	  population,	  the	  cell	  of	  origin	  for	  MSCs	  
remains	  in	  question.	  Many	  reports	  have	  proposed	  a	  neural	  cell	  origin	  for	  MSCs	  
deriving	  either	  from	  the	  neuroepithelium	  or	  the	  neural	  crest,	  although	  other	  reports	  
suggest	  a	  hematopoietic	  stem	  cell	  origin	  for	  MSCs	  (10-­‐16).	  
	  
Stems	  cells	  are	  broadly	  defined	  as	  an	  undifferentiated	  cell	  type	  capable	  of	  self-­‐
renewal	  and	  further	  cell	  differentiation	  (17,	  18).	  Despite	  increasing	  consensus	  that	  
MSCs	  can	  be	  considered	  a	  stem	  cell,	  some	  argument	  remains	  as	  to	  whether	  they	  
should	  be	  called	  mesenchymal	  stromal	  cells	  or	  skeletal	  stem	  cells.	  Agreement	  is	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higher	  with	  regard	  to	  the	  term	  skeletal	  stem	  cells	  as	  MSCs	  have	  been	  shown	  to	  form	  
heterotopic	  bone	  in	  mice	  in	  serial	  transplantation	  assays.	  Sacchetti	  et	  al.	  conducted	  
the	  first	  in	  vivo	  serial	  transplantation	  assays	  evaluating	  bone	  formation	  in	  2007(19).	  
In	  vivo	  differentiation	  following	  serial	  transplantation	  has	  not	  been	  demonstrated	  
for	  adipogenic	  and	  chondrogenic	  lineages.	  The	  basis	  for	  the	  stem	  cell	  controversy	  is	  
based	  on	  the	  heterogeneous	  nature	  of	  MSCs	  and	  the	  lack	  of	  a	  single	  definitive	  
marker	  for	  the	  population.	  The	  lack	  of	  additional	  in	  vivo	  transplantation	  assays	  
demonstrating	  ectodermal,	  endodermal,	  and	  mesodermal	  tissue	  formation	  adds	  to	  
this	  controversy	  (20).	  	  Bianco	  et	  al.	  additionally	  argue	  that	  MSCs	  unlike	  other	  stem	  
cell	  populations	  have	  functions	  beyond	  solely	  serving	  as	  a	  progenitor	  population	  
and	  that	  MSCs	  from	  different	  organ	  sources	  produce	  cells	  with	  varying	  
differentiation	  capacity.	  MSCs	  have	  been	  shown	  to	  function	  in	  vascular	  niche	  
organization,	  peripheral	  injury	  repair,	  and	  immune	  modulation	  (11,	  20,	  21).	  MSCs	  
have	  clear	  documented	  roles	  as	  progenitor	  cells	  for	  a	  number	  of	  different	  
populations	  both	  in	  the	  bone	  marrow	  and	  in	  the	  periphery	  with	  critical	  
physiological	  functions	  in	  these	  environments.	  	  
	  
Differences	  between	  human	  and	  murine	  MSC	  populations	  in	  isolation	  procedures	  
and	  markers	  have	  been	  identified.	  Murine	  MSC	  populations	  are	  without	  proper	  
sorting	  or	  enrichment	  often	  contaminated	  by	  hematopoietic	  progenitors	  capable	  of	  
plastic	  adherence.	  Murine	  strains	  display	  marker	  specific	  differences	  and	  differ	  in	  
their	  optimized	  media	  for	  growth	  (22).	  Recently,	  Stro-­‐1	  has	  further	  been	  identified	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as	  a	  strong	  candidate	  for	  a	  single	  positive	  marker	  of	  human	  MSCs	  with	  Stro-­‐1	  
expression	  critical	  to	  colony	  formation	  in	  human	  MSCs.	  This	  marker	  is	  unfortunately	  
not	  expressed	  in	  murine	  cell	  populations	  (21,	  23,	  24).	  Although	  differences	  exist	  
between	  human	  and	  murine	  MSC	  populations,	  murine	  MSCs	  have	  demonstrated	  
consistent	  behavior	  with	  human	  MSCs	  leading	  to	  significant	  contributions	  to	  
understanding	  human	  MSCs	  both	  physiologically	  and	  therapeutically.	  Many	  of	  these	  
discoveries	  are	  further	  expanded	  upon	  later	  in	  this	  introduction.	  	  
	  
As	  a	  consequence	  of	  different	  operating	  definitions	  used	  for	  MSCs	  in	  publications,	  
the	  International	  Society	  for	  Cell	  Therapy	  convened	  in	  2006	  to	  establish	  a	  consensus	  
definition	  of	  MSCs	  to	  be	  used	  in	  future	  literature	  (25).	  Four	  factors	  were	  established	  
as	  critical	  to	  defining	  an	  MSC	  population	  including	  colony	  formation,	  tri-­‐lineage	  
differentiation,	  and	  a	  specific	  marker	  expression.	  Positive	  markers	  for	  MSC	  
expression	  reaching	  consensus	  included	  CD73,	  CD90,	  and	  CD105	  in	  conjunction	  
with	  the	  absence	  of	  hematopoietic	  markers	  CD45,	  CD34,	  CD14,	  CD11b,	  CD79a,	  CD19,	  
and	  HLA	  DR	  (17,	  18).	  The	  establishment	  of	  a	  consensus	  definition	  for	  MSCs	  greatly	  
advanced	  the	  field	  and	  created	  a	  uniform	  framework	  for	  comparison	  and	  replication	  
of	  MSC	  research.	  
	  
MSCs	  can	  be	  isolated	  from	  adipose	  tissue,	  peripheral	  blood,	  cord	  blood,	  umbilical	  
cord	  tissue,	  muscle,	  pancreas,	  fetal	  tissue,	  heart,	  bone,	  and	  skin.	  Bone	  marrow	  
isolated	  MSCs	  are	  the	  most	  common	  source	  of	  MSCs	  due	  to	  the	  lack	  of	  surgical	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intervention	  required	  for	  harvesting	  (26).	  Furthermore,	  bone	  marrow-­‐derived	  MSCs	  
have	  the	  highest	  concentration	  of	  MSCs	  per	  number	  of	  cells	  composing	  only	  0.01-­‐
0.0001%	  of	  bone	  marrow	  cells	  (17).	  Bone	  marrow	  and	  spleen	  derived	  MSCs	  in	  mice	  
demonstrate	  the	  greatest	  capacity	  for	  differentiation	  as	  compared	  to	  those	  isolated	  
from	  alternate	  sources	  (27).	  The	  incidence	  of	  MSCs	  decreases	  with	  increasing	  age.	  A	  
ten-­‐fold	  decrease	  in	  MSC	  incidence	  is	  observed	  between	  birth	  and	  the	  teenage	  years.	  
A	  second	  ten-­‐fold	  decrease	  is	  observed	  between	  the	  teenage	  years	  and	  late	  
adulthood.	  When	  considerations	  for	  autologous	  as	  compared	  to	  allogeneic	  stem	  cell	  
transplant	  are	  given,	  the	  age	  of	  the	  cell	  donor	  remains	  an	  important	  consideration	  
(28,	  29).	  	  
	  
Consistent	  with	  their	  stem	  cell	  nature,	  MSCs	  express	  many	  transcription	  factor	  
markers	  common	  with	  embryonic	  stem	  cells	  (ESCs)	  and	  other	  adult	  stem	  cell	  
populations.	  These	  markers	  are	  often	  used	  as	  indicators	  of	  the	  undifferentiated	  
status	  of	  the	  cells.	  Pluripotency	  factors	  described	  for	  MSCs	  include	  Nanog,	  Oct-­‐4,	  
SSEA-­‐4,	  and	  Sox-­‐2.	  First	  identified	  in	  2002	  in	  ESCs,	  Nanog	  overexpression	  maintains	  
ESC	  self-­‐renewal	  in	  part	  through	  regulation	  of	  Id1	  expression	  (17).	  Oct-­‐4,	  a	  second	  
pluripotency	  factor,	  functions	  in	  a	  complex	  with	  Sox2	  on	  the	  DNA.	  	  The	  two	  factors	  
in	  concert	  program	  a	  transcriptional	  network	  of	  genes	  promoting	  pluripotency.	  Rex-­‐
1	  can	  also	  function	  as	  stem	  cell	  factor	  that	  is	  regulated	  by	  expression	  of	  Nanog,	  Oct4,	  
and	  Sox2	  (30).	  Pluripotency	  factors	  as	  in	  other	  stem	  cell	  populations	  represent	  a	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critical	  avenue	  of	  investigation	  in	  MSC	  research	  in	  determining	  the	  balance	  between	  




MSCs	  function	  both	  in	  the	  bone	  marrow	  and	  the	  periphery	  through	  cell-­‐cell	  
interactions,	  differentiation,	  and	  autocrine	  and	  paracrine	  mechanisms.	  In	  the	  bone	  
marrow,	  MSCs	  maintain	  the	  bone	  marrow	  microenvironment	  and	  in	  particular	  in	  
the	  maintenance	  of	  the	  hematopoietic	  stem	  cell	  compartment	  (28).	  MSCs	  reside	  in	  
the	  low	  oxygen	  regions	  of	  the	  bone	  marrow	  and	  are	  especially	  prevalent	  lining	  the	  
bone	  and	  serving	  as	  osteoblastic	  precursors	  (31,	  32).	  It	  is	  therefore	  not	  surprising	  
that	  MSCs	  maintained	  ex	  vivo	  under	  hypoxic	  conditions	  comparable	  to	  that	  of	  the	  
bone	  marrow	  display	  increased	  stem	  cell	  characteristics,	  improved	  self-­‐renewal,	  
and	  delayed	  senescence.	  The	  role	  of	  MSCs	  in	  the	  periphery	  differs	  from	  that	  of	  the	  
bone	  marrow	  with	  the	  bone	  marrow	  cells	  having	  the	  unique	  capacity	  to	  home	  to	  
sites	  of	  injury	  and	  contribute	  to	  repair.	  Although	  MSCs	  can	  differentiate	  at	  the	  site	  to	  
which	  they	  are	  recruited,	  differentiation	  only	  occurs	  to	  a	  limited	  capacity	  (28,	  33-­‐
36).	  MSC	  secretion	  of	  cytokines	  and	  chemokines	  contributes	  to	  local	  tissue	  repair	  
and	  recruits	  other	  cell	  types	  responsible	  for	  tissue	  repair.	  The	  role	  of	  tissue	  residing	  
MSCs	  has	  not	  yet	  been	  actively	  investigated	  in	  peripheral	  tissue	  repair	  (28).	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MSC	  contribution	  to	  tissue	  repair	  is	  especially	  important	  in	  the	  context	  of	  chronic	  
wounds,	  especially	  those	  resulting	  from	  diabetes,	  trauma,	  or	  vascular	  insufficiency	  
(37).	  Depending	  on	  the	  stage	  of	  wound	  healing,	  the	  MSC	  contribution	  to	  healing	  
changes	  based	  on	  the	  requirements	  of	  this	  stage	  of	  repair.	  During	  the	  initial	  
inflammatory	  phase	  MSCs	  mitigate	  the	  inflammatory	  reaction	  by	  secretion	  of	  TNF	  
and	  decreased	  T	  cell	  proliferation.	  In	  the	  secondary	  proliferative	  phase	  of	  wound	  
healing,	  MSC	  secretion	  of	  VEGF,	  HGF,	  and	  FGF	  mediates	  cell	  recruitment	  of	  the	  
appropriate	  progenitor	  cells	  and	  fibroblasts	  to	  repopulate	  the	  region.	  Finally,	  in	  the	  
remodeling	  phase,	  MSCs	  regulate	  collagen	  and	  ECM	  deposition	  through	  TBFβ	  and	  
MMPs/TIMPS	  (37).	  MSCs	  have	  been	  readily	  identified	  in	  the	  perivascular	  region	  of	  
peripheral	  tissues	  often	  located	  ensheathing	  the	  vasculature.	  MSCs	  are	  a	  critical	  
component	  to	  wound	  healing	  in	  both	  acute	  and	  chronic	  injuries.	  
	  
MSC	  immune	  function	  
	  
MSCs	  are	  unique	  in	  their	  immunoprivileged	  nature	  making	  their	  clinical	  use	  highly	  
attractive	  due	  to	  their	  potential	  for	  allogeneic	  transplantation.	  The	  decreased	  
immune	  recognition	  is	  mediated	  in	  part	  by	  their	  low	  MHC	  I	  expression	  and	  lack	  of	  
MHC	  II	  expression.	  MSCs	  further	  lack	  expression	  of	  co-­‐stimulatory	  molecules	  
including	  CD40,	  CD80,	  and	  CD86.	  Furthermore,	  MSCs	  produce	  cytokines	  that	  
downregulate	  immune	  and	  inflammatory	  responses	  (1,	  38).	  Secreted	  factors	  
released	  from	  MSCs	  that	  may	  contribute	  to	  this	  reduced	  inflammatory	  response	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include	  Nitric	  oxide,	  indolamine	  2,3	  dioxygenase,	  and	  heme	  oxygenase,	  
prostaglandin	  E2	  and	  IL-­‐10	  	  (28,	  39).	  	  Beyond	  their	  capacity	  to	  evade	  immune	  
surveillance,	  MSCs	  exert	  critical	  alterations	  in	  the	  immune	  system.	  
	  
MSCs	  impact	  immune	  function	  through	  interactions	  with	  both	  the	  innate	  immune	  
system	  and	  the	  adaptive	  immune	  system.	  Within	  the	  innate	  immune	  system	  MSCs	  
can	  inhibit	  the	  proliferation	  and	  function	  of	  NK	  cells.	  MSCs	  further	  hinder	  
macrophage	  and	  dendritic	  cell	  proliferation	  while	  simultaneously	  enhancing	  the	  
tolerance	  of	  dendridic	  cells	  (40).	  Additional	  interactions	  between	  MSCs	  and	  the	  
innate	  immune	  system	  include	  research	  investigating	  MSC	  functions	  in	  complement,	  
toll	  like	  receptor	  signaling,	  neutrophil	  function,	  and	  mast	  cell	  function.	  	  
	  
Within	  the	  adaptive	  immune	  system,	  MSCs	  can	  shift	  the	  balance	  of	  T	  cell	  
differentiation	  promoting	  increased	  Th2	  response	  rather	  than	  a	  Th1	  response.	  MSCs	  
can	  additionally	  increase	  Th17	  and	  Treg	  differentiation.	  Decreased	  T	  cell	  
proliferation	  is	  observed	  following	  MSC	  secretion	  of	  IDO	  and	  PGE2.	  MSC	  modulation	  
of	  B	  cell	  proliferation	  and	  function	  has	  been	  observed	  (41,	  42).	  MSCs	  are	  recruited	  
to	  sites	  of	  injury	  by	  the	  action	  of	  CXCL12,	  CXCL10,	  CXCL9,	  and	  CCL2.	  MSCs	  interact	  
with	  many	  aspects	  of	  the	  immune	  system	  under	  the	  appropriate	  conditions	  and	  
ongoing	  research	  seeks	  to	  analyze	  the	  individual	  interactions	  with	  different	  immune	  
mediators	  given	  that	  both	  MSC	  secretory	  factors	  and	  direct	  cell	  interactions	  are	  
involved	  pending	  on	  the	  interaction	  being	  characterized.	  	  




Despite	  ongoing	  research	  seeking	  to	  understand	  the	  processes	  that	  govern	  MSC	  self-­‐
renewal,	  many	  of	  these	  factors	  remain	  poorly	  understand.	  The	  pluripotency	  factors	  
expressed	  by	  MSCs	  have	  been	  the	  best-­‐characterized	  factors	  associated	  with	  the	  
promotion	  of	  MSC	  self	  renewal.	  Among	  these	  factors,	  the	  most	  extensive	  research	  
that	  has	  been	  conducted	  has	  investigated	  the	  role	  of	  Nanog	  in	  MSC	  self-­‐renewal.	  
Nanog	  expression	  diminishes	  in	  differentiating	  cells	  and	  whereas	  it	  is	  highly	  
expressed	  in	  proliferating	  ones.	  Nanog	  has	  been	  shown	  in	  MSCs	  to	  increase	  
expression	  of	  cell	  cycle	  genes,	  promote	  DNA	  replication,	  increase	  DNA	  damage	  
repair,	  improve	  proliferation	  capacity,	  increase	  clonogenicity,	  and	  improve	  
differentiation	  potential	  overcoming	  many	  of	  the	  effects	  of	  aging	  on	  MSCS	  (43).	  One	  
downstream	  target	  of	  Nanog	  thought	  to	  contribute	  to	  these	  changes	  is	  Dnmt1,	  
activation	  of	  which	  leads	  to	  changes	  in	  DNA	  methylation	  resulting	  in	  modification	  of	  
cell	  cycle	  proteins	  including	  p16	  and	  p21	  (44).	  Some	  reports	  indicate	  that	  Nanog	  
expression	  is	  induced	  by	  the	  in	  vitro	  culture	  environment	  and	  is	  not	  expressed	  in	  
freshly	  isolated	  cells	  (45).	  	  Although	  one	  of	  the	  best-­‐characterized	  transcription	  
factors	  impacting	  self-­‐renewal,	  Nanog	  does	  not	  function	  independently	  and	  
cooperates	  in	  a	  network	  of	  pluripotency	  factors.	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  Oct-­‐4	  and	  Sox2	  are	  two	  additional	  pluripotency	  factors	  initially	  identified	  in	  ESCs	  
have	  also	  been	  identified	  as	  critical	  factors	  in	  MSCs	  self-­‐renewal.	  Oct4	  directly	  
inhibits	  bmp4	  leading	  to	  decreased	  ectodermal	  and	  endodermal	  differentiation.	  Oct-­‐
4	  knockout	  MSCs,	  unlike	  Nanog	  and	  Sox2	  knockout	  cells,	  are	  still	  capable	  of	  
differentiation	  and	  colony	  formation	  but	  knockout	  cells	  express	  decreased	  levels	  of	  
both	  Nanog	  and	  Sox2	  (46).	  	  Additional	  factors	  have	  been	  identified	  as	  functioning	  in	  
the	  self-­‐renewal	  pathways	  of	  MSCs.	  These	  pathways	  include	  leukemia	  inhibitory	  
factor	  (LIF),	  fibroblast	  growth	  factor	  2,	  and	  the	  Wnt	  signaling	  pathway	  (21).	  	  These	  
are	  putative	  factors	  and	  more	  work	  needs	  to	  be	  done	  to	  further	  characterize	  their	  
contribution.	  	  
	  
Environmental	  conditions	  can	  additionally	  impact	  the	  potential	  for	  MSC	  self-­‐
renewal	  and	  differentiation.	  	  One	  such	  environmental	  factor	  thought	  to	  contribute	  to	  
MSC	  self-­‐renewal	  is	  the	  culturing	  of	  MSCs	  under	  low	  oxygen	  conditions.	  Hypoxia	  can	  
mimic	  the	  1-­‐7%	  O2	  conditions	  characteristic	  of	  the	  bone	  marrow	  niche	  in	  which	  
MSCs	  reside.	  	  Decreased	  ex	  vivo	  expansion	  time	  and	  increased	  populations	  of	  Sca-­‐1+	  
CD44+	  cells	  have	  been	  observed	  under	  1%	  hypoxic	  conditions	  as	  compared	  to	  cells	  
cultured	  under	  standard	  cell	  culture	  conditions	  (47,	  48).	  Decreased	  adipogenic	  
differentiation	  has	  been	  observed	  under	  hypoxia	  that	  is	  reversible	  with	  the	  
restoration	  of	  oxygen	  rich	  environment	  (49).	  	  Further	  exploration	  on	  the	  role	  of	  
hypoxia	  in	  MSC	  function	  and	  ex	  vivo	  expansion	  has	  significant	  potential	  to	  impact	  
clinical	  use	  of	  MSCs.	  	  




Although	  classified	  based	  on	  their	  tri-­‐lineage	  differentiation	  into	  osteocytes,	  
chondrocytes,	  and	  adipocytes,	  MSC	  are	  increasingly	  being	  reported	  to	  differentiate	  
into	  a	  number	  of	  different	  cell	  types	  within	  the	  mesenchymal	  lineage	  as	  well	  as	  
transdifferentiation	  into	  endodermal	  and	  ectodermal	  lineages.	  	  These	  cell	  types	  
include	  but	  are	  not	  limited	  to	  myocytes,	  endothelial	  cells,	  cardiomyocytes,	  ectoderm,	  
smooth	  muscle	  cells,	  neuronal	  cells,	  and	  tumor	  associated	  fibroblasts.	  	  Diminished	  
cell	  differentiation	  has	  been	  observed	  with	  an	  increasing	  number	  of	  passages	  and	  
increased	  MSC	  senescence.	  Twenty	  to	  forty	  population	  doublings	  have	  been	  
reported	  prior	  to	  expression	  of	  senescence	  markers	  (26).	  	  
	  
Osteogenic	  differentiation	  is	  controlled	  by	  its	  master	  regulator	  Runx2	  (Runt	  related	  
transcription	  factor	  2;CBFA1).	  Runx2	  has	  two	  known	  isoforms	  and	  can	  be	  repressed	  
under	  hypoxic	  conditions	  by	  Twist	  following	  HIF-­‐1α	  induction.	  Studies	  in	  murine	  
MSCs	  using	  siRNA	  and	  overexpression	  systems	  have	  demonstrated	  that	  Runx2	  is	  
both	  necessary	  and	  sufficient	  for	  osteogenic	  differentiation	  (50-­‐52).	  The	  critical	  
function	  of	  Runx2	  in	  osteogenic	  differentiation	  is	  further	  supported	  by	  the	  
embryonic	  lethality	  of	  Runx2	  knock	  out	  mice,	  which	  die	  at	  birth	  due	  to	  respiratory	  
failure	  and	  lack	  of	  calcified	  bone.	  Transcription	  factors	  that	  modify	  Runx2	  in	  MSCs	  
include	  B-­‐catenin,	  Msx2,	  and	  Dlx5.	  Runx	  programs	  this	  osteogenic	  downstream	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signaling	  pathway	  through	  activation	  of	  alkaline	  phosphatase,	  bone	  sialoprotein,	  
collagen	  type	  I	  alpha	  I,	  osteopontin,	  and	  osteocalcin	  (51).	  Osterix,	  a	  transcription	  
factor	  impacted	  by	  Runx2	  function,	  can	  be	  activated	  by	  MAPK	  to	  promote	  increased	  
MSC	  osteogenic	  differentiation.(53).	  A	  constellation	  of	  factors	  primarily	  controlled	  
by	  Runx2	  but	  with	  contributions	  from	  a	  number	  of	  other	  factors	  influence	  MSC	  
differentiation.	  	  
	  
Expression	  of	  Runx2	  results	  in	  a	  repression	  of	  the	  critical	  adipogenic	  differentiation	  
regulator	  PPARγ	  (Peroxisome	  proliferation	  activated	  receptor	  gamma).	  PPARγ	  is	  
sufficient	  for	  adipogenic	  differentiation	  with	  C/EBPalpha	  also	  functioning	  as	  a	  
critical	  adipogenic	  factor	  by	  binding	  the	  PPAR-­‐gamma	  promoter.	  Chondrocyte	  
differentiation	  is	  mediated	  by	  Sox9	  and	  the	  least	  is	  known	  about	  this	  differentiation	  
pathway.	  (Sry	  box	  containing	  gene	  9)	  (30)(31,	  32).	  Sox	  9	  	  is	  a	  critical	  transcription	  
factor	  promoting	  expression	  of	  and	  acting	  synergistically	  with	  	  bone	  morphogenic	  
protein	  2	  (BMP-­‐2).	  This	  functions	  both	  in	  the	  promotion	  of	  chondrogenic	  
differentiation	  and	  in	  the	  inhibition	  of	  osteogenic	  differentiation.	  MSC	  
differentiation	  is	  controlled	  by	  a	  set	  of	  pluripotency	  genes	  as	  well	  as	  pathway	  
specific	  factors.	  Given	  the	  information	  currently	  understood	  about	  MSC	  self-­‐renewal	  
and	  differentiation	  and	  the	  balance	  of	  these	  factors,	  it	  is	  reasonable	  to	  determine	  the	  
factors	  that	  promoted	  MSC	  maintenance.	  Maintenance	  is	  defined	  as	  the	  capacity	  for	  
MSCs	  to	  proliferate	  in	  an	  equipotent	  fashion	  with	  comparable	  expression	  of	  
pluripotency	  factors	  and	  differentiation	  capacity.	  	  	  




MSCs	  have	  been	  explored	  as	  therapy	  for	  a	  variety	  of	  acute	  and	  chronic	  disease	  
conditions.	  MSCs	  are	  an	  attractive	  stem	  cell	  population	  due	  to	  their	  ease	  of	  isolation,	  
ability	  to	  modulate	  the	  immune	  response,	  and	  diminished	  immune	  recognition.	  
However,	  the	  clinical	  use	  of	  MSCs	  is	  limited	  by	  the	  number	  of	  cells	  that	  can	  be	  
acquired	  both	  due	  to	  their	  low	  concentration	  in	  the	  bone	  marrow	  and	  their	  limited	  
ex	  vivo	  proliferation	  and	  differentiation	  capacity.	  Reports	  have	  indicated	  that	  only	  
approximately	  2000	  MSCs	  can	  be	  obtained	  from	  a	  human	  bone	  marrow	  sample	  (30).	  	  
Most	  therapies	  have	  used	  bone	  marrow	  isolated	  MSCs	  as	  other	  MSC	  sources,	  such	  as	  
from	  the	  spleen	  or	  adipose	  tissue,	  require	  surgical	  intervention	  for	  isolation.	  	  MSCs	  
can	  be	  delivered	  either	  systemically	  by	  IV	  treatment	  or	  locally	  in	  the	  interstitium	  or	  
vasculature.	  When	  delivered	  systemically	  MSCs	  were	  found	  to	  prominently	  
accumulate	  in	  the	  lungs	  and	  spleen	  in	  the	  first	  72	  hours,	  prior	  to	  clearance	  of	  non-­‐
engrafted	  cells	  (26).	  Mechanisms	  for	  improved	  disease	  control	  include	  MSC	  
differentiation	  at	  the	  site	  of	  injury	  and	  secretion	  of	  soluble	  factors	  essential	  for	  the	  
recruitment	  of	  cell	  populations	  required	  for	  healing	  or	  that	  themselves	  promote	  the	  
healing	  process	  (36,	  54-­‐56).	  Although	  limited	  differentiation	  and	  engraftment	  
occurs,	  secreted	  factors	  have	  been	  identified	  as	  primarily	  responsible	  for	  the	  
enhanced	  tissue	  regeneration.	  In	  one	  model,	  it	  was	  estimated	  that	  99%	  of	  
transplanted	  cells	  died	  within	  4	  days	  of	  delivery	  (57).	  Clinical	  evaluation	  of	  both	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allogeneic	  and	  autologous	  MSC	  transplant	  has	  demonstrated	  some	  promising	  initial	  
results	  with	  ongoing	  Phase	  I-­‐III	  clinical	  trials	  in	  the	  treatment	  of	  graft-­‐versus-­‐host	  
disease,	  Crohn’s	  disease,	  multiple	  sclerosis,	  Type	  I	  diabetes,	  chronic	  obstructive	  
pulmonary	  disease,	  bone	  conditions,	  arthritis,	  autoimmune	  conditions,	  and	  
following	  myocardial	  infarction	  or	  solid	  organ	  transplant	  (10,	  11,	  30,	  58-­‐61).	  
	  
In	  four	  clinical	  trials	  for	  heart	  disease,	  no	  side	  effects	  or	  toxicity	  were	  reported	  with	  
improved	  cardiac	  function.	  Safety	  concerns	  associated	  with	  MSC	  therapy	  include	  the	  
risk	  of	  increased	  arrhythmias	  when	  used	  for	  cardiac	  disease	  and	  tumor	  formation.	  
At	  present,	  there	  is	  no	  evidence	  of	  these	  toxicities	  with	  MSC	  treatment	  in	  clinical	  
trial	  patients,	  however	  observation	  is	  ongoing.	  MSCs	  have	  been	  shown	  to	  have	  the	  
potential	  for	  spontaneous	  in	  vitro	  malignant	  transformation	  and	  this	  is	  the	  reason	  
identified	  for	  the	  neoplastic	  safety	  concerns	  (62).	  MSCs	  have	  shown	  initial	  promise	  
in	  clinical	  trials	  although	  technical	  difficulties	  need	  to	  be	  overcome	  in	  delivery	  and	  
retention.	  
	  
MSCs	  and	  Cancer	  
	  
The	  tumor	  microenvironment	  is	  composed	  of	  a	  number	  of	  different	  factors	  
including	  cancer	  cells,	  carcinoma	  associated	  fibroblasts	  (CAF),	  vasculature,	  smooth	  
muscle	  cells,	  adipocytes,	  immune	  cells,	  and	  MSCs	  (63,	  64).	  MSCs	  impacting	  the	  
tumor	  microenvironment	  are	  derived	  both	  from	  tissue	  resident	  MSCs	  and	  through	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bone	  marrow	  derived	  MSCs.	  MSCs	  have	  been	  shown	  to	  home	  to	  breast,	  lung,	  
pancreatic,	  colon,	  ovarian,	  prostatic,	  and	  melanoma	  tumors	  (65).	  MSCs	  are	  recruited	  
to	  tumors	  by	  TGF-­‐ss1,	  IL-­‐8,	  neurotropin	  3,	  EGF,	  HGF,	  bFGF,	  PDGF,	  MCP-­‐1,	  
CXCL12/CCR4,	  VEGF,	  and	  SCK/ckit	  (1).	  MSCs	  within	  tumors	  increased	  cancer	  cell	  
proliferation,	  motility,	  invasion,	  metastasis,	  angiogenesis,	  and	  desmoplasia.	  MSCs	  
have	  also	  been	  associated	  with	  decreased	  tumor	  immune	  recognition.	  These	  effects	  
are	  thought	  to	  be	  achieved	  through	  several	  proposed	  mechanisms	  including	  
paracrine	  factors,	  proangiogenic	  cell	  recruitment,	  MSC	  differentiation	  into	  CAFs,	  
increased	  metastatic	  potential,	  chemotherapy	  resistance,	  and	  immunomodulation.	  
Tumors	  containing	  MSCs	  have	  an	  increased	  cancer	  stem	  cell	  content	  and	  a	  greater	  
tumor	  initiating	  capacity	  (66).	  	  
	  
The	  paracrine	  factors	  secreted	  by	  MSCs	  serve	  both	  to	  influence	  the	  local	  tumor	  
microenvironment	  and	  to	  recruit	  cells	  for	  the	  tumor	  associated	  stroma	  (64).	  MSC	  
secretion	  in	  co-­‐culture	  with	  tumor	  cells	  upregulates	  gene	  clusters	  associated	  with	  
metastasis,	  proliferation,	  and	  chemoresistance	  (67).	  In	  the	  bone	  marrow,	  MSCs	  can	  
attract	  tumor	  cells	  creating	  a	  metastatic	  niche	  for	  tumor	  cells	  and	  encouraging	  
osteolysis	  and	  drug	  resistance	  (34).	  A	  diagram	  outlining	  the	  mechanism	  of	  tumor	  
promotion	  by	  MSCs	  is	  shown	  in	  Figure	  1	  indicating	  the	  signaling	  pathways	  and	  
mechanisms	  involved	  in	  MSC	  influence	  on	  tumor	  vasculature	  and	  tumor	  cells	  
survival	  as	  the	  metastatic	  potential	  of	  the	  cells	  the	  downregulation	  of	  immune	  
components	  is	  also	  addressed.	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In	  some	  cases,	  although	  much	  less	  frequently	  reported	  ,	  MSCs	  recruited	  to	  tumors	  
can	  inhibit	  tumor	  progression.	  This	  effect	  may	  be	  dependent	  on	  the	  time	  at	  which	  
MSCs	  are	  delivered	  in	  cancer	  development.	  The	  mechanism	  for	  tumor	  inhibition	  has	  
been	  proposed	  as	  a	  diminished	  immune	  reaction.	  This	  effect	  has	  been	  reported	  in	  
selected	  publications	  for	  leukemia,	  melanoma,	  and	  breast	  cancer	  (62,	  68,	  69).	  
	  
	  
Figure	  1:	  Role	  of	  MSCs	  in	  the	  tumor	  microenvironment	  (Bergfield	  et	  al.	  2010):	  MSCs	  impacts	  tumor	  
growth	  and	  protection	  through	  their	  multi-­faceted	  interaction	  with	  the	  tumor	  microenvironment.	  These	  
effects	  include	  interactions	  with	  the	  tumor	  vasculature,	  tumor	  cells	  themselves,	  and	  the	  immune	  system	  
by	  causing	  immunomodulation	  through	  interactions	  between	  both	  the	  innate	  and	  adaptive	  immune	  
system..	  These	  mechanisms	  are	  further	  reviewed	  in	  the	  article	  by	  Bergfield	  et	  al.	  2010.	  
	  
CAFs	  express	  their	  pro-­‐tumorigenic	  effect	  through	  a	  number	  of	  mechanisms.	  The	  
first	  of	  these	  is	  secretion	  of	  CXCL12/SDF-­‐1	  secretion	  and	  expression	  that	  results	  in	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the	  recruitment	  of	  pro-­‐inflammatory	  cells	  to	  the	  tumor	  microenvironment	  and	  
increases	  CCL5	  expression	  that	  promotes	  the	  metastatic	  ability	  of	  the	  cancer.	  
Additionally	  CAFs	  secrete	  a	  number	  of	  additional	  growth	  factors	  including	  EGF,	  
TGFβ,	  and	  HGF.	  CAFs	  are	  frequently	  defined	  by	  their	  expression	  of	  alpha	  smooth	  
muscle	  actin,	  fibroblast	  activating	  protein,	  FSP1,	  NG2,	  and	  PDGF	  beta	  (70).	  Many	  of	  
these	  CAFs	  are	  though	  to	  derive	  from	  bone	  marrow	  precursors	  with	  one	  report	  
indicating	  that	  20%	  of	  CAFS	  are	  derived	  from	  bone	  marrow	  MSCs	  in	  the	  gastric	  
tumor	  microenvironment	  (71).	  Once	  differentiated,	  these	  MSC	  derived	  CAFs	  can	  
secrete	  factors	  that	  recruit	  additional	  MSCs	  to	  the	  tumor	  microenvironment.	  Beyond	  
their	  role	  in	  differentiating	  into	  CAFs	  or	  their	  paracrine	  effects	  MSCs	  have	  been	  
identified	  as	  the	  tumor-­‐initiating	  cell	  in	  Ewings	  Sarcoma	  and	  osteosarcoma	  (63)	  (5,	  
6,	  65).	  
	  
Cancer	  therapies	  have	  been	  proposed	  and	  tested	  with	  potent	  anti-­‐tumor	  effects	  
include	  using	  MSCs	  as	  a	  vector	  for	  delivery	  of	  gene	  therapy	  including	  interferon	  
beta,	  cytosine	  deaminase,	  and	  TRAIL	  (72-­‐76).	  The	  timing	  of	  MSC	  introduction	  to	  the	  
tumor	  may	  be	  the	  critical	  factor	  determining	  the	  impact	  of	  MSCs	  on	  the	  tumor	  
microenvironment	  with	  other	  differences	  attributed	  to	  the	  tumor	  model	  and	  tumor	  
heterogeneity	  (3-­‐6).	  The	  source	  of	  MSCs	  used	  for	  delivery	  does	  not	  appear	  to	  impact	  
this.	  Much	  of	  this	  relates	  to	  MSC	  recruitment	  to	  wounds	  and	  tumors	  acting	  as	  an	  
inflammatory	  wound	  that	  never	  heals	  (77-­‐79).	  MSCs	  have	  been	  shown	  to	  promoted	  
tumor	  growth	  in	  vivo	  in	  colon	  cancer,	  lymphoma,	  and	  melanoma	  (4,	  80).	  




Prostate	  cancer	  is	  a	  cancer	  with	  a	  high	  incidence	  in	  older	  men	  with	  variable	  
prognosis	  depending	  on	  the	  local	  or	  metastatic	  state	  of	  the	  disease	  has	  a	  significant.	  
Prostate	  cancer	  is	  diagnosed	  more	  frequently	  with	  increasing	  age.	  Forty	  percent	  of	  
men	  over	  the	  age	  of	  50	  are	  diagnosed	  with	  prostate	  cancer	  and	  among	  this	  
population	  the	  disease	  only	  a	  small	  percentage	  have	  prostate	  cancer	  as	  their	  cause	  
of	  mortality.	  In	  2012,	  there	  were	  241,740	  new	  cases	  of	  prostate	  cancer	  with	  28,170	  
deaths	  (American	  Cancer	  Society).	  High	  grade	  prostatic	  intraepithelial	  neoplasia	  
(PIN)	  characterized	  by	  cell	  proliferations	  within	  the	  ducts	  and	  acini	  of	  the	  prostate	  
gland	  with	  prominent	  nuclear	  and	  nucleolar	  enlargement	  without	  disruption	  of	  the	  
basal	  cell	  layer	  (81,	  82).	  Prostate	  cancer	  develops	  over	  the	  course	  of	  decades	  
moving	  from	  normal	  prostate	  tissue	  to	  a	  precancerous	  histology	  call	  prostatic	  
intraepithelial	  neoplasia	  (PIN)	  before	  progressing	  to	  prostate	  cancer	  and	  metastatic	  
prostate	  cancer.	  	  Current	  evidence	  does	  not	  suggest	  that	  either	  low	  grade	  PIN	  and	  
adenomas	  do	  not	  progress	  to	  prostatic	  adenocarcinomas.	  Common	  sites	  of	  
metastasis	  for	  prostate	  cancer	  include	  the	  bone,	  lungs,	  and	  liver.	  Although	  prostate	  
cancer	  has	  been	  studied	  for	  many	  decades,	  the	  cell	  of	  origin	  for	  prostate	  cancer	  
remains	  under	  debate	  and	  both	  basal	  cell	  and	  luminal	  cells	  of	  the	  prostate	  remain	  
potential	  sources	  of	  malignant	  transformation.	  Treatment	  includes	  radical	  
prostatectomy,	  radiation,	  or	  watchful	  waiting	  for	  local	  disease	  and	  androgen	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ablation	  therapy	  for	  more	  advanced	  disease.	  Androgen	  ablation	  long	  term	  often	  
results	  in	  resistance	  to	  therapy	  commonly	  starting	  after	  2	  years	  of	  treatment	  (83).	  	  
	  
Although	  prostate	  cancer	  has	  a	  very	  good	  prognosis	  for	  localized	  disease,	  the	  
prognosis	  is	  substantially	  worse	  for	  metastatic	  or	  disseminated	  disease	  with	  only	  
33%	  five-­‐year	  survival.	  	  Identification	  of	  markers	  or	  mechanisms	  of	  tumor	  
progression	  are	  therefore	  critical	  to	  understanding	  differences	  between	  localized	  
and	  metastatic	  disease	  (83).	  As	  MSCs	  have	  a	  role	  in	  cancer	  progression,	  
invasiveness,	  and	  metastasis,	  understanding	  the	  role	  of	  MSCs	  within	  the	  prostate	  
cancer	  microenvironment	  could	  be	  critically	  important	  in	  understanding	  the	  
transition	  from	  localized	  to	  metastatic	  disease.	  	  	  
	  
MSC	  and	  prostate	  cancer	  
	  
Comparable	  to	  the	  role	  of	  MSCs	  in	  other	  cancer	  settings,	  MSCs	  home	  to	  prostate	  
cancer	  tumors	  and	  increase	  tumor	  invasion	  and	  metastasis	  (84-­‐88).	  This	  effect	  is	  
accomplished	  through	  a	  number	  of	  different	  mechanisms.	  Recent	  work	  has	  
identified	  the	  PCa-­‐CxCl16	  ligand	  and	  its	  interaction	  with	  Sxcr6	  as	  facilitating	  MSC	  
recruitment	  to	  prostate	  tumors	  (89,	  90).	  Following	  MSC	  recruitment,	  increases	  in	  
the	  PCa	  stem	  cell	  population	  were	  observed.	  This	  increase	  in	  the	  stem	  cell	  
population	  is	  associated	  with	  increased	  CCL5,	  decreased	  androgen	  receptor	  nuclear	  
translocation,	  and	  increased	  metastatic	  gene	  expression	  and	  metastasis	  in	  vivo	  (91).	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These	  effects	  are	  accomplished	  in	  part	  by	  MSC	  secretion	  of	  Il-­‐6,	  Il-­‐10	  and	  increased	  
MMP	  expression	  in	  the	  tumor	  microenvironment	  (33,	  34).	  
	  
Prostate	  cancer	  stem	  cells	  
	  
Somatic	  stem	  cells	  are	  a	  heterogeneous	  population	  of	  self-­‐renewing	  stem	  cells	  (89).	  
Cancer	  stem	  cells	  (CSCs)	  are	  similar	  in	  that	  they	  have	  similar	  phenotypes	  and	  
functional	  heterogeneity.	  Comparable	  to	  other	  stem	  cell	  populations,	  cancer	  stem	  
cells	  have	  been	  characterized	  as	  mostly	  quiescent	  cells.	  CSCs	  are	  thought	  to	  be	  
responsible	  for	  relapse	  following	  therapy	  although	  they	  may	  not	  be	  the	  cell	  of	  origin	  
for	  original	  tumor	  (92).	  	  Two	  ways	  to	  trace	  stem	  cell	  populations	  are	  either	  by	  
marker	  expression	  or	  lineage	  tracing	  and	  serial	  transplantation	  assays	  (93).	  Cancer	  
stem	  cells	  differ	  from	  typical	  stem	  cells	  in	  that	  they	  lack	  the	  multi-­‐lineage	  
differentiation	  that	  embryonic	  stem	  cells	  possess.	  In	  PCa,	  markers	  of	  prostate	  cancer	  
stem	  cells	  include	  CD44+,	  α2β1	  integrin+,	  CD166+,	  Tra-­‐1-­‐60+,	  CD151+,	  and	  Aldh+.	  
These	  markers	  were	  selected	  in	  part	  based	  on	  the	  high	  clonogenicity	  of	  the	  CD44+	  
α2β1	  integrin+,	  CD133+	  population	  and	  the	  high	  tumorigenicity	  of	  the	  
aldh+CD44+alpha2b1+	  cells	  that	  compose	  0.1%	  of	  the	  tumor	  population	  of	  human	  
prostate	  cancer	  (93-­‐95).	  Prostate	  cancer	  stem	  cells	  are	  a	  critical	  avenue	  of	  
investigation	  to	  better	  understand	  disease	  progression	  and	  to	  develop	  curative	  
therapies.	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Erk/MAPK	  Signaling/DUSP-­1	  
	  
Mitogen	  activated	  protein	  kinases	  (MAPKs)	  are	  a	  family	  of	  serine/threonine	  kinases	  
that	  mediate	  signal	  transduction	  through	  modification	  of	  nuclear	  transcription	  
factors	  thereby	  connecting	  the	  plasma	  membrane	  and	  the	  extracellular	  environment	  
to	  nuclear	  and	  cytoplasmic	  events	  (96).	  MAPKs	  are	  involved	  in	  proliferation,	  
differentiation,	  migration	  and	  apoptosis	  (97).	  The	  MAPKs	  are	  composed	  on	  Erk,	  JNK,	  
and	  p38	  proteins	  that	  differ	  in	  their	  activation	  by	  a	  dual	  specificity	  Threonine-­‐x-­‐
tyrosine	  tripeptide	  motif.	  The	  Erk	  family	  members	  are	  best	  characterized	  for	  
responses	  to	  growth	  factor	  stimulation	  whereas	  p38	  and	  JNK	  proteins	  are	  involved	  
more	  in	  cell	  stress	  response	  pathways.	  JNK	  has	  been	  shown	  to	  be	  upregulated	  
following	  UV	  radiation,	  growth	  factor	  deprivation,	  and	  DNA	  damage	  whereas	  p38	  is	  
upregulated	  following	  environment	  stress	  and	  inflammatory	  cytokines	  (98).	  MAPKs	  
are	  activated	  by	  MAPK	  kinases	  that	  are	  in	  turn	  activated	  by	  MAPK	  kinase	  kinases.	  
For	  example,	  Erk1/2	  a	  MAPK,	  is	  activated	  by	  Mek	  1/2,	  MAPK	  kinases,	  which	  are	  
activated	  by	  three	  Raf	  isoforms,	  MAPK	  kinase	  kinases.	  This	  pathway	  is	  frequently	  
downstream	  of	  Ras-­‐GTPase	  signaling	  (97).	  	  
	  
Erk	  1/2	  proteins	  constitute	  one	  class	  of	  mitogen	  activated	  protein	  kinases	  (MAPK)	  
with	  signaling	  downstream	  of	  Ras.	  Erk	  1/2	  also	  known	  as	  p44	  and	  p42	  MAPK	  were	  
first	  identified	  in	  1989	  with	  83%	  sequence	  homology	  between	  the	  two	  isoforms	  
(97).	  	  It	  can	  be	  phosphorylated	  at	  two	  sites	  with	  dual	  specificity	  protein	  kinases	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(Mek	  ½)	  responsible	  for	  complete	  activation	  of	  Erk.	  Over	  200	  downstream	  signaling	  
substrates	  of	  Erk	  have	  been	  identified	  with	  Erk	  activation	  promoting	  proliferation,	  
differentiation,	  survival,	  apoptosis,	  and	  stress	  response	  (99-­‐101).	  Commonly	  
investigated	  transcription	  factors	  regulated	  by	  Erk	  include	  Elk-­‐1,	  c-­‐fos,	  and	  c-­‐jun.	  
Regulation	  of	  Erk	  has	  been	  described	  through	  a	  number	  of	  mechanisms	  including	  
duration	  and	  intensity	  of	  activation,	  scaffold	  interactions,	  compartmentalization,	  
and	  substrate	  availability	  (100).	  Erk	  activation	  can	  be	  mediated	  by	  GαI	  and	  Gαq	  with	  
deficiency	  of	  Gα12	  and	  Gα13	  GTPase	  resulting	  in	  increased	  focal	  formation	  in	  3T3	  
cells	  (102).	  	  
	  
Deactivation	  of	  MAPKs	  is	  mediated	  by	  the	  MAPK	  phosphatases	  or	  MKPs	  with	  the	  
best-­‐described	  family	  member	  being	  MKP-­‐1/DUSP-­‐1.	  MAPK	  phostphastase	  (MKP-­‐
1),	  first	  isolated	  twenty	  years	  ago,	  is	  phosphorylated	  following	  Erk	  activation	  to	  
protect	  the	  protein	  from	  proteosomal	  degradation	  (102).	  MKP-­‐1	  can	  
dephosphorylate	  all	  3	  classes	  of	  MAPKs	  with	  knockout	  mice	  demonstrating	  a	  
normal	  phenotype	  and	  increased	  innate	  immune	  responses	  (103,	  104).	  Sphingosine	  
1-­‐phosphate	  (S1P)	  has	  been	  shown	  to	  activate	  all	  3	  MAPK,	  but	  has	  also	  been	  shown	  
to	  activate	  MKP-­‐1	  on	  an	  mRNA	  and	  protein	  level	  by	  a	  p38	  dependent	  mechanism.	  
S1P	  stimulation	  therefore	  simultaneously	  upregulates	  the	  pathway	  and	  its	  negative	  
feedback	  (105).	  Given	  the	  pleiotropic	  effects	  of	  S1P	  stimulation	  on	  cells,	  the	  
differential	  activation	  of	  different	  MAPK	  pathways	  is	  therefore	  important	  with	  each	  
cell	  type	  response	  influenced	  by	  its	  receptor	  composition.	  	  




Sphingolipids	  are	  a	  class	  of	  membrane	  lipids	  providing	  critical	  structural	  roles	  in	  the	  
lipid	  bilayer	  and	  impacting	  membrane	  fluidity	  (106).	  	  Originally	  named	  by	  J.L.W.	  
Thudichum	  for	  their	  “enigmatic”	  nature	  in	  1884,	  the	  structural	  role	  of	  these	  lipids	  
was	  identified	  before	  the	  prominent	  signaling	  pathways	  were	  identified.	  	  
Sphingolipids	  are	  amphipathic	  molecules	  composed	  of	  a	  hydrophobic	  sphingoid	  
long	  chain	  base	  combined	  with	  a	  fatty	  acid	  with	  a	  hydrophilic	  head	  group	  in	  some	  
classes.	  Sphingolipds	  levels	  are	  regulated	  on	  several	  tiers	  by	  control	  of	  enzyme	  
expression,	  subcellular	  location,	  post	  translational	  modification,	  and	  allosteric	  
isomers	  (107).	  S1P	  was	  first	  identified	  by	  Sarah	  Spiegel	  in	  the	  early	  1990’s	  (108).	  
S1P	  is	  synthesized	  from	  ceramide	  by	  the	  actions	  of	  ceramidases	  and	  sphingosine	  
kinases.	  Ceramide	  is	  the	  central	  molecule	  in	  sphingolipid	  signaling	  promoting	  
general	  anti-­‐proliferative	  functions	  with	  growth	  inhibition,	  apoptosis,	  
differentiation,	  and	  senescence.
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Figure	  2:	  Diagram	  of	  Sphingolipid	  metabolism	  (Waeber	  et	  al.	  2004):	  The	  central	  molecule	  of	  
sphingolipid	  metabolism	  ceramide.	  Ceramide	  can	  be	  synthesized	  from	  a	  number	  of	  pathways	  including	  
de	  novo	  synthesis	  of	  ceramide	  from	  palmitoyl	  CoA	  and	  Serine.	  It	  can	  additionally	  be	  formed	  from	  the	  
salvage	  pathway	  from	  sphingomyelin.	  Once	  formed	  ceramide	  can	  be	  converted	  to	  sphingosine	  and	  
sphingosine	  1-­phosphate	  by	  the	  action	  of	  ceramidases	  and	  sphingosine	  kinases.	  Sphingosine	  kinase	  can	  
be	  further	  irreversible	  broken	  down	  by	  S1P	  lyase.	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Ceramide	  is	  formed	  from	  three	  pathways	  including	  the	  de	  novo	  pathway,	  
sphingomyelin	  hydrolysis,	  and	  cerebrosides.	  Once	  formed	  ceramide	  can	  generate	  
S1P	  reversibly	  through	  the	  activity	  of	  ceramidases	  and	  sphingosine	  kinases.	  Both	  of	  
these	  pathways	  are	  shown	  in	  Figure	  2	  above	  showing	  sphingolipid	  metabolism	  and	  
the	  structure	  of	  the	  lipids	  involved.	  Lipids	  at	  each	  level	  in	  this	  pathway	  are	  highly	  
interconnected	  as	  small	  changes	  in	  sphingomyelin	  result	  in	  large	  changes	  in	  
ceramide	  due	  to	  the	  ten-­‐fold	  decrease	  in	  basal	  concentrations.	  Further	  downstream	  
of	  this	  metabolic	  pathway,	  3-­‐10%	  increases	  in	  ceramide	  result	  in	  a	  doubling	  of	  
sphingosine	  and	  1-­‐3%	  increases	  in	  sphingosine	  result	  in	  a	  doubling	  of	  S1P	  
concentrations.	  At	  each	  enzymatic	  level,	  the	  concentration	  of	  each	  lipid	  is	  highly	  
regulated	  in	  its	  synthesis	  and	  degradation	  because	  small	  perturbations	  can	  have	  
significant	  impact	  on	  the	  signaling	  of	  downstream	  molecules	  (109).	  	  
	  
At	  the	  other	  side	  of	  this	  ceramide/S1P	  rheostat,	  S1P	  provides	  proliferative,	  
inflammatory,	  vasculogenic,	  apoptotic	  resistant,	  and	  motility	  functions.	  It	  mediates	  
these	  actions	  primarily	  through	  autocrine	  and	  paracrine	  functions	  although	  
intracellular	  S1P	  signaling	  is	  documented	  (42,	  106,	  110,	  111).	  S1P	  is	  composed	  of	  a	  
polar	  head	  group	  and	  hydrophobic	  tail	  as	  shown	  in	  Figure	  2	  (112).	  Regulation	  of	  
S1P	  signaling	  can	  be	  mediated	  by	  changes	  in	  expression	  and	  the	  subcellular	  
localization	  of	  the	  lipids	  composing	  this	  pathway	  (106).	  S1P	  can	  be	  reversibly	  
degraded	  back	  to	  sphingosine	  by	  phosphatases	  or	  irreversibly	  degraded	  by	  S1P	  
lyase.	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Following	  synthesis	  S1P	  is	  secreted	  from	  the	  cell	  to	  provide	  an	  S1P	  source	  for	  
paracrine	  and	  autocrine	  signaling	  through	  membrane	  G-­‐protein	  coupled	  receptors.	  
Spinster-­‐2	  (Spns2)	  is	  the	  only	  true	  transporter	  of	  S1P	  with	  a	  unique	  capacity	  to	  
transport	  FTY720.	  	  Mice	  deficient	  in	  Spinster-­‐2	  expression	  have	  50%	  less	  
extracellular	  S1P	  (113).	  Additional	  transportation	  of	  S1P	  is	  through	  the	  ATP	  binding	  
cassettes	  (ABC)	  transporters	  including	  ABCC1,	  ABCA,	  and	  ABCG2.	  Intracellular	  S1P	  
signaling	  is	  mediated	  through	  inhibition	  of	  HDAC1	  and	  2,	  TRAF2	  mediated	  
stimulation	  of	  E3	  lipase	  and	  R1P,	  and	  cytoskeleton	  regulation	  through	  NfkB	  
regulated	  dynamics	  (114-­‐116).	  	  
	  
The	  S1P	  gradient	  between	  the	  plasma	  and	  lymph	  and	  tissue	  levels	  has	  a	  significant	  
impact	  on	  physiological	  function	  especially	  with	  regard	  to	  the	  mobilization	  of	  
circulating	  cells.	  Following	  injury	  such	  as	  cardiac	  and	  hepatic	  injury,	  it	  has	  been	  
demonstrated	  that	  tissue	  levels	  and	  plasma	  levels	  rise	  following	  the	  initial	  insult.	  
Plasma	  S1P	  levels	  are	  0.1-­‐0.6	  μM	  S1P	  levels	  whereas	  tissue	  levels	  are	  in	  nM	  levels	  
(115-­‐117).	  The	  high	  level	  of	  S1P	  in	  the	  serum	  is	  provided	  by	  the	  platelet	  and	  
erythrocyte	  production	  of	  S1P	  due	  to	  the	  absence	  of	  S1P	  degrading	  enzymes	  in	  
these	  cells.	  Vascular	  endothelial	  cells	  also	  commonly	  secrete	  S1P.	  Due	  to	  the	  
hydrophilic	  nature	  of	  the	  protein,	  S1P	  is	  primarily	  transported	  in	  the	  plasma	  
through	  lipid	  carriers.	  Thirty-­‐five	  percent	  of	  S1P	  in	  the	  plasma	  uses	  albumin	  as	  a	  
transporter	  and	  65	  binds	  to	  ApoM	  in	  HDL	  (42).	  S1P	  is	  a	  critical	  lipid	  mediator	  of	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migratory,	  vasculogenic,	  and	  inflammatory	  processes	  although	  the	  variability	  in	  
these	  processes	  is	  explained	  by	  the	  simultaneous	  stimulation	  of	  S1P	  receptors	  with	  
differing	  downstream	  signaling.	  Within	  the	  circulation	  S1P	  has	  a	  critical	  role	  in	  
endothelial	  cell	  barrier	  function	  by	  promoting	  increased	  endothelial	  cell	  




More	  prominent	  than	  the	  signaling	  of	  S1P	  through	  intracellular	  mechanisms	  is	  the	  
signaling	  through	  5	  g-­‐protein	  coupled	  receptors	  called	  S1PR1-­‐S1PR5.	  Originally	  
identified	  as	  Edg	  receptors	  (endothelial	  differentiation	  genes),	  this	  is	  one	  of	  the	  
most	  heavily	  researched	  areas	  of	  S1P	  signaling.	  All	  of	  the	  receptors	  have	  similar	  kd	  
values	  in	  response	  to	  S1P	  with	  the	  Kd,	  a	  dissociation	  constant	  reflecting	  the	  
concentration	  at	  which	  S1P	  binds	  in	  the	  nM	  range	  (119).	  (Brock	  TG,	  Sphingolipids:	  
The	  sphinx	  of	  lipids)	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Figure	  3:	  Diagram	  of	  S1P	  receptor	  signaling:	  S1P	  can	  signal	  through	  S1PR1-­S1PR5.	  These	  receptors	  vary	  
in	  their	  signaling	  through	  G-­proteins	  and	  therefore	  in	  their	  down	  steam	  signaling.	  	  Different	  cell	  types	  
have	  different	  expression	  levels	  of	  S1P	  receptors.	  	  Each	  S1PR	  has	  characteristic	  and	  unique	  downstream	  
signaling	  pathway	  based	  on	  the	  G	  proteins	  and	  other	  proteins	  with	  which	  it	  interacts.	  	  
	  
The	  receptors	  vary	  in	  their	  downstream	  signaling	  and	  in	  their	  coupling	  with	  
GTPases.	  Whereas	  S1PR1	  signals	  solely	  through	  Gi,	  S1PR2	  and	  3	  signal	  through	  Gi,	  
Gq,	  and	  G12/13.	  These	  receptors	  are	  ubiquitously	  expressed	  whereas	  S1PR4	  and	  5	  
have	  limited	  expression	  restricted	  primarily	  to	  immune	  and	  natural	  killer	  (NK)	  and	  
neuronal	  expression	  respectively.	  S1PR4	  and	  R5	  couple	  with	  Gi	  and	  G12/13	  (120).	  
Each	  cell	  type	  has	  its	  own	  unique	  distribution	  of	  receptor	  expression	  thereby	  giving	  
each	  cell	  a	  unique	  response	  to	  S1P	  stimulation.	  
	  
	   29	  
S1PR1	  is	  formerly	  called	  Edg1	  (endothelial	  differentiation	  gene	  1).	  S1PR1	  signals	  
through	  Gi	  with	  increased	  cell	  survival	  mediated	  by	  Akt	  activation	  and	  Ras-­‐Erk	  
activation	  (113).	  Knock	  out	  (KO)	  animals	  	  for	  S1PR1	  die	  at	  embryonic	  day	  12.5-­‐14.5	  
by	  hemorrhage	  caused	  by	  deficient	  vascular	  development	  especially	  in	  the	  aorta	  
(42).	  S1PR1	  is	  required	  for	  endothelial	  cell	  vascular	  barrier	  functions	  by	  promoting	  
the	  formation	  of	  adherens	  junctions	  (42).	  Another	  critical	  role	  for	  S1PR1	  is	  in	  the	  
immune	  system	  where	  the	  receptor	  regulates	  lymphocyte	  migration	  out	  of	  
secondary	  lymphoid	  organs	  into	  blood	  and	  lymph	  counteracting	  the	  retention	  
signals	  of	  CCR7.	  S1PR1	  is	  also	  required	  for	  B	  cell	  trafficking	  between	  the	  follicle	  and	  
marginal	  zone	  of	  the	  spleen	  by	  a	  CD69	  dependent	  mechanism	  (108).	  	  S1PR1	  is	  
additionally	  involved	  in	  neutrophil	  and	  dendritic	  cell	  (DC)	  recruitment,	  activation,	  
and	  migration	  (10-­‐13).	  Decreased	  S1PR1	  expression	  results	  in	  decreased	  tumor	  
melanoma	  growth	  (113).	  
	  
	  
The	  immunologic	  role	  of	  S1PR1	  in	  the	  regulating	  lymphocyte	  egress	  has	  been	  
harnessed	  for	  treatment	  of	  multiple	  sclerosis	  	  and	  other	  autoimmune	  conditions.	  
FTY720	  (Gilenya)	  received	  FDA	  approval	  is	  a	  functional	  antagonist	  of	  S1PR1,	  R3,	  R4,	  
and	  R5	  although	  much	  of	  its	  function	  has	  been	  attributed	  to	  the	  role	  of	  S1PR1.	  This	  
(42)is	  the	  basis	  for	  FTY720	  treatment	  of	  MS	  and	  autoimmune	  conditions,	  where	  
FTY720	  is	  the	  first	  FDA	  approved	  oral	  therapy	  for	  MS	  (42).	  	  FTY720	  treatment	  
results	  in	  both	  lymphopenia	  and	  a	  decreased	  TH17	  cell	  response	  dependent	  upon	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S1PR1	  receptor	  internalization	  (42).	  The	  immunosuppressive	  effect	  of	  FTY720	  has	  
put	  it	  as	  a	  prime	  candidate	  for	  FDA	  approval	  following	  solid	  organ	  transplant	  with	  a	  
Phase	  III	  clinical	  trial	  currently	  in	  progress	  (108).	  	  
	  
S1PR3	  knockout	  mice	  have	  a	  normal	  phenotype	  with	  decreased	  litter	  sized	  (42).	  	  
Most	  published	  studies	  involving	  S1PR3	  function	  are	  tied	  to	  redundant	  functions	  
with	  S1PR1	  or	  S1PR2.	  Independent	  S1PR3	  functions	  are	  in	  DCs	  where	  it	  is	  critical	  to	  
switching	  the	  immune	  response	  to	  T	  helper	  cell	  expression	  (121).	  S1PR3	  plays	  a	  
critical	  role	  in	  sepsis	  where	  there	  are	  decreases	  in	  vascular	  resistance,	  and	  
permeability	  (113).	  S1PR3	  primarily	  has	  a	  role	  in	  B	  cell	  migration	  but	  most	  work	  
has	  been	  conducted	  in	  vitro	  and	  additional	  in	  vivo	  characterization	  is	  required	  (42).	  	  
	  
S1PR4	  has	  a	  more	  limited	  expression	  than	  S1PR1,	  R2,	  and	  R3	  with	  primary	  
expression	  on	  lymphocytes.	  S1PR5	  demonstrates	  the	  highest	  expression	  of	  neuronal	  
cells	  and	  natural	  killer	  cells	  (NK).	  In	  NK	  cells,	  S1PR5	  permits	  cell	  egress	  through	  
inhibition	  of	  the	  CXCR4	  dependent	  retention	  signals	  (122,	  123).	  	  
	  
S1PR2	  has	  more	  complex	  signaling	  and	  functions	  than	  that	  of	  S1PR1	  due	  to	  the	  
multiple	  small	  GTPases	  that	  it	  is	  capable	  of	  interacting	  with.	  Signaling	  through	  Gi	  
results	  in	  increased	  Erk	  activation	  and	  PI3K/Akt	  activation	  and	  downstream	  Rac	  
activation.	  Gq	  primarily	  signals	  through	  Phospholipase	  C.	  G12/13	  signals	  both	  
through	  Rho	  and	  Adenylate	  cyclase.	  Rho	  is	  antagonized	  both	  Akt	  and	  Rac.	  Additional	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S1P	  actions	  involve	  increased	  PLD,	  JNK,	  and	  P38	  activation	  (117).	  	  Rho	  GTPases	  
have	  a	  critical	  role	  in	  cytoskeletal	  signaling	  and	  actin	  stress	  fiber	  formation	  by	  
coordinating	  assembly	  of	  paxillin	  and	  alpha-­‐actinin	  (26).	  The	  preferential	  signaling	  
of	  this	  receptor	  through	  G12/13	  allows	  S1PR2	  to	  function	  both	  in	  parallel	  with	  and	  
antagonistic	  to	  the	  role	  of	  the	  other	  receptors.	  G12/13	  activation	  promotes	  
activation	  of	  Rho	  GTPase	  and	  VE	  Cadherin	  resulting	  in	  both	  a	  pro-­‐apoptotic	  and	  
prosurvival	  functions	  (117).	  	  
	  
The	  study	  and	  characterization	  of	  S1PR2	  knockout	  mice	  has	  greatly	  enhanced	  our	  
knowledge	  about	  S1PR2	  function	  physiologically	  and	  developmentally.	  Although	  
these	  mice	  are	  viable,	  they	  have	  a	  number	  of	  defects	  consistent	  with	  proposed	  roles	  
of	  S1PR2.	  As	  mentioned	  previously,	  S1PR2	  knockout	  mice	  have	  an	  increased	  risk	  of	  
seizures	  perinatally	  and	  are	  deaf	  perinatally	  due	  to	  defective	  cell	  migration.	  	  Female	  
mice	  may	  have	  hidden	  reproductive	  defects	  that	  result	  in	  reduced	  litter	  size	  (120).	  	  	  
Another	  tool	  used	  in	  the	  evaluation	  of	  S1PR2	  signaling	  and	  functional	  roles	  is	  that	  of	  
JTE013.	  JTE013	  is	  a	  competitive	  antagonist	  of	  S1PR2	  at	  an	  IC50	  of	  20	  nM.	  Recent	  
work	  has	  suggested	  that	  JTE013	  treatment	  may	  impact	  other	  S1PRs	  at	  higher	  doses	  
with	  changes	  in	  S1PR4	  at	  higher	  concentrations	  (42).	  
	  
In	  the	  vascular	  system,	  many	  of	  the	  antagonistic	  effects	  of	  S1PR2	  to	  S1PR1	  are	  
observed.	  S1PR2	  increases	  paracellular	  permeability	  by	  disruption	  of	  endothelial	  
cell	  adherens	  junctions	  through	  the	  Rho/ROCK	  pathway.	  	  Decreased	  vascular	  tone	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has	  been	  observed	  in	  the	  S1PR2	  knockout	  mice	  (124).	  S1P	  increases	  the	  senescence	  
of	  endothelial	  cells	  contributing	  to	  this	  function	  and	  increases	  neovascularization	  
following	  hypoxic	  retinal	  damage	  (42,	  113,	  117).	  Within	  the	  innate	  immune	  system,	  
mast	  cell	  degranulation	  requires	  S1PR2	  (112,	  113).	  S1PR2	  is	  increased	  with	  kidney	  
ischemia	  reperfusion	  injury	  and	  knockout	  mice	  protected	  promotes	  increased	  
vascular	  permeability	  through	  VCAM/ICAM1	  and	  increased	  angiogenic	  sprouting	  
through	  RhoC	  and	  LARG	  (42).	  S1PR2	  promotes	  mouse	  skeletal	  muscle	  regeneration	  
(2).	  S1PR2	  decreases	  chemotactic	  migration	  and	  increased	  membrane	  ruffling	  with	  
S1PR1	  and	  S1PR3	  promote	  increased	  chemotactic	  migration	  (125).	  S1PR2	  is	  
involved	  in	  intracellular	  calcium	  release	  and	  muscle	  cell	  contraction	  (113).	  S1PR2	  
KO	  mice	  are	  protected	  from	  diabetes	  with	  decreased	  islet	  cell	  apoptosis,	  increased	  
insulin	  release	  and	  decreased	  blood	  glucose.	  These	  mice	  further	  have	  a	  decreased	  
fibrotic	  response	  following	  hepatic	  injury	  (126).	  
	  
There	  is	  conflicting	  data	  on	  the	  role	  of	  S1PR2	  in	  neoplasia	  with	  variations	  in	  the	  
effect	  of	  S1PR2	  inhibition	  depending	  on	  the	  type	  of	  cancer	  being	  evaluated.	  	  
Anticancer	  effects	  of	  S1PR2	  include	  decreased	  melanoma	  migration	  through	  RhoA	  
and	  Rac,	  decreased	  lung	  metastasis,	  and	  decreased	  glioblastoma	  progression.	  B	  cell	  
lymphomas	  occur	  in	  S1PR2	  knockout	  mice	  with	  increasing	  age	  with	  over	  half	  of	  
mice	  developing	  tumors	  by	  1.5-­‐2	  years	  (126).	  A	  correlation	  has	  been	  observed	  
between	  higher	  S1PR2	  expression	  and	  increased	  breast	  cancer	  survival	  (114,	  127,	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128).	  To	  date,	  no	  studies	  have	  addressed	  the	  role	  of	  S1PR2	  in	  MSCs	  and	  its	  impact	  
on	  cancer	  promotion	  and	  development.	  
	  
In	  contrast,	  S1PR2	  promotes	  cancer	  in	  a	  variety	  of	  cancer	  types.	  In	  gliomas,	  S1PR2	  
increased	  tumor	  cell	  proliferation,	  but	  more	  importantly	  increased	  the	  invasiveness	  
of	  the	  cancer	  by	  upregulating	  cell	  adhesion	  molecules	  CCN1/Cyr61	  (129).	  In	  Hela	  
cells,	  the	  ERM	  proteins	  (exrin	  radixin,	  moesin)	  that	  link	  actin	  with	  the	  plasma	  
membrane	  and	  coordinate	  cytoskeletal	  rearrangement	  in	  response	  to	  EGF	  
treatment	  activates	  the	  SK/S1P	  pathway	  through	  S1PR2	  resulting	  in	  cell	  
polarization,	  lammellipodia	  formation	  and	  increased	  cell	  invasion	  (130,	  131).	  
Increased	  tumor	  progression	  is	  observed	  in	  hepatoma	  models,	  neuroblastoma,	  
melanoma,	  wilms	  tumor,	  bladder	  cancer	  and	  breast	  cancer	  (132-­‐135).	  In	  chronic	  
myelogenous	  leukemia	  increased	  drug	  resistance	  is	  observed	  by	  promoting	  the	  
stabilization	  of	  bcr-­‐able	  (113,	  136-­‐138).	  	  
	  
The	  work	  on	  the	  role	  of	  S1PR2	  in	  prostate	  cancer	  has	  been	  limited	  but	  a	  pro-­‐
cancerous	  role	  has	  been	  reported	  in	  the	  available	  literature.	  S1PR2	  is	  part	  of	  a	  
critical	  oncogenic	  pathway	  in	  prostate	  cancer	  through	  acid	  ceramidase	  and	  Sk1	  
(139,	  140).	  Increased	  work	  evaluating	  the	  role	  of	  S1PR2	  in	  prostate	  cancer	  
specifically	  is	  essential	  to	  determining	  its	  role	  in	  cancer	  progression	  and	  the	  tumor	  
microenvironment.	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Targeting	  S1P	  in	  the	  clinical	  setting	  
	  
Many	  chemical	  compounds	  are	  in	  the	  drug	  discovery	  spectrum	  aimed	  at	  treating	  
various	  inflammatory	  and	  neoplastic	  conditions.	  The	  most	  prominent	  of	  these	  is	  
FTY720	  or	  Gilenya,	  the	  first	  available	  FDA	  approved	  oral	  treatment	  for	  MS.	  
Following	  treatment,	  FTY720	  is	  phosphorylated	  by	  SK2.	  This	  results	  in	  functional	  
antagonism	  of	  all	  receptors	  except	  for	  S1PR2	  through	  receptor	  internalization.	  	  
S1PR2	  is	  not	  impacted	  by	  FTY720	  based	  on	  binding	  affinity	  studies	  of	  P-­‐
FTY720(141).	  Inhibition	  of	  S1PR1	  results	  in	  lymphopenia	  and	  therefore	  decreased	  
MS	  symptoms	  and	  inflammation.	  Recent	  literature	  has	  suggested	  additional	  
interactions	  with	  the	  T	  cell	  polarization	  and	  response.	  Another	  prominent	  therapy	  
in	  the	  pipeline	  is	  monoclonal	  antibodies	  against	  S1P.	  Anti-­‐S1P	  antibodies	  are	  
currently	  in	  Phase	  I/II	  clinical	  trials	  as	  iSONEP	  and	  aSONEP	  for	  age	  related	  macular	  
degeneration	  and	  solid	  tumors	  respectively	  (114-­‐116,	  127,	  128,	  142).	  	  
	  
S1P	  in	  Embryonic	  stem	  cells	  
	  
Embryonic	  stem	  cells	  (ESCs)	  have	  been	  shown	  to	  express	  S1PR1-­‐R3	  with	  murine	  
ESCs	  expressing	  S1PR5	  as	  well.	  The	  role	  of	  S1P	  in	  promoting	  self-­‐renewal	  and	  a	  
stem	  cell	  phenotype	  has	  been	  documented	  primarily	  in	  its	  role	  in	  ESCs.	  Strategies	  
designed	  to	  culture	  ESCs	  in	  vitro	  under	  serum	  free	  conditions	  have	  demonstrated	  
that	  the	  combination	  of	  S1P	  and	  PDGF	  supplementation	  results	  in	  increased	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proliferation	  of	  ESCs	  in	  an	  undifferentiated	  state	  with	  decreased	  apoptosis(143-­‐
145).	  In	  hESCs,	  S1P	  is	  critical	  to	  proliferation	  and	  survival	  with	  Erk1/2	  activation	  
increased	  following	  S1P	  treatment	  resulting	  in	  increased	  cell	  cycle	  proliferation	  and	  
decreased	  apoptosis.	  However,	  these	  changes	  were	  accompanied	  by	  decreased	  
expression	  of	  pluripotency	  factors	  including	  Nanog	  and	  Oct4	  with	  increasing	  
passages.	  Other	  studies	  have	  demonstrated	  that	  S1P	  regulates	  ESC	  self-­‐renewal	  
through	  Erk	  1/2	  with	  decreased	  spontaneous	  cell	  differentiation	  (142).	  ESCs	  highly	  
express	  S1P	  lyase	  and	  knock	  down	  increases	  the	  stem	  cell	  phenotype	  with	  increased	  
SSEA	  and	  OCT4	  expression	  and	  increased	  proliferation.	  In	  this	  system,	  a	  ten	  fold	  
increase	  in	  S1PR2	  expression	  was	  observed	  (143).	  	  S1P	  has	  been	  shown	  to	  be	  
important	  in	  stem	  cell	  self-­‐renewal	  and	  maintenance	  in	  other	  stem	  cell	  populations.	  
Further	  work	  evaluating	  the	  role	  of	  S1P	  and	  more	  specifically	  individual	  receptor	  
contributions	  in	  ESCs	  will	  further	  inform	  characterization	  and	  ex	  vivo	  proliferation	  
of	  this	  stem	  cell	  population.	  
	  
S1P	  in	  Hematopoietic	  stem	  cells	  
	  
Hematopoietic	  stem	  cells	  (HSCs)	  reside	  in	  a	  quiescent	  state	  within	  the	  bone	  marrow	  
with	  a	  basal	  level	  of	  circulating	  cells	  within	  the	  peripheral	  blood.	  Following	  stress	  or	  
injury,	  often	  the	  result	  of	  infection,	  tissue	  damage,	  or	  exercise,	  HSCs	  can	  be	  
mobilized	  to	  the	  peripheral	  blood	  and	  site	  of	  injury	  (146-­‐151).	  	  Historical	  
understanding	  of	  this	  mobilization	  relied	  on	  retention	  signaling	  from	  the	  SDF-­‐
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1/CXCR4	  and	  VLA-­‐4/VCAM-­‐1	  axes	  (150).	  Based	  on	  this	  research,	  treatment	  with	  
AMD3100,	  an	  inhibitor	  of	  CXCR4,	  results	  in	  HSC	  mobilization	  for	  harvesting	  of	  HSCs.	  
HSCs	  are	  known	  to	  express	  S1PR1-­‐R4	  but	  lack	  S1PR5.	  Recently,	  S1P	  has	  been	  shown	  
to	  provide	  a	  counter	  signal	  to	  the	  SDF-­‐1/CXCR4	  retention	  signaling	  promoting	  HSC	  
mobilization	  and	  egress	  from	  the	  bone	  marrow.	  These	  egress	  signals	  are	  thought	  to	  
utilize	  S1PR1	  as	  expression	  of	  this	  receptor	  is	  required	  for	  mobilization	  of	  cells	  in	  
response	  to	  an	  S1P	  gradient.	  S1P	  however	  is	  limited	  in	  its	  egress	  capacity	  as	  
complementary	  inhibition	  of	  CXCR4	  signaling	  is	  required	  for	  increased	  cell	  
mobilization	  (150,	  152).	  Ongoing	  research	  suggests	  that	  in	  cases	  of	  bone	  marrow	  
depletion	  such	  as	  following	  irradiation	  prior	  to	  transplant,	  S1P	  may	  promote	  
homing	  of	  MSCs	  to	  the	  bone	  marrow	  (153).	  Although	  S1P	  has	  been	  best	  
characterized	  for	  this	  mobilization	  process	  ceramide	  1-­‐phosphate	  released	  from	  
damaged	  cells	  may	  also	  contribute	  to	  HSC	  mobilization.	  Although	  the	  role	  of	  S1P	  in	  
HSCs	  has	  been	  documented,	  HSCs	  actively	  interact	  with	  MSCs	  in	  the	  bone	  marrow	  
and	  MSC	  behavior	  in	  response	  to	  S1P	  impacts	  the	  function	  of	  HSCs.	  Within	  the	  bone	  
marrow,	  S1P	  signaling	  in	  MSCs	  is	  essential	  for	  the	  crosstalk	  with	  HSCs	  and	  
maintenance	  of	  the	  hematopoietic	  compartment	  (151,	  154-­‐156).	  
	  
S1P	  and	  Mesenchymal	  Stem	  Cells	  
	  
S1P	  and	  signaling	  downstream	  of	  the	  S1P	  receptors	  has	  been	  shown	  to	  impact	  MSC	  
migration,	  differentiation,	  and	  capacity	  to	  respond	  to	  injury.	  S1P	  has	  been	  shown	  to	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increase	  and	  promote	  cell	  migration	  in	  MSCs	  (157).	  S1P	  induces	  MSC	  migration	  
through	  an	  Erk,	  Rho	  Kinases,	  and	  MMP	  dependent	  pathways.	  Activation	  of	  this	  
pathway	  results	  in	  rapid	  cytoskeletal	  remodeling	  starting	  as	  early	  as	  one	  minute	  
after	  treatment	  and	  this	  effect	  was	  sustained	  6	  hours	  later	  with	  increased	  cellular	  
lammellipodia	  and	  filipodia	  formation.	  S1PR1	  and	  S1PR2	  are	  the	  most	  prominent	  
receptors	  involved	  in	  this	  chemotactic	  effect	  through	  their	  effect	  on	  the	  family	  of	  
Rho	  GTPase.	  S1PR2	  in	  particular	  stimulated	  RhoA	  through	  G12/13	  with	  the	  result	  
being	  stress	  fiber	  formation	  and	  a	  migratory	  and	  invasive	  phenotype	  (158).	  Within	  
the	  bone	  marrow	  environment,	  osteoclasts	  can	  secrete	  S1P	  that	  stimulates	  MSC	  
chemotaxis.	  RhoA	  was	  activated	  but	  did	  not	  contribute	  to	  migration.	  S1PR1/S1PR2	  
however	  contributed	  to	  this	  chemotaxis	  using	  downstream	  Jak/Stat3	  and	  PI3K	  
signaling	  (154).	  These	  functions	  are	  contrary	  to	  the	  canonical	  role	  of	  S1PR2	  in	  
inhibition	  of	  cell	  migration.	  	  
	  
Alteration	  in	  the	  sphingolipid	  balance	  can	  influence	  MSC	  differentiation.	  S1P	  dose	  
dependently	  stimulates	  adipose	  derived	  smooth	  muscle	  cells	  based	  on	  protein	  
expression	  and	  actin	  organization	  (159).	  S1P	  similarly	  promotes	  cardiomyocyte	  
differentiation	  (160,	  161).	  	  C6	  ceramide	  treatment	  in	  contrast	  decreases	  adipogenic	  
differentiation	  through	  decreases	  in	  PPARγ	  and	  C/EBP	  expression.	  	  Maintenance	  of	  
low	  ceramide	  levels	  through	  the	  addition	  of	  exogenous	  acid	  ceramidase	  allows	  for	  
increased	  MSC	  chondrogenesis	  (162).	  In	  combination,	  this	  suggests	  that	  a	  shift	  in	  
the	  sphingolipid	  balance	  to	  favor	  S1P	  generation	  promotes	  increased	  MSC	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differentiation	  and	  processes	  that	  work	  antagonistically	  to	  this	  result	  in	  decreased	  
MSC	  differentiation.	  Additionally	  ceramide	  treatment	  in	  adipose	  derived	  MSCs	  
increases	  cell	  apoptosis	  and	  decreases	  differentiation	  (163).	  
	  
S1P	  signaling	  is	  critical	  to	  the	  physiological	  function	  of	  MSCs	  both	  in	  their	  peripheral	  
role	  and	  in	  the	  bone	  marrow.	  S1P	  and	  the	  S1P	  gradient	  are	  critical	  to	  MSC	  
mobilization	  through	  interactions	  with	  the	  Rho,	  MMP	  and	  Erk	  dependent	  pathways	  
(57,	  132).	  Li	  et	  al.	  demonstrated	  in	  their	  2009	  and	  2013	  publications	  with	  a	  carbon	  
tetrachloride	  liver	  injury	  model	  that	  MSCs	  migrate	  to	  the	  liver	  injury	  was	  dependent	  
on	  an	  S1P	  gradient	  and	  once	  at	  the	  liver	  they	  are	  capable	  of	  differentiating	  into	  
myofibroblasts	  through	  S1PR1	  and	  S1PR3	  (57,	  132,	  164).	  Treatment	  with	  the	  S1P	  
receptor	  agonist	  FTY720	  results	  in	  decreased	  severity	  of	  liver	  injury	  in	  this	  model	  
with	  decreased	  MSC	  migration	  to	  the	  site	  of	  injury	  (165).	  	  
	  
S1P	  and	  Neural	  progenitor	  cells	  
	  
Neural	  progenitor	  cells	  are	  a	  cell	  population	  required	  for	  the	  development	  of	  the	  
embryonic	  nervous	  system	  and	  for	  nervous	  system	  repair.	  The	  neural	  progenitors	  
highly	  express	  both	  S1PR1	  and	  S1PR2.	  Cell	  mobilization	  to	  sites	  of	  ischemia	  is	  
associated	  with	  increased	  S1P	  and	  decreased	  CXCR4	  signaling.	  Inhibition	  of	  S1PR2	  
using	  both	  shRNA	  and	  JTE013	  resulted	  in	  increased	  progenitor	  cell	  migration.	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Ongoing	  work	  is	  further	  characterizing	  neural	  progenitor	  migration	  and	  response	  to	  
injury	  (153).	  	  
	  
	  
Sphingolipids	  and	  sphingolipid	  metabolism	  have	  been	  shown	  to	  have	  multiple	  
intersections	  with	  stem	  cell	  signaling	  and	  function.	  To	  date,	  modulation	  of	  
sphingolipids	  pathways	  has	  been	  shown	  to	  impact	  stem	  cell	  self-­‐renewal	  pathways,	  
differentiation,	  and	  mobilization	  in	  embryonic	  stem	  cells,	  hematopoietic	  stem	  cells,	  
neural	  progenitor	  cells,	  and	  mesenchymal	  stem	  cells.	  	  Much	  of	  this	  work	  has	  focused	  






MSCs	  are	  increasingly	  being	  investigated	  in	  clinical	  use	  either	  through	  autologous	  or	  
allogeneic	  transplant	  for	  a	  number	  of	  conditions	  resulting	  from	  its	  impact	  on	  the	  
inflammatory	  environment,	  cell	  differentiation,	  and	  cell	  recruitment	  potential.	  The	  
role	  of	  S1P	  and	  its	  receptors	  have	  been	  shown	  to	  have	  a	  strong	  impact	  on	  a	  wide	  
range	  of	  biological	  functions	  including	  many	  of	  the	  functions	  critical	  to	  stem	  cell	  
function	  and	  regeneration.	  Further	  evaluation	  of	  the	  role	  of	  S1P	  in	  mediating	  the	  
functions	  of	  MSCs	  both	  in	  self-­‐renewal	  and	  in	  the	  periphery	  will	  elucidate	  the	  
clinical	  and	  translational	  potential	  of	  MSCs.	  S1PR2	  is	  perhaps	  the	  most	  interesting	  of	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these	  signaling	  pathways	  due	  to	  the	  potential	  of	  this	  receptor	  to	  act	  both	  with	  and	  
against	  the	  canonical	  function	  of	  S1PR	  depending	  on	  cell	  type.	  In	  this	  project,	  we	  
seek	  to	  assess	  the	  role	  of	  the	  S1P	  receptors	  in	  mesenchymal	  stem	  cell	  function	  and	  
signaling.	  The	  impact	  of	  MSCs	  in	  the	  prostate	  cancer	  microenvironment	  is	  also	  



















	   41	  
Materials and Methods: 
 
 
Cell Culture and Reagents 
 
Animal models 
Murine MSCs were isolated from C57Bl/6 mice ordered from the National Cancer 
Institute or Charles River Laboratories. GFP transgenic C57Bl/6 mice were generously 
provided by Dr. Okabe at Osaka University in Osaka, Japan (5, 6, 166). S1PR2KO mice 
were a gift from Dr. Richard Proia at the NIDDK (167, 168). DUSP-1 knock out mice 
were kindly provided by Dr. Kirkwood at the Medical University of South Carolina in 
Charleston, SC(169).  S1PR3 KO mice were a gift from the COBRE Lipidomics and 
Pathobiology Animal Core at the Medical University of South Carolina in Charleston, 
South Carolina (167, 168). All animal work was conducted with IACUC approval.  
Chemical inhibitors and substrates 
JTE013, an S1PR2 inhibitor dissolved in dimethylsulfoxide, and VPC, an S1PR1 and 3 
inhibitor dissolved in ethanol, were purchased from Cayman Chemicals and FR180204 
from Fisher Scientific. The Erk inhibitor U0126 was purchased from Cell Signaling and 
dissolved in DMSO. S1P was synthesized by the Lipidomics Synthetic Core and 
delivered in a 2% BSA solution.  
Cell isolation protocols and culturing 
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Whole bone marrow was harvested from the femurs of mice sacrificed by CO2 inhalation. 
Bones were placed a phosphate buffered saline solution containing 2% FBS and bone 
marrow was released using a mortar and pestle using the “flush and crush method” (170). 
Additional digestion with 3 mg/mL Collagenase I (Sigma) was conducted with cell 
shaking at 300 rpm at 37 degrees cells. Cells were filtered using a 70 μM cell strainer 
(Fisher Scientific). Red blood cells were lysed in ACK buffer containing ammonium 
chloride, potassium bicarbonate, and EDTA.  Cells were plated in Alpha Modified Eagles 
Medium (Invitrogen) supplemented with 20% fetal bovine serum (Atlas Biologicals), 2 
mM L-glutamine (R&D), and pen-strep amphotericin (Lonza). All cells were incubated 
in 5% CO2 at 37°F. When indicated, hTERT MSCs were cultured under low oxygen 
conditions (171). MSCs were stored in a vacuum-sealed plastic container at 2% oxygen 
and 37 degrees Celsius for the indicated times. Relevant normoxic controls were stored in 
the same incubator under standard conditions.   
After 3 days, non-adherent cells were discarded, plates washed with PBS, and adherent 
cells cultured for 4 passages. Cells were sorted on a BD FACS ARIA II cell sorter. Data 
was analyzed using FlowJo vX (TreeStar inc.). Gating strategy included isolating CD45 
and CD11b double negative cells and selecting for Sca1+ and CD105+ cells or CD105+ 
CD73+ cells using flow Cytometry antibodies provided by BD bioscience. Cells were 
plated immediately following cell sorting and allowed to recover from the cell sorting 
process. Twenty-four to forty-eight hours following cell-sorting cells were trypsinized 
and used for the experimental procedures outlined below.  
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Cell lines 
HTERT immortalized MSCs were a gift of Dr. Frank Marini at Wake Forest Medical 
Center and were cultured in Alpha Modified Eagles Medium containing 10% Bovine 
growth serum (Atlas Biologicals). Tramp C2 cells were obtained from the laboratory of 
Dr. Jennifer Wu at the Medical University of South Carolina. Cells were cultured in high 
glucose Dulbecco’s modified eagle’s medium containing 10% FBS and 
Penstrep/Amphotericin. C4-2 LnCap cells were cultured in RPMI containing 10% FBS 
and were obtained from the ATCC.  
Lipidomics analysis 
Ceramides species, sphingosine, and S1P from cell pellets, culture supernatants, and 
xenograft homogenates were collected and analyzed with LC-MS/MS by the Lipidomics 
Shared Resource, MUSC, as previously described (172). Briefly, mass spectrometric 
analysis of lipids was performed using electrospray ionization MS/MS analysis on a 
Thermo Finnigan TSQ 7000 triple quadruple mass spectrometer, operating in multiple 
reaction-monitoring positive ionization mode as described previously. About 2-3 × 106 
cells were fortified with the internal standards (ISs; C17 base D-erythrosphingosine, N-
palmitoyl-D-erythro-C13-sphingosine, and heptade-canoyl-D-erythrosphingosine). 
Calibration curves were constructed by plotting peak area ratios of synthetic standards 
corresponding to each target analyte with respect to the appropriate internal standard. The 
target analyte peak areas from the samples were similarly normalized to their respective 
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internal standard and then compared with the calibration curves using a linear regression 
model. Results were normalized to total protein levels. 
Clonogenic Survival Assay 
Clonogenic survival was assessed as previously described (172). To conduct the 
clonogenic cell assays, 24-48 hours following sorting cells were plated in triplicate in 6-
well cell culture plates (Corning, NY). Treatment was delivered 2 hours prior to initiation 
of clonogenic assay when indicated. Following 10-14 days in culture, cells were fixed in 
3.7% formaldehyde and stained with 1% crystal violet.  For analysis, 200-1000 cells per 
plate were plated depending on the treatment group. Colonies were counted when 
containing > 50 cells using a dissecting microscope. Colony formation was calculated as 
the ratio of colonies formed compared to the number of cells plated normalized to 
untreated or wild type controls.   
 
Quantitative Real-time PCR Analysis and genotyping 
RNA was synthesized by RNEASY (Qiagen) from cultured cells according to 
manufacturer’s instructions or by trizol extraction procedures. RNA was quantified based 
on the ratio of A260/280. 2ug of RNA was used for cDNA synthesis using the Biorad 
iScript cDNA synthesis kit according to manufacturers instructions using a Biorad 
thermocyler. Real-time RT-PCR was performed with primers in Sybr Green Supermix 
(Biorad) was used for thermocycling reactions. Cycling conditions were as follows: pre-
incubation, 50º C for 10 minutes, 95º C for 3 minutes, followed by 25-35 cycles of 
denaturation at 95º C, 30 seconds; annealing/extension between 52 and 60º C, 45 
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seconds. Relative mRNA concentration was calculated as 2^-(CtTarget-CtCalibrator). All 
primers are shown below in Table 1.  
 
Genotyping was conducted following tail clipping of ear-tagged mice just prior to 
weaning. Tails were digested and DNA isolated according to the qiagen DNEASY kit 
manufacturers instructions. PCR reactions using genotyping primers 1-3 listed below 
were conducted as directed by Kono et al (2004)(167, 168). PCR reactions were 
conducted using DNA master mix at 40 cycles of 1 min each of 94 degree and 72 degree 
temperatures. Wild type expression resulted in 170 base 
Table	  1:	  Table	  of	  primers	  used	  for	  genotyping	  and	  qPCR	  analysis:	  The	  first	  five	  primers	  listed	  are	  the	  
mouse	  primers	  used	  for	  qRT	  PCR.	  The	  remainder	  of	  the	  primers	  listed	  are	  murine	  specific	  primers	  
except	  those	  primers	  designated	  with	  an	  “h”	  following	  them.	  Genotyping	  primers	  1,	  2,	  and	  3	  are	  from	  
Kono	  et	  al.	  2004.	  	  
 
pair product whereas knockout gene expression resulted in a 220 base pair product.  
Gene Forward Primer Reverse Primer 
S1PR1 CTCCACCGTGCTCCCGCTCTA GGAGATGTTCTTGCGGAAGGTCAGG 
S1PR2 GCGTGGTCACCATCTTCTCC CGTCTGAGGACCAGCAACATC 
S1PR3 CATCGCCTTCCTCATCAGTATCTTC CACAATCACTACGGTCCGCA 
S1PR4 GCACCTTGAGCATAACAGGA CGGGGACAGACTGAGAGAGG 
S1PR5 ACTGCTTAGGACGCCTGGAA CCGCACCTGACAGTAAATCCTT 
Oct4 ACACCTGGCTTCGGATTTCG  GGCGATGTGGCTGATCTGCT 
Nanog GGTTGAAGACTAGCAATGGTCTGA TGCAATGGATGCTGGGATACTC 
Sox2 GCACATGAACGGCTGGAGCAACG TGCTGCGAGTAGGACATGCTGTAGG 
GAPDH CAATGACCCCTTCATTGACC GATCTCGCTCCTGGAAGATG 
Acid Ceramidase TTACCCTTGGGTCCTTGGCCATAA TCTGCCACGATGTTGAAGTAGCCT- 
SK1 TGAGCAGGTCACCAATGAAG TGTGCAGAGACAGCAGGTTC 
SK2 GGAGGAAGCTGTGAAGATGC GCAACAGTGAGCAGTTGAGC 
S1PR1h GAAGGGGGAGAATACGAACA !""###$!##"""$$$#!!# 
S1PR2 h CACCTGGAAAGGCCAGATAA CAGTGCAAGATTCCGTCTCA 
S1PR3 h GCCGACGGAGGAGCCCTTTTTC ATGCTCCCGCAGGGTCTCGTT 
S1PR4 h CCAAGCGCTACATCCTCTTC CAGAGGTTGGAGCCAAAGAC 
Genotypying 1 GCAGTGACAAAAGCTGCCGAATGCTGATG 
Genotyping 2 AGATGGTGACCACGCAGAGCACGTAGTG 
Genotyping 3 TGACCGCTTCCTCGTGCTTTACGGTATCG 
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Proliferation Assays 
 
MSCs were plated in 96 well plates at a concentration of 5,000 cells/well in at least 
triplicate. Absorbance was measured using a Fluostar Optima (BMG labtech) plate reader 
at 490 nm following MTS substrate delivery (Promega) starting the day prior to treatment 
and following treatment. Absorbance was measured 1 hr and 2 hours after addition of 20 
uL of substrate. Proliferation was assessed according to the Incucyte Zoom kinetic 
proliferation assay protocol. Using the microscope contained within the incubator, an 
algorithm was developed to specifically detect both MSC cell number and confluence on 
the plate. Following cell plating in 96-well plates, images were taken and analyzed every 
15 minutes for the duration of the experiment.  Additional proliferation assays were 
conducted using crystal violet staining. Cells were set up and cultured for the indicated 
period of time. At the completion of the experiment cells were fixed in formaldehyde and 
stained with 5 mg/ml crystal violet in PBS. Stained cells were washed with PBS and 
water then the stain lifted using 2% SDS. Absorbance was measured from vortexed 





Two experimental approaches to migration were taken. In the first, 80-120,000 cells/well 
were plated to confluence in 24 well collagen coated plates. Cell scratches were initiated 
following cell attachment using 10-100 uL pipette tips and media changed to remove any 
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detached cells immediately prior to treatment. Scratches were imaged every 6 hours until 
24 hours using a Zeiss axiovert 200 microscope examining at the same field of cells at 
each time point. Scratch distance and percent closure were quantified using Image J. 
Further validation of MSC migration findings was conducted using Incucyte Zoom 
evaluation of migration. Cells were plated to confluence in image locked 96-well plates 
coated with collagen I. Wound delivery was given using the 96 pin wound maker 
equipped with PFTE pin tips creating a 730-750 uM wound width. High definition phase 
contrast images were taken every fifteen minutes with cells identified using MSC specific 
algorithm. Analysis was conducted using Essen Incucyte software to determine scratch 
width and wound confluence. Analysis was conducted using three types of analysis. The 
first is wound width and evaluated the distance between each side of the scratch. The 
second is wound confluence that evaluates the area occupied by the cells as compared to 
initial wound area. The final analysis is relative wound density in which the spatial cell 
density of the wound area is compared to the cell density of unwounded areas. The final 
analysis allows for some compensation for cell proliferation in addition to using time 




Differentiation was induced as directed in chamber slides by the R&D Systems 
Mesenchymal Stem Cell Functional Identification Kit. Cells were plated to confluence at 
30,000 cells per chamber in millicell ez slide 4 chamber slides. Following attachment 
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cells were switched to induction media. Adipogenic supplementation included 
hydrocortisone, isobutylmethylxanthine, and indomethacin and osteogenic supplement 
included dexamethasone, ascorbate-phosphate, proline, pyruvate and recombinant human 
TGFβ3. Concentrations of these agents are proprietary information. Induction media was 
changed every 2-3 days for 14 days for adipogenic media and up to 21 days for 
osteogenic media. Following completion of this time, cells were fixed, permeabilized 
with Triton x-100, and blocked. Osteogenic induction was evaluated by goat anti-mouse 
osteopontin and adipogenic induction was evaluated by goat anti-mouse FABP4. 
Secondary antibody stain to visualize included Alexafluor 555 donkey anti-goat for 
GFP+ cells or Alexafluor 488 donkey anti-goat for non-GFP transgenic cells. Cells were 
co-stained with nuclear stain To-pro-3. Imaging of stained cells was conducted using 
Zeiss LSM 510 META confocal microscope. A minimum of 10 images at 63x 
magnification were taken and cells counted from each image obtained. Differentiation 




Immunoblot analyses of cell lysates were performed as previously described (172) using 
antibodies to detect p-Erk, total Erk, p-Akt (Ser 473), total Akt, Rac 1/2/3, RhoA, RhoB, 
Rho C, CD44, Nanog (Cell Signaling), GAPDH (Santa Cruz Biotechnology sc-32233), 
and P38 (Gift of Dr. K. Kirkwood). Acid ceramidase antibody used for western blotting 
was provided by BD 612302. Whole cell lysates were obtained using RIPA buffer 
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(ThermoScientific, Waltham, MA) and protease inhibitors (Sigma).  25- 50 ug of protein 
quantified by BCA assay was run on a 12.5% polyacrylamide gel before being transferred 
to a nitrocellulose membrane. Blocking of non-specific binding was conducted using 5% 
non-fat milk prior to overnight exposure to primary antibody at 4 degrees Celsius. 
Secondary anti-mouse antibody (Santa Cruz) was used at 1:15,000 and anti-rabbit at 
1:30,000.  Visualization of expression was conducted using Chemoluminescent HRP 
substrate (Fisher).  
 
In vitro co-culture experiments 
 
Tramp C2 cells were seeded at the base of either 6 or 12 well BD transwell plates in high 
glucose DMEM with MSCs seeded to confluence at the top inserts in alpha MEM on the 
plate. For vehicle controls, media with the appropriate vehicle or chemical inhibitor was 
given in the top insert. The next morning, cell adhesion treatment was administered as 
indicated. Cells were harvested for the appropriate analysis described previously for 




Analysis of cell populations was conducted with BD antibodies listed previously during 
cell sorting. Further evaluation of cell populations was conducted by flow Cytometry 
using either the BD LSR Fortessa or BD FACS Calibur. Staining for cell trace violet 
	   50	  
(Life Technologies) was conducted according to manufacturer’s instructions with a 5 
minute 37 degrees Celsius staining time for the cell suspension. Aldefluor expression 
analysis was conducted according to manufacturer’s instructions (Stem Cell).  Briefly 
cells are suspended and substrate added for 30 to 60 minutes with a negative control 
provided by the DEAB inhibitor. Visualization of Aldefluor expression was conducted 
using flow cytometry on the GFP channel of a BD Fortessa flow cytometer. Cell cycle 
analysis was conducted on treated cells trypsinized to a single cell suspension following 
treatment then fixed with cold ethanol. Cells were stained with 40 ug/ml propidium 




RNA was analyzed for RNA copy number using Nanostring analysis conducted by 
murine code set -1 developed my the Medical University of South Carolina Center for 
Oral Health Research (COHR). 100 ng of RNA isolated using RNEASY from primary 
murine MSCs and quantified by spectrophotometry was provided to the COHR for 
analysis. Briefly nanostring technology begins with an initial hybrization phase using 
mRNA probes followed by a purification and immobilization phase. Following 
immobilization, fluorescent barcodes associated with each probe can be identified and 
individual mRNA levels of each product counted. For data analysis, data was normalized 
to positive controls using nSolver Analysis software with background reduced to 
accurately depict RNA copy number.  
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Tumor initiation and in vivo tumor analysis 
 
Tumors were initiated in 6 to 8 week old C57/Bl6 mice using TRAMP C-2 cells by 
subcutaneous injection 2 million cells in the right flank of mice delivered in 200 μL of 
1:1 matrigel:phosphate buffered saline. Tumor volume and animal weight were 
monitored three times a week. Treatment with 3 mg/kg of JTE013 was given 
intraperitoneally as two injections 72 hours apart. These injections were delivered on day 
30 and day 33 following tumor initiation. JTE013 was dissolved in ethanol prior to 
dilution to delivery dose in sterile PBS. A comparable solution was delivered for the 
vehicle treatment group. Animals were sacrificed when tumor volumes reached 1500 
mm2. All animals were sacrificed at the same time for consistency of tumor digestion and 
flow cytometry analysis. Following extraction of tumors, tumors were digested using 
Collagenase I overnight, digested cells pelleted, and subsequently analyzed by flow 
cytometry. Flow cytometry analysis consisted of evaluation for expression of CD45, 
Aldefluor, and CD133. Desired cells were CD45 negative cell based on prior analysis of 
TRAMP-C2 expression.  
 
Statistical Analysis 
Unless otherwise indicated, data represent mean + standard error for 3 independent 
experiments and were tested for statistical significance by one-sided student t-test. * 
indicates p<0.05, ** indicates p<0.01, and *** indicates p<0.001. 
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RESULTS	  AND	  DISCUSSION	  
	  
Chapter	  1:	  S1PR2	  signaling	  in	  human	  immortalized	  hTERT	  MSCs	  
	  
Based	  on	  the	  available	  information	  suggesting	  a	  role	  of	  S1P	  in	  stem	  cells,	  we	  sought	  
to	  initially	  examine	  the	  role	  of	  S1P	  and	  S1P	  receptor	  signaling	  in	  MSCs.	  To	  initiate	  
preliminary	  evaluation	  of	  this	  interaction,	  we	  employed	  the	  use	  of	  hTERT	  
immortalized	  human	  MSCs.	  These	  cells	  were	  a	  gift	  of	  Dr.	  Frank	  Marini	  out	  of	  Wake	  
Forest	  University.	  HTERT	  MSCs	  express	  markers	  characteristic	  human	  MSCs	  with	  
demonstrated	  retention	  of	  differentiation	  capacity	  and	  colony	  formation	  (173).	  
These	  markers	  include	  positive	  expression	  of	  CD19,	  CD73,	  CD44,	  CD90,	  CD105,	  
CD105,	  CD166	  and	  negative	  expression	  of	  CD14,	  CD19,	  CD34,	  CD45.	  HTERT	  MSCs	  
Figure	  5:	  MSC	  receptor	  expression	  in	  hTERT	  immortalized	  
MSCs:	  S1PR1-­4	  are	  shown	  are	  evaluated	  in	  this	  experiment	  
with	  magnitude	  of	  expression	  based	  on	  relative	  mRNA	  
expression.	  Relative	  mRNA	  expression	  was	  calculated	  as	  
compared	  to	  GAPDH	  expression	  by	  the	  formula	  provided	  in	  
the	  materials	  and	  methods	  section.	  Image	  shown	  is	  a	  
representative	  experiment	  from	  two	  independent	  
experiments.	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have	  an	  extended	  lifespan	  with	  an	  increased	  number	  of	  passages	  as	  compared	  to	  
non-­‐immortalized	  MSCs.	  When	  the	  cells	  are	  injected	  subcutaneously	  into	  mice,	  no	  
tumors	  formed	  indicating	  that	  the	  cells	  were	  immortalized	  but	  not	  transformed.	  	  
Comparable	  to	  MSC	  populations	  in	  mice	  shown	  previously,	  hTERT	  MSCs	  express	  
S1PR	  1-­‐4	  with	  the	  highest	  expression	  of	  S1PR1	  and	  S1PR2	  as	  shown	  in	  Figure	  4.	  	  
	  
Treatment	  of	  MSCs	  with	  increasing	  doses	  of	  S1P	  resulted	  in	  decreased	  cell	  
proliferation	  as	  assessed	  by	  cell	  number	  as	  shown	  in	  Figure	  5a.	  	  Consistent	  with	  
these	  results	  we	  found	  that	  alterations	  in	  the	  cell	  cycle	  distribution	  of	  MSCs	  with	  a	  
bias	  toward	  an	  increased	  percent	  of	  S	  phase	  cells	  and	  diminished	  Go/G1	  cells	  as	  
shown	  in	  Figure	  5b.	  For	  evaluation	  of	  
	  
Figure	  6:	  Impact	  of	  S1P	  treatment	  on	  MSC	  proliferation	  (a)	  Evaluation	  of	  cell	  proliferation	  by	  cell	  counts	  
at	  the	  indicated	  days.	  S1P	  concentrations	  between	  0	  nM	  and	  1000	  nM	  were	  evaluated	  with	  the	  values	  
reported	  in	  increments	  of	  105	  cells	  (b)	  Cell	  cycle	  analysis	  of	  MSCs	  following	  S1P	  treatment	  in	  hTERT	  
MSCs.	  The	  percent	  of	  cells	  in	  each	  phase	  of	  the	  cell	  cycle	  is	  reported	  for	  S1P	  concentrations	  between	  0-­
1000	  nM.	  Experiment	  shown	  is	  representative	  of	  two	  independent	  experiments.	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proliferation,	  cells	  were	  plated	  in	  6	  well	  plates	  and	  allowed	  to	  attach	  in	  standard	  
and	  lifted	  at	  the	  indicated	  time	  points	  for	  counting	  with	  a	  Millipore	  sceptor.	  The	  
Sceptor	  has	  the	  capacity	  to	  calculate	  cell	  number	  and	  size	  with	  error	  of	  less	  than	  5%	  
when	  used	  properly.	  Cell	  cycle	  analysis	  was	  conducted	  with	  cells	  plated	  and	  treated	  
overnight	  with	  S1P	  at	  the	  indicated	  concentrations	  before	  trypsinization	  to	  a	  single	  
cell	  suspension.	  These	  cells	  were	  fixed	  in	  cold	  ethanol,	  stained	  with	  propidium	  
iodine,	  and	  analyzed	  by	  flow	  cytometry.	  Following	  fluorophore	  detection,	  cell	  cycle	  
Figure	  7:	  Impact	  of	  S1P	  treatment	  on	  MSCs	  and	  S1P	  receptor	  distribution.	  a)	  Western	  blot	  analysis	  of	  
S1P	  treated	  hTERT	  MSCs	  after	  2	  hour	  treatment	  with	  S1P	  at	  the	  indicated	  doses.	  S1P	  concentrations	  
between	  0	  nM	  and	  1000	  nM	  were	  evaluated.	  (b)	  Relative	  mRNA	  expression	  of	  hTert	  MSCs	  for	  S1PR1,	  
R2,	  and	  R3	  following	  2	  hour	  treatment	  with	  200	  nM	  S1P	  in	  PBS.	  (c)	  Transcriptional	  expression	  of	  
S1PR1,	  R2,	  and	  R3	  following	  b.i.d	  S1P	  treatment	  for	  10	  days.	  S1P	  was	  prepared	  freshly	  for	  each	  
treatment.	  Statistical	  analysis	  using	  a	  Student’s	  T-­test	  demonstrate	  that	  S1PR1	  has	  significantly	  
decreased	  expression	  for	  S1PR1	  with	  p<0.01	  	  for	  S1PR3	  for	  p<0.05.	  n>	  3	  for	  all	  graphs	  shown	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distribution	  was	  determined	  by	  Modfit	  analysis.	  S1P	  treatment	  in	  MSCs	  therefore	  
decreases	  MSC	  proliferation	  and	  impacts	  cell	  cycle	  distribution.	  	  	  
Consistent	  with	  the	  reduction	  in	  MSC	  proliferation	  observed	  following	  S1P	  
treatment	  there	  was	  a	  reduction	  in	  MAPK	  activation	  following	  S1P	  treatment.	  
Treatment	  with	  increasing	  doses	  of	  S1P	  resulted	  in	  diminished	  expression	  of	  
phosphorylated	  Erk	  as	  shown	  in	  Figure	  6.	  Changes	  in	  the	  Akt	  activation	  relative	  to	  
actin	  expression	  were	  only	  observed	  at	  the	  highest	  concentrations	  of	  S1P	  treatment.	  
Changes	  in	  MAPK	  activation	  appear	  to	  parallel	  proliferative	  changes	  following	  S1P	  
treatment	  as	  shown	  in	  Figure	  4.	  We	  sought	  to	  investigate	  the	  changes	  in	  the	  S1P	  
receptors	  following	  S1P	  stimulation	  in	  MSCs.	  	  
	  	  
To	  accomplish	  this,	  S1PR2	  was	  evaluated	  following	  realtime	  quantitative	  PCR.	  
Treatment	  with	  200	  nM	  of	  S1P	  for	  resulted	  in	  a	  trend	  toward	  increased	  expression	  
of	  S1PR1-­‐R3.	  When	  S1P	  treatment	  was	  given	  twice	  daily	  for	  ten	  days,	  a	  significant	  
decrease	  in	  S1PR1	  and	  R3	  was	  observed.	  In	  contrast	  to	  these	  two	  receptors,	  the	  
mRNA	  transcript	  levels	  of	  S1PR2	  were	  maintained.	  In	  combination,	  this	  suggests	  
that	  following	  treatment	  with	  S1P	  mRNA	  levels	  of	  the	  S1P	  receptors	  increase	  
acutely	  followed	  by	  a	  subsequent	  decline	  in	  mRNA	  transcript	  levels	  of	  S1R1	  and	  
S1PR3	  suggestive	  of	  receptor	  internalization.	  Receptor	  internalization	  has	  been	  best	  
characterized	  for	  S1PR1	  although	  it	  has	  been	  demonstrated	  for	  S1PR2	  as	  well	  (174-­‐
177).	  Long	  term	  treatment	  with	  S1P	  resulting	  in	  decreased	  receptor	  expression	  is	  
consistent	  with	  the	  decreased	  proliferation	  observed	  following	  5	  days	  of	  b.i.d	  S1P	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treatment	  whereas	  short	  term	  increases	  in	  transcriptional	  RNA	  expression	  for	  the	  
S1PR	  is	  consistent	  with	  the	  increased	  number	  of	  cycling	  cells	  following	  overnight	  
S1P	  treatment.	  	  Figure	  7	  shows	  the	  images	  of	  hTERT	  MSCs	  treated	  with	  S1P	  at	  the	  
indicated	  concentrations	  b.i.d	  for	  ten	  days.	  At	  the	  higher	  concentrations	  of	  S1P,	  a	  
population	  of	  cells	  indicated	  by	  arrows	  results	  that	  has	  a	  distinct	  morphology	  
separate	  from	  that	  of	  the	  remainder	  of	  the	  MSC	  population.	  This	  morphology	  
appears	  more	  characteristic	  of	  a	  differentiated	  cell.	  This	  suggests	  that	  S1P	  may	  
promote	  MSC	  differentiation	  although	  further	  characterization	  of	  the	  cells	  with	  this	  
morphology	  needs	  to	  be	  addressed.	  The	  retention	  of	  S1PR2	  expression	  following	  
long	  term	  S1P	  treatment	  suggests	  that	  S1PR2	  may	  have	  a	  critical	  function	  in	  MSC	  
maintenance.	  	  Maintenance	  of	  MSCs	  in	  this	  context	  is	  defined	  as	  the	  capacity	  for	  
undifferentiated	  proliferation	  without	  a	  loss	  of	  differentiation	  capacity.	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Figure	  8:	  Images	  of	  hTERT	  MSCs	  treated	  with	  increasing	  concentrations	  of	  S1P.	  Cells	  were	  treated	  with	  	  
0-­5000	  nM	  S1P	  b.id	  for	  10	  days.	  	  Arrows	  in	  the	  higher	  treatment	  groups	  indicate	  cells	  with	  an	  increased	  
level	  of	  differentiation.	  Pictures	  were	  taken	  using	  a	  Zeiss	  Axiovert	  cell	  culture	  microscope	  using	  the	  10x	  
lens.	  	  An	  increased	  number	  of	  differentiated	  cells	  were	  observed	  with	  increasing	  concentration	  of	  S1P	  in	  
all	  fields	  examined.	  Representative	  images	  are	  shown	  for	  3	  or	  more	  independently	  treated	  cells.	  
	  
Based	  on	  our	  previous	  findings,	  we	  sought	  to	  further	  explore	  the	  role	  of	  S1PR2	  
through	  the	  use	  of	  JTE013	  as	  a	  chemical	  antagonist	  of	  S1PR2.	  Due	  to	  the	  presence	  of	  
S1P	  in	  the	  serum,	  S1P	  stimulation	  was	  not	  provided	  in	  future	  experiments	  in	  which	  
JTE013	  treatment	  was	  given.	  	  Serum	  levels	  of	  S1P	  are	  shown	  in	  Figure	  8	  as	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evaluated	  by	  the	  Lipidomics	  Analytic	  Core	  of	  the	  Medical	  University	  of	  South	  
Carolina.	  Alpha-­‐MEM	  media	  containing	  5	  or	  10	  percent	  FBS	  serum	  contained	  over	  8	  
pmol/ml	  of	  S1P.	  The	  same	  lot	  of	  FBS	  was	  used	  throughout	  the	  experiments	  
presented	  in	  this	  dissertation.	  	  	  
	  
	  
Figure	  9:	  Lipidomics	  analysis	  of	  media	  concentration	  of	  S1P	  with	  different	  serum	  concentrations.	  S1P	  
concentration	  was	  evaluated	  by	  the	  Lipidomics	  Core	  as	  described	  in	  the	  materials	  and	  methods	  section.	  
Percentages	  reflect	  the	  percent	  of	  Atlas	  Biologicals	  Tet	  free	  serum	  in	  Invitrogen	  Alpha-­MEM	  cell	  culture	  
media.	  Consistency	  between	  S1P	  levels	  throughout	  evaluation	  was	  provided	  by	  consistency	  of	  batch	  
number	  for	  Serum.	  	  
	  
Following	  the	  identification	  of	  basal	  S1P	  as	  important	  for	  MSC	  maintenance,	  we	  
sought	  to	  investigate	  the	  role	  of	  S1PR2	  within	  MSCs	  using	  JTE013.	  Treatment	  of	  
hTERT	  MSCs	  with	  1	  uM	  JTE	  resulted	  in	  increased	  MSC	  migration	  across	  a	  scratch	  
wound	  and	  increased	  clonogenicity	  as	  shown	  in	  Figure	  9.	  For	  scratch	  wound	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analysis,	  cells	  were	  plated	  in	  6-­‐well	  plates	  to	  confluence.	  A	  scratch	  was	  made	  with	  a	  
1000	  μL	  pipette	  tip	  and	  treatment	  of	  JTE013	  or	  DMSO	  vehicle	  followed.	  Images	  
below	  represent	  migration	  24	  hours	  after	  initiation	  of	  the	  scratch	  wound.	  For	  the	  
clonogenic	  assay,	  treatment	  with	  1	  μM	  JTE013	  was	  initiated	  at	  the	  time	  of	  cell	  
plating.	  Colonies	  were	  fixed	  and	  stained	  10-­‐14	  days	  following	  treatment	  when	  
colonies	  were	  grossly	  visible.	  	  Colonies	  were	  counted	  using	  a	  dissecting	  microscope	  
when	  plates	  contained	  between	  10-­‐75	  colonies.	  Colony	  counts	  were	  normalized	  to	  
both	  the	  cell	  plating	  number	  and	  the	  untreated	  control.	  	  
	  
Figure	  10:	  Effect	  of	  JTE013	  treatment	  on	  hTERT	  MSCs	  (a)	  Scratch	  assay	  evaluation	  of	  hTERT	  cells	  treated	  
with	  either	  vehicle	  or	  1	  μM	  JTE013	  for	  18	  hours.	  Cells	  were	  stained	  with	  crystal	  violet	  for	  easier	  
identification	  (b)	  Clonogenic	  evaluation	  of	  JTE013	  treated	  hTERT	  MSCs.	  Error	  bars	  represent	  mean	  +	  
SEM	  for	  each	  condition.	  *	  indicates	  p<0.05	  from	  Student’s	  T-­test.	  n>3.	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The	  role	  of	  S1PR2	  is	  critical	  in	  the	  maintenance	  of	  hTERT	  MSCs	  with	  S1PR2	  
functioning	  as	  inhibitory	  to	  cell	  migration	  and	  clonogenic	  growth.	  	  
	  
Further	  evidence	  of	  the	  role	  of	  sphingolipids	  in	  the	  maintenance	  MSC	  self-­‐renewal	  
and	  proliferation	  was	  obtained	  through	  evaluation	  of	  the	  role	  of	  hypoxia	  on	  MSC	  
proliferation.	  	  It	  has	  previously	  been	  demonstrated	  that	  hypoxia	  promotes	  the	  MSC	  
self-­‐renewal	  as	  evidenced	  by	  the	  increased	  undifferentiated	  cell	  proliferation	  of	  
MSCs	  as	  compared	  to	  standard	  cell	  culture	  controls	  (49,	  178).	  Hypoxia	  was	  
generated	  by	  introduction	  of	  cell	  culture	  plates	  into	  a	  vacuum-­‐sealed	  chamber	  
perfused	  with	  a	  gas	  mixture	  containing	  2%	  oxygen	  in	  a	  standard	  cell	  culture	  
incubator.	  Comparable	  to	  previously	  published	  findings,	  we	  observed	  increased	  cell	  
proliferation	  of	  MSCs	  under	  low	  oxygen	  conditions.	  The	  low	  oxygen	  conditions	  
tested	  approximate	  the	  oxygen	  concentration	  of	  the	  bone	  marrow,	  which	  has	  been	  
reported	  to	  be	  at	  1-­‐7%	  oxygen.	  Increased	  proliferation	  was	  observed	  in	  hTERT	  
MSCs	  as	  evaluated	  by	  MTS	  assay	  as	  shown	  in	  Figure	  10a	  with	  fold	  change	  evaluated	  
as	  compared	  to	  when	  the	  cells	  were	  introduced	  to	  the	  hypoxic	  chamber.	  Due	  to	  
concerns	  regarding	  the	  potential	  of	  low	  oxygen	  to	  impact	  the	  mitochondria	  of	  the	  
MSCs	  and	  therefore	  the	  MTS	  assay,	  we	  evaluated	  proliferation	  using	  crystal	  violet	  
staining	  with	  staining	  evaluation	  assessed	  by	  absorbance	  at	  OD620.	  Cells	  were	  
washed,	  fixed	  in	  5%	  formaldehyde,	  and	  stained	  with	  crystal	  violet.	  Following	  
staining	  and	  washing	  of	  the	  wells	  to	  remove	  excess	  crystal	  violet,	  a	  2%	  SDS	  solution	  
was	  added	  to	  each	  well	  and	  cells	  placed	  on	  a	  shaker	  at	  room	  temperature	  for	  30	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minutes.	  Absorbance	  was	  measured	  by	  triplicate	  samples	  of	  the	  solution.	  By	  crystal	  
violet	  proliferation	  analysis,	  hypoxic	  cells	  demonstrate	  increased	  proliferation	  as	  
compared	  to	  normoxic	  controls.	  Using	  both	  methods	  for	  proliferation	  analysis,	  
increased	  MSC	  proliferation	  was	  observed	  with	  inhibition	  of	  S1PR2.	  This	  change	  
was	  accompanied	  by	  increases	  in	  the	  expression	  of	  the	  13	  kd	  a	  band	  of	  acid	  
ceramidase	  (AC)	  as	  shown	  in	  figure	  10c.	  Increased	  AC	  results	  in	  increased	  
metabolism	  of	  ceramide	  to	  sphingosine	  and	  ultimately
	  
Figure	  11:	  Evaluation	  of	  hTERT	  MSCs	  under	  low	  oxygen	  conditions	  	  (a)	  MTS	  proliferation	  assay	  of	  hTERT	  
MSCs	  cultures	  in	  standard	  cell	  culture	  conditions	  at	  20%	  oxygen	  and	  under	  2%	  oxygen	  conditions.	  Blue	  
lines	  indicated	  standard	  cell	  culture	  conditions	  and	  red	  lines	  indicated	  	  low	  oxygen	  conditions	  (b)	  
Crystal	  violet	  proliferation	  analysis	  of	  Day	  9.	  Cells	  were	  cultured	  under	  the	  indicated	  conditions	  and	  
cells	  were	  fixed,	  stained,	  lifted,	  and	  absorbance	  measured	  to	  evaluate	  cell	  concentrations	  (c)	  Western	  
blot	  analysis	  of	  	  the	  active	  band	  of	  AC	  	  Lane	  1	  represents	  the	  normoxic	  control	  and	  the	  second	  represents	  
hypoxic	  conditions	  (d)	  Scratch	  assay	  of	  crystal	  violet	  stained	  cells	  under	  both	  normoxic	  controls	  and	  
under	  hypoxic	  conditions	  at	  18	  hours.	  	  Representative	  images	  are	  shown	  for	  a	  minimum	  of	  3	  
experiments.	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increased	  S1P	  generation.	  	  Increased	  MSC	  migration	  was	  observed	  in	  cells	  cultured	  
under	  low	  oxygen	  conditions	  as	  compared	  to	  those	  under	  standard	  cell	  culture	  
oxygen	  conditions	  as	  shown	  in	  figure	  10d.	  	  
	  
	  
Our	  initial	  evaluation	  of	  the	  effect	  of	  S1P	  in	  hTERT	  MSCs	  revealed	  that	  S1P	  
treatment	  results	  in	  decreased	  cell	  proliferation	  with	  a	  corresponding	  decrease	  in	  
phosphorylation	  of	  Erk	  that	  likely	  impacts	  the	  proliferative	  capacity	  of	  these	  cells.	  
Similar	  to	  our	  evaluation	  of	  primary	  murine	  MSCs,	  hTERT	  MSCs	  have	  high	  S1PR2	  
expression	  that	  increases	  in	  transcriptional	  expression	  with	  S1P	  treatment.	  Unlike	  
receptors	  1	  and	  3	  that	  decrease	  in	  expression	  following	  long-­‐term	  treatment,	  S1PR2	  
expression	  is	  maintained	  suggesting	  that	  it	  has	  a	  critical	  function	  to	  the	  maintenance	  
of	  an	  MSC	  population.	  Inhibition	  of	  S1PR2	  by	  treatment	  with	  JTE013	  results	  in	  
increased	  MSC	  migration	  and	  clonogenicity.	  Based	  on	  this	  evaluation,	  we	  conclude	  
that	  S1P	  is	  critical	  to	  impacting	  the	  function	  of	  MSCs	  and	  furthermore	  that	  S1PR2	  
expression	  and	  function	  is	  critical	  to	  the	  maintenance	  of	  MSC	  populations.	  Further	  
evaluation	  of	  these	  criteria	  and	  evaluation	  of	  their	  impact	  on	  MSC	  self-­‐renewal	  will	  
need	  to	  be	  conducted	  in	  primary	  cells	  as	  the	  immortalization	  of	  cells	  can	  impact	  the	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Chapter	  2:	  MSC	  isolation	  and	  characterization	  
	  
The	  previous	  chapter	  addressed	  the	  impact	  of	  S1P	  and	  S1P	  receptor	  signaling	  in	  
human	  immortalized	  MSCs.	  In	  this	  chapter,	  the	  data	  presented	  demonstrates	  
changes	  in	  cell	  proliferation	  and	  MAPK	  activation	  with	  S1P	  treatment	  and	  increased	  
clonogenicity	  and	  migration	  with	  inhibition	  of	  S1PR2.	  These	  findings	  suggest	  a	  role	  
of	  S1P	  and	  S1P2	  on	  the	  propagation	  of	  MSCs.	  	  For	  further	  evaluation	  of	  these	  
findings	  and	  to	  better	  assess	  the	  role	  of	  S1PRs	  on	  MSC	  stem	  cell	  characteristics	  a	  
switch	  was	  made	  to	  primary	  murine	  MSCs.	  Cells	  were	  isolated	  in	  accordance	  with	  
the	  guidelines	  established	  by	  the	  stem	  cell	  community	  for	  MSCs.	  The	  criteria	  for	  
evaluation	  are	  discussed	  further	  in	  the	  proceeding	  paragraphs.	  	  
	  
The	  Tissue	  Stem	  Cell	  Committee	  of	  the	  International	  Society	  for	  cell	  therapy	  in	  2006	  
proposed	  a	  consensus	  definition	  for	  human	  MSCs.	  This	  definition	  sets	  forth	  the	  
central	  criteria	  defining	  MSCs.	  These	  criteria	  include	  plastic	  adherence,	  colony	  
formation,	  a	  characteristic	  surface	  marker	  expression,	  and	  multipotency.	  The	  
characteristic	  surface	  marker	  composition	  includes	  cells	  lacking	  expression	  of	  CD45,	  
CD34,	  CD14	  and	  positively	  expressing	  CD105,	  CD90,	  and	  CD73	  (25,	  179).	  This	  
surface	  marker	  definition	  eliminates	  hematopoietic	  and	  immune	  cell	  precursors.	  
Recent	  work	  conducted	  after	  the	  release	  of	  this	  report	  a	  population	  of	  Sca-­‐1	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expressing	  cells	  as	  a	  subpopulation	  of	  these	  human	  cells	  demonstrating	  enhanced	  
clonogenicity	  as	  compared	  to	  cells	  lacking	  expression.	  	  
	  
Classical	  criteria	  used	  to	  demonstrate	  multipotency	  in	  MSCs	  includes	  differentiation	  
into	  adipogenic,	  chondrogenic,	  osteogenic	  lineages.	  Although	  differentiation	  into	  
other	  lineages	  has	  been	  reported,	  there	  remains	  some	  controversy	  on	  the	  
functionality	  of	  the	  cells	  that	  are	  produced	  with	  different	  degrees	  of	  acceptance	  
depending	  the	  quality	  of	  functional	  performance	  markers	  that	  has	  been	  presented.	  
The	  scientific	  community	  is	  increasingly	  demanding	  not	  only	  marker	  expression	  but	  
also	  functional	  studies	  to	  correspond	  with	  differentiation	  reports	  when	  new	  
lineages	  for	  differentiation	  are	  being	  proposed.	  	  Adipogenic	  lineages	  can	  be	  
evaluated	  by	  immunofluorescent	  staining	  with	  Fatty	  acid	  binding	  protein	  4	  or	  by	  
staining	  with	  Oil	  Red	  O.	  Osteopontin	  staining	  can	  be	  used	  to	  evaluate	  osteogenic	  
differentiation	  or	  this	  can	  be	  accomplished	  by	  alizirin	  red	  staining.	  Collagen	  II	  
staining	  can	  be	  used	  to	  evaluate	  chondrocytic	  differentiation	  by	  immuofluorescence	  
or	  more	  classically	  Alcain	  blue	  staining	  has	  been	  used.	  	  The	  criteria	  for	  evaluation	  of	  
human	  MSCs	  is	  shown	  in	  Figure	  12	  showing	  the	  differentiation	  capacity,	  surface	  
marker	  expression,	  and	  minimum	  criteria	  as	  established	  in	  2006.	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Figure	  12:	  Criteria	  for	  the	  identification	  and	  characterization	  of	  mesenchymal	  stem	  cells.	  Image	  partially	  
derived	  from	  www.stemcell.org.	  	  	  
	  
Although	  this	  definition	  for	  MSCs	  derived	  from	  human	  sources	  has	  been	  well	  
established,	  there	  remains	  ongoing	  debate	  and	  controversy	  on	  isolation	  protocols	  
and	  characterizations	  for	  murine	  derived	  MSCs.	  Increased	  variation	  in	  marker	  
expression	  is	  observed	  in	  murine	  derived	  MSCs	  isolated	  from	  different	  sources	  and	  
strains	  of	  mice	  (180).	  Murine	  strains	  have	  been	  shown	  to	  differ	  in	  their	  optimal	  
media,	  proliferation	  rate,	  and	  expression	  of	  certain	  surface	  markers.	  Part	  of	  the	  
variation	  between	  MSC	  populations	  results	  from	  strain	  differences,	  however,	  
additional	  variation	  can	  result	  from	  different	  isolation	  strategies.	  MSC	  isolation	  
protocols	  from	  bone	  marrow	  vary	  in	  the	  degree	  of	  stringency	  of	  cell	  isolation.	  The	  
most	  basic	  isolation	  protocols	  have	  used	  selection	  based	  on	  plastic	  adherence	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whereas	  more	  selective	  protocols	  include	  mechanisms	  of	  cell	  sorting	  either	  through	  
magnetic	  bead	  selection	  and	  enrichment	  or	  flow	  cytometric	  sorting	  (170,	  181-­‐185).	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Based	  on	  these	  existing	  isolation	  protocols,	  we	  present	  a	  cell	  isolation	  scheme	  
utilizing	  a	  flush	  and	  crush	  method	  of	  bone	  marrow	  isolation	  followed	  by	  a	  
collagenase	  digestion.	  MSCs	  were	  selected	  from	  passage	  four	  bone	  marrow	  
preparations	  based	  on	  their	  selective	  plastic	  adherence.	  Based	  on	  insufficient	  cell	  
purity	  of	  this	  population,	  cell	  sorting	  is	  conducted	  for	  two	  positive	  and	  two	  negative	  
markers	  as	  described	  in	  Table	  2.	  Macrophages	  and	  hematopoietic	  lineage	  cells	  are	  
excluded	  by	  eliminating	  cells	  expressing	  CD45	  and	  CD11b.	  	  Cells	  expressing	  CD44+	  
and	  CD73+	  cells	  were	  positively	  selected.	  Further	  evaluation	  of	  Sca-­‐1+	  cells	  is	  
conducted	  and	  found	  to	  be	  positive	  given	  the	  gating	  strategy	  previously	  described.	  
Figure	  13	  demonstrates	  this	  cell	  isolation	  strategy.	  The	  impact	  of	  cell	  sorting	  is	  
shown	  with	  a	  more	  heterogeneous	  cell	  population	  in	  Figure	  13a	  as	  compared	  to	  a	  
more	  homogenous	  cell	  population	  shown	  in	  Figure	  13c.	  	  The	  appearance	  of	  these	  
cells	  is	  shown	  in	  Figure	  13.	  This	  cell	  isolation	  strategy	  results	  in	  selection	  for	  
elongated	  spindle	  shaped	  fibroblast	  cells	  characteristic	  of	  an	  MSC	  population.	  	  Less	  
than	  20%	  of	  the	  cells	  enriched	  for	  an	  MSC	  population	  using	  plastic	  adherence	  are	  








Table	  2:	  Murine	  MSC	  marker	  profile.	  Positive	  and	  negative	  markers	  of	  MSCS	  are	  indicated.	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Figure	  13:	  MSC	  isolation	  scheme	  (A)	  indicates	  the	  initial	  harvesting	  phase	  for	  the	  cells	  from	  the	  murine	  
bones	  and	  the	  resulting	  heterogeneous	  population	  of	  adherent	  cells	  from	  which	  it	  was	  derived.	  
Following	  initial	  selection	  by	  adherence,	  cells	  were	  sorted	  as	  shown	  in	  panel	  (B)	  using	  the	  markers	  
shown	  in	  table	  1.	  Sorted	  cells	  are	  shown	  in	  (C).	  This	  represents	  a	  more	  homogenous	  spindle-­like	  
population	  of	  cells	  that	  can	  subsequently	  be	  used	  for	  both	  in	  vitro	  and	  in	  vivo	  experiments.	  	  
	  
Following	  cell	  sorting,	  MSCs	  are	  cultured	  in	  vitro	  for	  24	  to	  48	  hours	  to	  allow	  cells	  to	  
recover	  from	  the	  cell	  sorting	  process.	  Many	  of	  the	  resulting	  cells	  from	  the	  sort	  are	  
unable	  to	  survive	  the	  stress	  of	  the	  cell	  sorting	  process.	  These	  cells	  do	  not	  attach	  and	  
are	  washed	  from	  the	  plate	  using	  PBS	  for	  trypsinization	  of	  the	  remained	  of	  the	  cells.	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The	  sorted	  cells	  are	  then	  further	  evaluated	  for	  differentiation	  ability	  to	  ensure	  that	  
an	  appropriately	  multipotent	  population	  of	  cells	  has	  been	  identified.	  	  
	  
Differentiation	  of	  the	  isolated	  MSC	  population	  into	  adipogenic	  and	  osteogenic	  
lineages.	  was	  evaluated.	  Differentiation	  assays	  were	  conducted	  in	  accordance	  with	  
the	  R&D	  Mouse	  Mesenchymal	  Stem	  Cell	  Functional	  Identification	  manufacturers	  
instructions.	  Cells	  are	  plated	  at	  a	  concentration	  of	  30,000	  cells	  per	  well	  in	  4-­‐well	  
Millicell	  chamber	  slides.	  	  Following	  cell	  adherence	  overnight,	  cell	  culture	  media	  was	  
changed	  to	  induction	  media.	  Media	  was	  subsequently	  changed	  every	  3	  days	  for	  14	  
days	  for	  adipogenic	  differentiation	  and	  21	  days	  for	  osteogenic	  differentiation.	  
Adipogenic	  media	  is	  composed	  of	  invitrogen	  αMEM	  with	  Tet-­‐free	  FBS	  and	  penstrep.	  
Additives	  to	  the	  media	  for	  the	  promotion	  of	  differentiation	  include	  hydrocortisone,	  
isobutylmethylxanthine,	  and	  indomethacin.	  Osteogenic	  differentiation	  media	  
contained	  the	  additives	  dexamethasone,	  ascorbate-­‐phosphate,	  proline,	  pyruvate,	  
and	  recombinant	  human	  TGFβ3	  to	  promote	  differentiation.	  After	  induction	  for	  the	  
allotted	  time,	  cells	  were	  fixed,	  permeabilized	  and	  stained	  for	  immunofluorescent	  
evaluation	  of	  differentiation	  using	  osteopontin	  and	  Fatty	  acid	  binding	  protein	  4.	  
Secondary	  antibodies	  for	  immunofluorescent	  staining	  included	  donkey	  anti-­‐goat	  
Alexafluor	  566	  or	  488.	  Cells	  were	  counterstained	  for	  identification	  of	  nuclei	  prior	  to	  
visualization	  by	  confocal	  microscopy.	  MSCs	  under	  these	  induction	  conditions	  
demonstrated	  differentiation	  into	  adipogenic	  and	  osteogenic	  lineages	  as	  compared	  
to	  uninduced	  control.	  Successful	  differentiation	  into	  these	  lineages	  supports	  the	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conclusion	  of	  a	  successful	  MSC	  isolation	  procedure.	  Differentiation	  is	  shown	  in	  
Figure	  14	  below.	  	  Based	  on	  the	  data	  presented	  thus	  far,	  we	  assert	  that	  we	  have	  
successfully	  isolated	  an	  MSC	  population.	  Differentiation	  into	  chondrogenic	  lineages	  
was	  investigated,	  however	  due	  to	  difficulty	  with	  cell	  pellet	  maintenance	  and	  in	  
consultation	  with	  the	  laboratory	  of	  Dr.	  Frank	  Marini,	  an	  expert	  in	  the	  MSC	  field,	  we	  
opted	  against	  further	  evaluation	  of	  chondrogenic	  differentiation.	  Evaluation	  of	  MSCs	  
72-­‐96	  hours	  following	  sorting	  indicates	  that	  11%	  of	  cells	  retain	  CD45+	  expression	  
the	  abundant	  majority	  of	  which	  positively	  co-­‐stain	  for	  CD11b	  indicating	  that	  
removal	  of	  the	  contaminating	  macrophage	  population	  is	  largely	  effectively	  even	  
when	  examining	  extended	  time	  point	  analysis	  following	  JTE013	  treatment.	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Figure	  14:	  Evaluation	  of	  MSC	  functional	  identity	  by	  immunofluorescent	  staining.	  Evaluation	  of	  
adipogenic	  staining	  was	  conducted	  by	  FABP4	  expression	  and	  osteogenic	  differentiation	  by	  osteopontin	  
staining	  as	  shown	  by	  the	  staining	  in	  red.	  Nuclear	  staining	  was	  conducted	  using	  Topro-­1	  and	  is	  shown	  in	  
blue.The	  top	  image	  indicates	  cells	  cultured	  with	  induction	  media	  and	  the	  bottom	  images	  represent	  cells	  
cultures	  in	  standard	  cell	  culture	  media.	  	  
	  
Some	  of	  the	  controversy	  regarding	  the	  impact	  of	  S1P	  stimulation	  on	  different	  cell	  
populations	  stems	  from	  variable	  S1P	  receptor	  expression	  and	  corresponding	  
downstream	  signaling.	  All	  five	  S1P	  receptors	  are	  highly	  sensitive	  to	  S1P	  stimulation	  
Kd	  values	  in	  the	  low	  nanomolar	  range.	  Current	  research	  does	  not	  appear	  to	  suggest	  
that	  S1P	  concentration	  differentially	  favors	  certain	  receptor	  activation.	  	  As	  a	  result	  
of	  the	  sequence	  and	  structural	  similarity	  between	  these	  receptors,	  it	  has	  been	  
difficult	  to	  generate	  quality	  antibodies	  that	  effectively	  recognize	  individual	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receptors.	  In	  light	  of	  the	  absence	  of	  good	  antibodies	  to	  evaluate	  receptor	  expression,	  
quantitative	  real	  time	  PCR	  has	  been	  established	  as	  a	  central	  technique	  to	  evaluate	  
cell	  type	  specific	  receptor	  expression.	  We	  therefore	  calculated	  the	  mRNA	  expression	  
of	  each	  receptor	  relative	  to	  GAPDH	  expression	  for	  MSCs	  derived	  from	  C57Bl/6	  mice.	  	  
The	  results	  from	  this	  are	  shown	  in	  Figure	  15	  below.	  Interestingly,	  there	  is	  an	  
abundance	  of	  S1PR2	  expression	  relative	  to	  the	  other	  four	  receptors	  with	  all	  5	  
receptors	  demonstrating	  some	  level	  of	  expression.	  	  S1PR1	  and	  S1PR3	  have	  the	  next	  
most	  abundant	  mRNA	  expression	  after	  S1PR2	  consistent	  with	  previous	  reports	  
suggesting	  their	  ubiquity	  of	  expression.	  	  
	  
Figure	  15:	  Relative	  mRNA	  S1P	  receptor	  expression	  in	  MSCs	  derived	  from	  C57BL/6	  mice	  as	  compared	  to	  
GAPDH	  expression.	  Primers	  used	  for	  evaluation	  are	  shown	  in	  the	  materials	  and	  methods	  section.	  This	  is	  
a	  representative	  experiment	  demonstrating	  the	  results	  of	  2	  independent	  trials.	  Experiment	  shown	  is	  
representative	  of	  3	  independent	  experiments.	  
	  
Following	  successful	  verification	  of	  MSC	  identity	  and	  S1PR	  transcriptional	  
expression,	  we	  sought	  to	  characterize	  changes	  in	  expression	  of	  these	  receptors	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following	  inhibition	  of	  S1PR2	  either	  subsequent	  to	  JTE013	  treatment	  or	  in	  S1PR2	  
KO	  cells.	  	  
	  
JTE013,	  a	  chemical	  antagonist	  of	  S1PR2,	  inhibits	  downstream	  signaling	  through	  this	  
receptor	  with	  a	  Kd	  of	  antagonism	  in	  the	  nM	  range	  and	  marked	  specificity	  into	  the	  
high	  μM	  range	  of	  treatment.	  JTE013	  treatment	  in	  these	  cells	  did	  not	  result	  in	  marked	  
changes	  in	  S1PR	  distribution	  following	  treatment	  as	  shown	  in	  Figure	  16a.	  The	  
mechanism	  of	  action	  of	  JTE013	  would	  not	  suggest	  that	  transcriptional	  changes	  in	  
receptor	  expression	  would	  be	  expected	  although	  changes	  in	  its	  activation	  and	  cell	  
signaling	  would	  nonetheless	  be	  expected.	  	  Furthermore,	  1	  μM	  JTE013	  treatment	  
during	  clonogenic	  evaluation	  of	  MSCs	  resulted	  in	  increased	  colony	  formation	  as	  
compared	  to	  vehicle	  treated	  cells	  as	  shown	  in	  Figure	  16b.	  The	  clonogenic	  assay	  was	  
conducted	  with	  JTE013	  or	  DMSO	  vehicle	  delivered	  at	  the	  time	  of	  cell	  plating	  with	  
500	  cells	  plated	  in	  each	  well	  of	  a	  6-­‐well	  plate.	  	  Colonies	  were	  counted	  after	  10-­‐14	  
days	  in	  cell	  culture	  following	  cell	  fixation	  and	  staining	  with	  crystal	  violet.	  Increased	  
clonogenicity	  indicates	  a	  greater	  capacity	  of	  MSCs	  to	  self-­‐renew	  and	  to	  regenerate	  
an	  MSC	  population.	  	  Inhibition	  of	  S1PR2	  results	  in	  increased	  clonogenicity	  of	  MSCs	  
without	  impacting	  the	  receptor	  distribution	  of	  S1PRs	  in	  MSCs.	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Figure	  16:	  Impact	  of	  JTE013	  treatment	  on	  MSC	  expression	  of	  S1P	  receptors	  and	  clonogenicity	  (a)	  
Evaluation	  of	  relative	  mRNA	  expression	  for	  the	  S1P	  receptors	  from	  MSCs	  derived	  from	  vehicle	  treated	  
MSCs	  and	  JTE013	  treated	  MSCs	  from	  C57BL/6	  mice.	  mRNA	  expression	  is	  shown	  relative	  to	  GAPDH	  (b)	  
Clonogenic	  evaluation	  of	  vehicle	  treated	  and	  JTE013	  treated	  MSCs	  from	  C57Bl/6	  mice.*	  indicates	  p<0.05	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The	  other	  mechanism	  of	  evaluating	  the	  absence	  of	  S1PR2	  in	  MSCS	  and	  its	  impact	  on	  
receptor	  distribution	  is	  the	  use	  of	  S1PR2	  knockout	  mice.	  S1PR2	  KO	  mice	  were	  
kindly	  provided	  by	  Dr.	  Richard	  Proia	  of	  the	  NIDDK	  (167,	  168).	  The	  mice	  were	  
generated	  by	  insertion	  of	  4.8	  kb	  neomycin	  insertion	  through	  an	  EcoRV	  open	  reading	  
frame	  of	  the	  S1PR2	  murine	  gene	  on	  mice	  of	  the	  129/Fv	  background	  as	  shown	  in	  
figure	  11	  (167,	  168).	  Genotyping	  of	  these	  mice	  can	  be	  conducted	  using	  primers	  1	  
and	  2	  to	  detect	  the	  170	  bp	  segment	  of	  the	  wild	  type	  allele	  and	  primers	  1	  and	  3	  to	  
detect	  the	  220	  bp	  knockout	  truncated	  MSC	  product.	  S1PR2	  knockout	  mice	  have	  
perinatal	  defects	  in	  their	  vestibular	  system	  resulting	  in	  deafness	  by	  1	  month	  of	  age.	  
Some	  mice,	  especially	  on	  the	  C57Bl/6	  background	  are	  prone	  to	  seizures	  in	  the	  first	  
couple	  weeks	  following	  birth.	  Female	  knockout	  mice	  have	  been	  demonstrated	  to	  
produce	  decreased	  litter	  sizes	  suggesting	  a	  need	  for	  further	  characterization	  of	  the	  
female	  reproductive	  system.	  The	  mice	  are	  otherwise	  phenotypically	  normal.	  Figure	  
17	  demonstrates	  the	  verification	  of	  the	  knockout	  allele	  and	  the	  mRNA	  expression	  of	  
Figure	  17:	  Generation	  of	  S1PR2	  knockout	  mice	  as	  described	  by	  Kono	  et	  al.	  2004.	  
Figure	  B	  shows	  the	  genotyping	  strategy	  employed	  in	  this	  project.	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the	  S1P	  receptors	  relative	  to	  GAPDH.	  The	  relative	  mRNA	  concentration	  of	  S1PR2	  
relative	  to	  GAPDH	  remains	  highly	  expressed	  in	  FVB	  mice.	  In	  S1PR2	  KO	  cells,	  
decreased	  transcriptional	  expression	  of	  the	  wild	  type	  form	  of	  S1PR2	  is	  expressed	  
whereas	  significantly	  higher	  expression	  of	  the	  mutant	  allele	  is	  expressed	  as	  shown	  
in	  Figure	  12a.	  S1PR1	  is	  more	  highly	  expressed	  than	  that	  of	  the	  C57Bl/6	  mice	  with	  
diminished	  S1PR3-­‐5	  expression.	  This	  transcriptional	  difference	  between	  strains	  of	  
mice	  in	  not	  inconsistent	  with	  previously	  published	  works	  indicating	  MSC	  RNA	  and	  
protein	  differences	  dependent	  on	  the	  strain	  of	  mouse	  from
	  
Figure	  18:	  A)	  Relative	  mRNA	  of	  wild	  type	  and	  S1PR2	  knockout	  MSCs	  relative	  to	  GAPDH	  expression.	  Blue	  
bars	  indicate	  WT	  expression	  and	  red	  bars	  indicate	  KO	  expression.	  MSCs	  were	  derived	  from	  FVB/129	  
mice	  consistent	  with	  the	  genotype	  of	  the	  KO	  mice	  (b)	  Genotyping	  of	  MSC	  knockout	  mice	  from	  tail	  vein	  
DNA	  following	  the	  genotyping	  strategy	  shown	  by	  Kono	  et	  al.	  
	  which	  they	  were	  derived.	  Importantly	  from	  Figure	  18a	  we	  demonstrate	  that	  the	  
knockout	  mice	  have	  diminished	  expression	  of	  the	  wild	  type	  S1PR2	  allele	  and	  other	  
transcriptional	  changes	  are	  not	  observed	  in	  these	  knockout	  mice	  as	  there	  is	  no	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evidence	  of	  receptor	  compensation	  in	  the	  knockout	  animals.	  This	  analysis	  allows	  us	  
to	  proceed	  to	  further	  analysis	  of	  MSCs	  derived	  from	  S1PR2	  KO	  animals.	  	  
	  	  
It	  can	  therefore	  be	  concluded	  that	  MSCs	  highly	  express	  S1PR2	  and	  inhibition	  of	  this	  
receptor	  results	  in	  increased	  clonogenicity.	  This	  work	  further	  characterizes	  the	  S1P	  
receptor	  expression	  of	  MSCs	  in	  a	  murine	  population	  following	  S1PR2	  inhibition	  
using	  JTE013	  and	  in	  S1PR2	  knockout	  MSCs.	  Although	  some	  strain	  variations	  have	  
been	  observed	  consistent	  with	  the	  literature,	  expression	  S1PR2	  in	  MSCs	  is	  present.	  	  
	  
This	  chapter	  establishes	  both	  that	  MSCs	  have	  successfully	  been	  isolated	  and	  further	  
the	  mechanisms	  for	  inhibition	  of	  S1PR2	  that	  will	  be	  employed	  in	  the	  proceeding	  
chapters.	  This	  therefore	  establishes	  the	  critical	  framework	  from	  which	  the	  future	  
results	  can	  be	  established.	  To	  better	  understand	  the	  role	  of	  S1PR2	  and	  the	  other	  S1P	  
receptors	  in	  MSCs,	  	  further	  characterization	  of	  this	  population	  is	  necessary	  focusing	  
on	  the	  capacity	  for	  proliferation,	  differentiation,	  bone	  marrow	  maintenance,	  and	  
tissue	  repair.	  	  These	  processes	  are	  essential	  for	  understanding	  the	  physiological	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Chapter	  3:	  	  Inhibition	  of	  S1PR2	  increases	  MSC	  
proliferation	  and	  migration	  
	  
S1P	  has	  critical	  roles	  in	  promoting	  migration	  and	  proliferation	  including	  in	  MSCs.	  
These	  effects	  are	  critically	  impacted	  by	  S1P	  receptor	  signaling.	  S1P	  receptor	  2	  
(S1PR2)	  is	  more	  complex	  than	  the	  other	  receptors	  based	  on	  its	  signaling	  through	  
both	  Gi,	  Gq,	  G12/13.	  Our	  initial	  analysis	  in	  Figure	  9	  demonstrates	  that	  inhibition	  of	  
S1PR2	  promotes	  increased	  MSC	  migration	  and	  proliferation	  in	  human	  Htert	  MSCs.	  It	  
is	  imperative	  that	  proliferation	  and	  migration	  be	  assessed	  in	  non-­‐immortalized	  
MSCs.	  	  	  
	  
Previous	  literature	  has	  suggested	  that	  inhibition	  of	  S1PR2	  has	  been	  shown	  to	  both	  
promote	  and	  inhibit	  migration	  depending	  on	  the	  cell	  type	  investigated.	  S1PR2	  has	  
been	  shown	  to	  negatively	  impact	  migration	  in	  satellite	  skeletal	  cells,	  vascular	  
smooth	  muscle	  cells,	  glioma	  cells,	  murine	  embryonic	  fibroblasts,	  mast	  cells,	  and	  
melanoma	  cells	  however	  it	  promotes	  migration	  in	  human	  lung	  fibroblasts(125,	  186-­‐
191).	  The	  controversial	  role	  of	  S1PR2	  in	  MSC	  migration	  is	  not	  limited	  to	  physiologic	  
cell	  types	  and	  additionally	  has	  been	  investigated	  in	  cancer	  cells.	  Similar	  
antagonizing	  roles	  have	  been	  proposed	  in	  cancer	  models	  with	  S1PR2	  promoting	  
increased	  invasion	  and	  metastasis	  in	  Hela	  cells,	  and	  esophageal	  cancer	  cells	  (130,	  
131,	  192)	  whereas	  it	  demonstrates	  inhibitory	  roles	  in	  glioma,	  melanoma,	  gastric	  
cancer,	  and	  CHO	  cells	  lines	  (129,	  190,	  193-­‐195).	  The	  available	  literature	  therefore	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more	  prominently	  endorses	  the	  role	  of	  S1PR2	  in	  inhibiting	  cell	  migration.	  The	  
differential	  impact	  in	  lung	  fibroblast	  may	  be	  the	  result	  of	  differences	  in	  S1PR	  
distribution	  favoring	  signaling	  through	  S1PR1.	  	  Differential	  expression	  of	  the	  S1PRs	  
within	  a	  cell	  type	  may	  be	  the	  critical	  factor	  dictating	  a	  cellular	  response	  to	  S1P	  
stimulation.	  No	  evidence	  for	  differential	  effect	  has	  been	  observed	  for	  S1P	  receptor	  
response	  based	  on	  different	  S1P	  concentrations.	  	  
	  
As	  this	  the	  response	  of	  cell	  to	  modification	  of	  S1PR2	  may	  be	  modulated	  by	  the	  type	  
of	  cell	  under	  consideration,	  the	  role	  of	  S1P2	  in	  MSCs	  may	  therefore	  be	  better	  
predictor	  of	  the	  role	  of	  S1PR2	  in	  MSCs.	  In	  Htert	  immortalized	  human	  MSCs,	  S1PR1	  
and	  S1PR2	  act	  jointly	  in	  the	  promotion	  of	  migration	  in	  a	  transwell	  assay	  (154).	  
Quint	  et	  al.	  in	  their	  2013	  publication	  reported	  that	  osteoclasts	  secrete	  S1P	  and	  that	  
this	  S1P	  can	  stimulate	  MSC	  chemotaxis	  by	  a	  RhoA	  dependent	  mechanism	  through	  
activation	  of	  protein	  kinase	  pathways	  including	  JAK/STAT3	  and	  FAK/P13K/AKT	  
dependent	  pathways.	  This	  study	  by	  Quint	  et	  al.,	  utilized	  a	  transwell	  assay	  as	  
compared	  to	  other	  studies	  generated	  using	  scratch	  assay	  a	  low	  dose	  of	  JTE013	  at	  
only	  20	  nM	  (154).	  The	  authors	  of	  this	  paper	  do	  not	  investigate	  the	  S1P	  
concentration	  within	  the	  conditioned	  media	  nor	  is	  S1P	  treatment	  delivered.	  Further	  
evaluation	  of	  S1PR	  expression	  and	  S1P	  concentration	  in	  the	  cell	  types	  and	  
experiments	  conducted	  would	  provide	  a	  greater	  context	  in	  which	  to	  understand	  
some	  of	  the	  apparently	  contradictory	  results	  regarding	  the	  role	  of	  S1PR2	  in	  
migration.	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The	  role	  of	  S1PR2	  in	  proliferation	  is	  similarly	  contentious	  with	  reports	  of	  S1PR2	  
inhibiting	  cell	  growth	  and	  promoting	  growth	  in	  alternate	  settings.	  S1PR2	  inhibits	  
cell	  proliferation	  in	  keratinocytes	  by	  decreasing	  Akt	  activation	  and	  inhibits	  smooth	  
muscle	  cell	  proliferation	  as	  well	  (196,	  197).	  	  Evaluation	  of	  cancer	  cell	  proliferation	  
in	  vitro	  shows	  that	  S1PR2	  promotes	  cancer	  cell	  proliferation	  in	  glioma	  cells	  and	  
prostate	  cancer	  cells	  by	  Stat3	  and	  Akt	  activation	  (138,	  198-­‐201).	  However	  in	  
primary	  non-­‐carcinogenic	  cell	  types	  S1PR2	  appears	  to	  inhibit	  the	  Gi	  mediated	  pro-­‐
proliferative	  effects	  of	  S1P.	  	  
	  
We	  sought	  to	  better	  understanding	  the	  competing	  roles	  of	  S1PR2,	  as	  both	  
synergistic	  and	  antagonistic	  to	  S1PR1,	  in	  MSC	  proliferation	  and	  migration.	  We	  had	  
previously	  observed	  that	  in	  hTERT	  immortalized	  human	  MSCs	  increased	  migration	  
with	  inhibition	  of	  S1PR2	  using	  JTE013.	  Both	  JTE013	  as	  a	  competitive	  antagonist	  of	  
S1PR2	  and	  S1PR2	  KO	  cells	  were	  employed	  as	  models	  for	  evaluation	  of	  these	  effects.	  
JTE013	  provides	  highly	  specific	  inhibition	  of	  S1PR2	  but	  based	  on	  its	  mechanism	  of	  
action	  this	  may	  not	  be	  as	  complete	  of	  an	  inhibition	  as	  in	  knockout	  cells.	  Knockout	  
animals,	  however,	  despite	  the	  complete	  inhibition	  of	  S1PR2	  may	  have	  altered	  S1P	  
signaling	  or	  compensation	  based	  on	  creation	  of	  a	  constitutive	  knock	  out	  animal.	  A	  
complete	  approach	  to	  evaluation	  of	  S1PR2	  signaling	  would	  employ	  both	  genetic	  and	  
chemical	  mechanisms	  to	  inhibit	  S1PR2	  to	  evaluate	  its	  function	  within	  MSCs.	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Evaluation	  of	  the	  growth	  of	  S1PR2	  KO	  cells	  and	  wild	  type	  cells	  with	  3	  uM	  JTE013	  by	  
MTS	  assay	  demonstrated	  significantly	  increased	  proliferation	  as	  compared	  to	  the	  
vehicle	  treated	  wild	  type	  cells	  as	  shown	  in	  Figure	  19a.	  We	  further	  observed	  this	  
effect	  to	  be	  dose	  dependent	  with	  increased	  proliferation	  at	  24	  hours	  in	  cells	  treated	  
with	  higher	  doses	  of	  JTE013	  as	  shown	  in	  Figure	  19b.	  	  
	  
Figure	  19:	  Proliferation	  of	  MSCs	  with	  S1PR	  inhibition	  (a)	  Proliferation	  of	  MSCs	  from	  day	  0	  to	  day	  4	  
evaluated	  by	  MTS	  assay	  .	  Squares	  indicate	  vehicle	  treatment,	  triangles	  JTE013	  treatment,	  and	  dashed	  
triangles	  indicate	  S1PR2	  KO	  cells	  (b)	  evaluation	  of	  the	  effect	  of	  increasing	  concentrations	  of	  JTE013	  on	  
MSC	  proliferation	  at	  24	  hours.	  Proliferation	  was	  evaluated	  by	  MTS	  assay	  with	  fold	  change	  calculated	  
relative	  to	  t=0	  absorbance.	  *	  indicates	  p,0.05	  **	  indicates	  p<0.01	  based	  on	  student’s	  t-­test	  analysis.	  
Following	  the	  evaluation	  of	  the	  proliferation	  of	  cells	  following	  S1P	  inhibition,	  we	  
evaluated	  migration	  by	  scratch	  assay,	  as	  described	  previously.	  In	  S1PR2	  knockout	  
cells	  as	  compared	  to	  controls	  cells	  from	  age	  matched	  wild	  type	  mice,	  increased	  
migration	  and	  a	  decreased	  scratch	  wound	  width	  was	  observed	  in	  the	  knockout	  cells	  
as	  shown	  in	  Figure	  20.	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Figure	  20:	  Evaluation	  of	  S1PR2	  knockout	  MSC	  migration	  by	  scratch	  assay.	  S1PR2	  KO	  mice	  were	  
evaluated	  for	  scratch	  length	  based	  on	  the	  length	  of	  the	  scratch	  following	  treatment.	  Representative	  
pictures	  of	  WT	  and	  KO	  scratches	  are	  shown	  above	  with	  quantification	  of	  scratch	  length.	  **	  indicates	  
p<0.01	  by	  Student’s	  T-­test	  
	  
Similarly,	  Essen	  analysis	  as	  described	  in	  materials	  and	  methods,	  was	  conducted	  to	  
determine	  MSC	  migration	  on	  96	  well	  plates.	  This	  analysis	  was	  conducted	  using	  the	  
image	  locked	  plates.	  Analysis	  of	  confluence	  and	  wound	  width	  was	  conducted	  with	  
pictures	  taken	  every	  15	  minutes	  without	  disruption	  of	  the	  cell	  plate	  within	  the	  
incubator.	  Scratches	  were	  made	  using	  a	  96-­‐pin	  Essen	  scratch	  wound	  technology	  to	  
generate	  equivalent	  scratch	  wounds	  on	  collagen-­‐coated	  plates.	  Analysis	  of	  wound	  
confluence	  and	  wound	  density	  both	  indicate	  increased	  cell	  migration	  with	  MSC	  
treatment	  with	  JTE013	  at	  all	  concentrations	  evaluated	  in	  Figure	  21.	  	  Importantly	  
increased	  migration	  was	  observed	  by	  Essen	  analysis	  at	  500	  nM	  JTE013	  at	  a	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differentiating	  migratory	  function	  from	  that	  of	  proliferation	  during	  that	  same	  time	  
period.	  	  	  
	  
Figure	  20:	  MSC	  migration	  as	  evaluated	  by	  Essen	  analysis	  following	  treatment	  with	  increasing	  JTE013	  
dosages	  shown	  .	  Relative	  wound	  density	  is	  shown	  in	  	  (a)	  and	  wound	  confluence	  (b).	  *	  indicates	  p<0.05	  **	  
indicated	  p<0.01	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Based	  on	  consistent	  data	  between	  both	  JTE013	  treatment	  and	  S1PR2	  KO	  cells,	  we	  
conclude	  that	  S1PR2	  is	  inhibitory	  to	  murine	  and	  human	  MSC	  migration	  and	  
therefore	  inhibition	  of	  this	  receptor	  results	  in	  increased	  migration.	  This	  has	  
significant	  implications	  for	  the	  in	  vivo	  mobilization	  of	  MSCs	  as	  this	  feature	  is	  critical	  
to	  their	  physiological	  function.	  This	  is	  not	  further	  evaluated	  within	  this	  body	  of	  
research	  but	  merits	  additional	  research	  especially	  given	  the	  findings	  on	  the	  impact	  
of	  reduction	  of	  S1P	  levels	  on	  MSC	  mobilization	  to	  sites	  of	  injury	  in	  a	  carbon	  
tetrachloride	  liver	  injury	  model	  (132).	  	  
	  
S1PR2	  is	  a	  critical	  inhibitory	  factor	  for	  MSC	  mobilization	  and	  proliferation.	  Further	  
evaluation	  of	  the	  role	  of	  S1PR2	  in	  MSCs	  mobilization	  is	  therefore	  essential	  to	  the	  
capacity	  of	  cells	  to	  function	  within	  the	  bone	  marrow	  and	  tissue	  injury	  environment	  
(132,	  151,	  157,	  164).	  	  In	  vivo,	  the	  balance	  between	  S1PR1	  in	  promoting	  cell	  egress	  
and	  S1PR2	  in	  inhibiting	  cell	  may	  be	  essential	  in	  maintaining	  cell	  concentrations	  
within	  the	  bone	  marrow	  to	  maintain	  the	  stem	  cell	  niche	  and	  allowing	  peripheral	  
mobilization	  of	  MSCs	  under	  injury	  situations.	  In	  vivo	  analysis	  of	  S1PR2	  in	  MSC	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Chapter	  4:	  Role	  of	  Erk	  on	  S1PR	  mediated	  migration	  
and	  proliferation	  	  
	  
Extracellular	  signal	  related	  kinase	  (Erk)	  is	  one	  of	  the	  MAPK	  (Mitogen	  activated	  
protein	  kinases)	  proteins	  along	  with	  P38	  and	  JNK.	  Activation	  of	  Erk	  is	  downstream	  
of	  Ras	  activation	  with	  phosphorylation	  of	  Erk	  mediated	  by	  MEK1/2	  at	  two	  different	  
phosphorylation	  sites.	  	  Erk	  activation	  promotes	  proliferation,	  differentiation,	  
survival,	  apoptosis,	  and	  stress	  response.	  Transcription	  factors	  downstream	  of	  Erk	  
include	  many	  factors	  although	  Elk-­‐1,	  c-­‐fos,	  and	  c-­‐jun	  have	  been	  most	  extensively	  
explored	  (100).	  	  Deactivation	  of	  Erk	  and	  the	  other	  MAPK	  proteins	  is	  mediated	  by	  
MAPK	  phosphatases	  the	  prominent	  of	  which	  is	  MKP-­‐1.	  MKP-­‐1	  is	  capable	  of	  
deactivating	  Erk,	  p38,	  and	  JNK	  although	  in	  vitro	  preference	  is	  given	  to	  p38	  and	  JNK	  
over	  Erk	  (202,	  203).	  
	  
Erk	  is	  a	  critical	  signaling	  molecule	  in	  cellular	  functions	  including	  proliferation	  and	  
migration.	  It	  has	  the	  capacity	  to	  phosphorylate	  and	  activate	  hundreds	  of	  cytoplasmic	  
and	  nuclear	  substrates	  (204,	  205).	  Downstream	  signaling	  pathways	  of	  Erk	  promote	  
G1/S	  progression.	  This	  is	  accomplished	  in	  part	  through	  the	  phosphorylation	  of	  Elk-­‐1	  
and	  the	  stabilization	  of	  c-­‐fos	  leading	  to	  AP-­‐1	  and	  cyclin	  D1	  activation	  promoting	  
G1/S	  progression	  (206).	  The	  pro-­‐proliferative	  function	  of	  Erk	  is	  however	  not	  limited	  
to	  these	  pathways.	  Erk	  has	  been	  shown	  to	  promote	  cell	  migration	  through	  the	  
phosphorylation	  of	  proteins	  such	  as	  calpain,	  focal	  adhesion	  kinase,	  and	  paxillin	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(207).	  Increased	  migration	  and	  invasion	  is	  also	  accomplished	  by	  the	  degradation	  of	  
the	  extracellular	  matrix	  through	  MMP	  induction.	  	  	  
	  
S1P	  is	  classically	  known	  to	  activate	  Erk	  through	  Gi	  activation	  of	  Ras	  and	  ultimately	  
Erk	  activation	  (113,	  129,	  199,	  208,	  209).	  This	  activation	  of	  Gi	  has	  been	  
demonstrated	  for	  both	  S1P	  delivery	  in	  BSA	  and	  on	  HDL	  (210).	  	  Erk	  activation	  
importantly	  results	  in	  increased	  cell	  proliferation	  and	  survival.	  For	  this	  reason	  Erk	  
activation	  has	  been	  implicated	  in	  the	  promotion	  of	  stem	  cell	  self	  renewal	  in	  
embryonic	  stem	  cells	  following	  S1P	  delivery	  (142).	  	  Analysis	  of	  S1P	  stimulated	  Erk	  
within	  MSCs	  was	  conducted	  by	  Meriane	  et	  al	  in	  2006	  (158).	  In	  this	  publication,	  S1P	  
delivery	  to	  bone	  marrow	  derived	  MSCs	  results	  in	  increased	  migration	  with	  
corresponding	  morphological	  changes	  in	  actin	  stress	  fiber	  formation	  mediated	  by	  a	  
Rho	  Kinase	  (ROCK),	  Erk,	  and	  MMP	  dependent	  pathway.	  	  Although	  S1PR1,	  R2,	  and	  R3	  
are	  capable	  of	  Gi	  activation,	  S1PR1	  and	  S1PR3	  rely	  most	  heavily	  on	  this	  mechanism	  
of	  signaling.	  S1PR2	  has	  been	  shown	  to	  activate	  Erk	  in	  cardiomyocytes	  with	  a	  60%	  
decrease	  in	  Erk	  activation	  in	  S1PR2	  KO	  cardiomyoctes	  as	  compared	  to	  wild	  type	  
controls	  (211).	  We	  sought	  to	  evaluate	  the	  role	  of	  MAPK	  activation	  in	  mediating	  the	  
functional	  changes	  in	  MSC	  migration	  and	  proliferation	  following	  S1PR2	  inhibition.	  	  
	  
We	  conducted	  western	  blot	  analysis	  of	  the	  downstream	  pathways	  impacted	  by	  
S1PR2	  inhibition.	  MSCs	  were	  treated	  with	  either	  3	  μM	  JTE013	  for	  30	  minutes	  or	  by	  
the	  use	  of	  S1PR2	  knockout	  cells.	  U0126	  is	  an	  Mek	  1	  and	  2	  inhibitor	  that	  prevents	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phosphorylation	  of	  Erk.	  The	  figure	  below	  shows	  that	  treatment	  of	  MSCs	  with	  U0126	  
diminishes	  Erk	  activation	  as	  expected	  based	  on	  previously	  published	  literature.	  	  
	  
Figure	  21:	  (a)	  Diagram	  of	  S1PR2	  signaling.	  	  Blue	  circles	  indicate	  G	  proteins	  with	  which	  the	  receptor	  
interacts	  and	  red	  circles	  indicate	  direct	  interactions.	  Downstream	  pathway	  interactions	  are	  shown.	  (b)	  
Western	  blot	  expression	  evaluating	  signaling	  downstream	  of	  S1PR2.	  U0126	  is	  an	  inhibitor	  of	  MEK1/2	  
preventing	  phosphorylation	  of	  Erk	  	  1/2.	  	  
	  
Based	  on	  this	  analysis,	  we	  found	  a	  marked	  upregulation	  of	  Erk	  activation	  following	  
S1PR2	  inhibition	  using	  JTE013	  as	  shown	  in	  Figure	  22.	  Akt	  activation	  remains	  
unchanged	  with	  S1PR2	  inhibition	  and	  no	  changes	  in	  Rac	  or	  Rho	  isoform	  expression	  
were	  observed.	  There	  was	  a	  marked	  increase	  in	  p38	  expression	  with	  S1PR2	  
inhibition.	  Having	  observed	  this	  in	  MSCs	  with	  JTE013	  treatment,	  we	  evaluated	  
whether	  this	  same	  change	  in	  Erk	  activation	  was	  present	  in	  our	  other	  systems	  using	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Figure	  22:	  Western	  blot	  evaluation	  of	  Erk	  activation	  in	  hTERT	  cells	  2	  hours	  following	  JTE013	  treatment.	  
Phosphorylated	  ant	  total	  Erk	  expression	  are	  shown	  following	  0-­2.5	  μM	  JTE013	  treatment	  	  (a)	  Erk	  
analysis	  in	  wild	  type	  and	  S1PR2	  KO	  cells	  (b)	  
	  
In	  both	  our	  hTERT	  treated	  cells	  and	  our	  S1PR2	  KO	  cells,	  increased	  Erk	  activation	  
was	  observed	  following	  inhibition	  of	  S1PR2	  as	  shown	  in	  Figure	  23.	  This	  suggests	  
that	  contrary	  to	  the	  canonical	  role	  of	  S1P	  on	  Erk	  activation,	  S1PR2	  is	  inhibitory	  to	  
this	  activation	  in	  MSCs	  that	  have	  a	  strong	  transcriptional	  expression	  of	  this	  receptor.	  
We	  propose	  that	  the	  mechanism	  of	  this	  activation	  may	  be	  mediated	  by	  changes	  in	  
the	  gene	  expression	  of	  DUSP-­‐1	  known	  as	  the	  protein	  MKP-­‐1.	  MKP-­‐1	  can	  be	  induced	  
in	  stress	  response	  pathways	  and	  can	  catalytically	  inactivate	  p38,	  JNK,	  and	  Erk	  at	  
tyrosine	  and	  threonine	  residues	  although	  an	  in	  vivo	  preference	  is	  given	  for	  p38	  and	  
JNK	  (203,	  212,	  213).	  In	  airway	  smooth	  muscle	  cells,	  S1P	  can	  activate	  all	  three	  MAPK	  
proteins	  but	  can	  also	  simultaneously	  activate	  its	  negative	  feedback	  controller	  MKP-­‐1	  
through	  a	  pathway	  involving	  adenylate	  cyclase,	  PKA,	  and	  P38	  (105).	  We	  evaluated	  
changes	  in	  DUSP-­‐1	  gene	  expression	  and	  its	  impact	  on	  Erk	  activation	  in	  MSC	  cells	  
following	  S1PR2	  inhibition	  to	  determine	  if	  this	  was	  a	  potential	  mechanism	  for	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changes	  in	  Erk	  phosphorylation.	  Thirty	  minute	  treatment	  with	  1	  μM	  JTE013	  
resulted	  in	  decreased	  DUSP-­‐1	  gene	  expression	  as	  shown	  in	  Figure	  24.	  When	  MSCs	  
were	  isolated	  from	  MKP-­‐1	  KO	  animals,	  a	  give	  of	  Dr.	  Keith	  Kirkwood	  at	  the	  Medical	  
University	  of	  South	  Carolina,	  and	  were	  subsequently	  treated	  with	  JTE013,	  no	  
increases	  in	  Erk	  phosphorylation	  were	  observed.	  This	  change	  in	  activation	  of	  Erk	  
suggests	  that	  diminished	  MKP-­‐1	  induction	  following	  inhibition	  of	  S1PR2	  might	  
result	  in	  decreased	  Erk	  dephosporylation	  and	  therefore	  increased	  Erk	  activation	  
after	  S1PR2	  inhibition.	  This	  possible	  explanation	  for	  the	  changes	  in	  Erk	  
phosphorylation	  bears	  further	  investigation	  and	  other	  factors	  may	  be	  responsible	  
for	  changes	  in	  Erk	  phosphorylation.	  	  	  	  
	  
Figure	  23:	  Evaluation	  of	  DUSP-­1	  treatment	  in	  MSCs	  (a)	  qPCR	  evaluation	  of	  DUSP-­1	  expression	  following	  
JTE013	  treatment	  DUSP-­1	  expression	  was	  normalized	  to	  GAPDH	  expression	  in	  the	  cells	  (b)	  Western	  Blot	  
analysis	  of	  	  Phospho	  and	  total	  Erk	  	  expression	  in	  MKP-­1	  KO	  cells	  
	  
Although	  we	  observed	  increased	  Erk	  phosphorylation	  following	  treatment	  with	  
JTE013,	  we	  sought	  to	  determine	  whether	  this	  change	  might	  impact	  the	  functional	  
changes	  observed	  in	  MSCs	  following	  S1PR2	  inhibition.	  U0126	  is	  a	  potent	  inhibitor	  of	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Mek	  1	  and	  2	  with	  an	  IC50	  value	  of	  0.5	  μM.	  	  Inhibition	  of	  Mek	  1	  and	  2	  results	  in	  
decreased	  activation	  of	  Erk	  1	  and	  2	  (Promega)(214).	  FR180204	  is	  an	  Erk	  inhibitor	  
with	  an	  IC50	  of	  0.14	  to	  0.31	  μM	  with	  no	  impact	  on	  P38	  until	  10	  μM	  concentrations	  
(Tocris).	  The	  mechanism	  of	  action	  for	  FR180204	  is	  by	  competing	  with	  ATP	  for	  
active	  site(215).	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Figure	  24:	  Evaluation	  of	  the	  role	  of	  Erk	  on	  JTE013	  mediated	  increases	  in	  MSC	  proliferation	  using	  U0126	  
by	  Essen	  analysis	  following	  MSC	  proliferation	  up	  until	  125	  hours	  (a)	  MTS	  analysis	  of	  MSC	  proliferation	  at	  
24	  hours	  using	  U0126	  (b)	  or	  using	  the	  FR	  inhibitor	  (c).	  *	  indicates	  p<0.05	  and	  ***	  indicates	  p<	  0.001.	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In	  part	  of	  A	  of	  Figure	  25,	  cell	  confluence	  was	  analyzed	  using	  the	  Essen	  machine	  
whereby	  an	  MSC	  specific	  set	  of	  cell	  detection	  parameters	  was	  established	  to	  assess	  
cell	  number	  and	  confluence	  in	  6-­‐well	  cell	  culture	  dishes.	  MSCs	  were	  plated	  and	  their	  
proliferation	  determined	  by	  pictures	  taken	  every	  15	  minutes	  for	  the	  time	  indicated.	  
The	  graph	  shown	  depicts	  time	  points	  from	  every	  6	  hours	  indicating	  that	  as	  shown	  
previously	  increased	  cell	  proliferation	  is	  observed	  following	  3	  uM	  JTE	  treatment.	  
U0126	  inhibition	  of	  Erk	  results	  in	  decreased	  cell	  proliferation	  as	  compared	  to	  
vehicle	  treated	  cells	  and	  proliferation	  is	  further	  reduced	  following	  combined	  JTE	  
and	  U0126	  treatment.	  When	  proliferation	  assays	  were	  conducted	  using	  MTS	  in	  
Figure	  2b,	  a	  similar	  result	  was	  observed	  indicating	  that	  S1PR2	  inhibition	  results	  in	  
Erk	  dependent	  increases	  in	  cell	  proliferation.	  These	  results	  were	  further	  verified	  by	  
the	  use	  of	  a	  second	  Erk	  inhibitor	  labeled	  FR	  and	  evaluated	  by	  MTS	  assay	  48	  hours	  
following	  treatment	  as	  shown	  in	  Figure	  26c.	  	  
	  
Following	  the	  observed	  proliferative	  changes	  with	  Erk	  inhibition	  in	  combination	  
with	  S1PR2	  inhibition,	  we	  further	  explored	  the	  role	  Erk	  in	  migration	  following	  
S1PR2	  inhibition	  as	  shown	  in	  Figure	  26.	  Inhibition	  of	  Erk	  activation	  results	  in	  
decreased	  MSC	  migration	  as	  compared	  to	  wild	  type	  cells,	  which	  is	  maintained	  with	  
combination	  treatment	  with	  JTE013	  using	  both	  U0126	  and	  FR180204.	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Figure	  25:	  The	  role	  of	  Erk	  in	  JTE013	  mediated	  increases	  in	  MSC	  migration	  using	  1	  μM	  U0126	  treatment.	  
Migration	  was	  assessed	  by	  Essen	  analysis	  of	  wound	  density	  following	  U0126	  treatment	  (a)	  and	  FR	  	  
treatment	  (b)	  where	  migration	  was	  assessed	  by	  scratch	  assay.	  **	  indicates	  p<0.01	  relative	  to	  vehicle	  
control,	  ***	  indicates	  p<0.001	  relative	  to	  vehicle	  control,	  ###	  indicates	  p<0.001	  relative	  to	  JTE013	  
treatment	  
	  
Based	  on	  the	  findings	  presented	  in	  this	  chapter,	  we	  conclude	  that	  S1PR2	  acts	  
antagonistically	  to	  S1PR1	  in	  downregulating	  Erk	  activation	  potentially	  through	  an	  
MKP-­‐1	  dependent	  mechanism.	  Inhibition	  of	  S1PR2	  therefore	  results	  in	  increased	  
Erk	  phosphorylation	  and	  corresponding	  increases	  in	  proliferation	  and	  migration.	  
These	  conclusions	  while	  demonstrating	  the	  role	  of	  Erk	  in	  MSC	  migration	  and	  
proliferation	  without	  identification	  of	  other	  downstream	  signaling	  factors	  that	  
might	  contribute	  to	  this	  process.	  These	  conclusions	  do	  not	  exclude	  the	  involvement	  
of	  other	  pathways	  in	  this	  process.	  Furthermore,	  more	  complete	  analysis	  of	  this	  
pathway	  would	  include	  a	  G	  protein	  pull	  down	  assay	  for	  Gi,	  Gq,	  and	  G12/13.	  	  
Nonetheless	  we	  have	  identified	  a	  critical	  component	  to	  the	  pathway	  controlling	  MSC	  
migration	  and	  proliferation.	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Chapter	  5:	  The	  role	  of	  the	  remaining	  S1PRs	  in	  MSC	  
behavior	  
	  
The	  previous	  chapters	  focused	  on	  the	  role	  of	  S1PR2	  in	  moderating	  MSC	  behavior	  
and	  self-­‐renewal.	  As	  S1PR2	  does	  not	  function	  in	  isolation,	  it	  is	  critical	  to	  assess	  the	  
role	  of	  the	  remainder	  of	  these	  receptors.	  In	  this	  chapter,	  we	  therefore	  look	  to	  focus	  
on	  the	  role	  of	  the	  other	  receptors	  in	  impacting	  MSC	  signaling,	  proliferation,	  and	  
migration.	  Limited	  focus	  was	  placed	  in	  this	  body	  of	  research	  on	  S1PR4	  and	  S1PR5	  
due	  to	  the	  low	  levels	  of	  expression	  in	  MSCs	  and	  their	  documented	  roles	  primarily	  in	  
lymphocytes	  and	  neuronal	  cells	  and	  natural	  killer	  cells,	  respectively.	  	  Unlike	  with	  
S1PR2,	  both	  S1PR1	  and	  S1PR3	  demonstrate	  more	  dominant	  signaling	  through	  Gi	  
with	  the	  functional	  impact	  of	  these	  receptors	  highly	  aligned	  with	  the	  canonical	  
proinflammatory,	  pro-­‐migratory,	  and	  proliferative	  effects	  of	  S1P	  signaling.	  S1PR3	  
due	  to	  its	  capacity	  for	  signaling	  through	  Gq	  and	  G12/13	  does	  however	  have	  more	  
complex	  potential	  pathways.	  	  
	  
S1PR1	  was	  the	  first	  S1P	  receptor	  identified	  with	  knock	  out	  animals	  embryonic	  lethal	  
between	  E11.5	  and	  E14.5	  as	  a	  result	  of	  defective	  blood	  vessel	  development.	  S1PR1	  
has	  been	  best	  characterized	  for	  its	  roles	  in	  T	  and	  B	  lymphocyte	  egress	  that	  is	  the	  
basis	  for	  FTY720	  treatment	  in	  multiple	  sclerosis	  (168,	  216).	  FTY720	  is	  an	  orally	  
available	  agent	  used	  in	  the	  treatment	  of	  multiple	  sclerosis	  through	  its	  actions	  as	  a	  
functional	  antagonist	  of	  S1PR1,	  R3,	  R4,	  and	  R5	  (217).	  Beyond	  this	  role	  in	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lymphocytes,	  S1PR1	  has	  critical	  angiogenic	  functions	  (42).	  S1PR3	  is	  most	  often	  
characterized	  for	  its	  functions	  in	  collaboration	  for	  S1PR1	  and	  S1PR2.	  Knockout	  mice	  
for	  S1PR3	  are	  viable	  although	  decreased	  litter	  size	  has	  been	  notes	  (167,	  168).	  S1PR3	  
has	  critical	  functions	  in	  dendridic	  cell	  mediated	  switch	  to	  a	  TH1	  response.	  S1PR3	  
has	  been	  observed	  to	  be	  induced	  in	  astrocytes	  within	  multiple	  sclerosis	  suggesting	  a	  
proinflammatory	  function	  of	  this	  receptor.	  S1PR3	  has	  also	  recently	  been	  proposed	  
as	  a	  biomarker	  for	  the	  inflammation	  associated	  with	  acute	  lung	  injury	  (113).	  
	  	  
In	  this	  chapter,	  we	  employ	  both	  genetic	  and	  chemical	  methods	  to	  antagonize	  S1P	  
receptor	  function.	  VPC23019	  is	  a	  pharmacological	  antagonist	  of	  S1PR1	  and	  R3	  
(Tocris/Avanti).	  We	  further	  explore	  the	  individual	  role	  of	  S1PR3	  through	  the	  use	  of	  
knockout	  mice	  that	  were	  kindly	  provided	  by	  the	  laboratory	  of	  Dr.	  Kelley	  Argraves	  
from	  the	  Medical	  University	  of	  South	  Carolina.	  S1PR3	  knockout	  mice	  are	  
phenotypically	  normal	  although	  a	  smaller	  litter	  size	  is	  produced	  (113,	  168).	  	  
	  
The	  final	  pharmacologic	  agent	  that	  we	  use	  in	  this	  study	  is	  FTY720	  or	  fingolimod	  
marketed	  by	  Novartis	  under	  the	  trade	  name	  Gilenya.	  	  FTY720	  is	  phosphorylated	  by	  
sphingosine	  kinase	  2	  within	  the	  cell	  to	  produce	  the	  active	  metabolite	  of	  the	  drug.	  It	  
is	  an	  agonist	  at	  a	  picomolar	  range	  for	  S1PR1	  and	  S1PR3-­‐5	  resulting	  in	  significant	  
functional	  antagonism	  of	  these	  receptors	  (42).	  The	  drug	  is	  FDA	  approved	  as	  an	  
immunosuppressant	  for	  relapsing	  and	  remitting	  multiple	  sclerosis	  and	  is	  the	  first	  
orally	  available	  approved	  therapy	  for	  this	  condition	  (42).	  	  Although	  demonstrating	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effectiveness	  as	  a	  disease-­‐modifying	  agent	  in	  MS	  with	  an	  acceptable	  safety	  profile,	  
adverse	  effects	  commonly	  reported	  from	  the	  drug	  include	  bradycardia	  and	  
hypertension	  (218).	  Treatment	  with	  FTY720	  results	  in	  lymphopenia	  as	  a	  result	  of	  
decreased	  lymphocyte	  egress	  into	  peripheral	  circulation	  with	  an	  increased	  
regulatory	  T	  cell	  population	  (42).	  These	  effects	  are	  largely	  mediated	  by	  S1PR1	  
receptor	  endocytosis	  and	  degradation	  decreasing	  lymphocyte	  egress	  signaling.	  	  	  
	  
We	  sought	  to	  initially	  investigate	  the	  role	  of	  S1PR1	  and	  S1PR3	  treatment	  on	  MSCs	  
through	  the	  use	  of	  the	  pharmacologic	  antagonist	  VPC.	  Thirty-­‐minute	  treatment	  of	  
primary	  murine	  MSCs	  with	  VPC	  did	  not	  impact	  Erk	  activation	  as	  shown	  in	  Figure	  
27a.	  Evaluation	  of	  migration	  with	  increasing	  doses	  of	  VPC	  delivered	  at	  the	  start	  of	  
the	  migration	  assay	  was	  conducted	  by	  Essen	  analysis	  as	  previously	  described.	  No	  
changes	  in	  migration	  was	  observed	  between	  0	  nM	  and	  5	  μM	  VPC	  treatment	  as	  
shown	  in	  Figure	  27b.	  Treatment	  with	  3	  μM	  VPC	  initiated	  at	  the	  time	  0	  results	  in	  
increased	  MSC	  proliferation	  as	  evaluated	  by	  percent	  confluence.	  Inhibition	  of	  S1PR1	  
and	  R3	  therefore	  does	  not	  impact	  MSC	  Erk	  activation	  or	  migration	  but	  promotes	  cell	  
proliferation.	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Figure	  26:	  Evaluation	  of	  VPC	  treatment	  of	  MSCs	  (a)	  Western	  blot	  analysis	  of	  Phospho	  and	  total	  Erk	  
expression	  following	  VPC	  treated	  MSCs	  (b)	  Essen	  migration	  analysis	  of	  VPC	  treated	  MSCs	  from	  
concentrations	  of	  250	  nM	  to	  5	  μM.	  No	  significant	  differences	  in	  relative	  wound	  density	  were	  observed.	  
(c)	  Essen	  proliferation	  analysis	  of	  VPC	  treated	  MSCs	  P<0.001	  for	  VPC	  vs.	  Vehicle.	  	  
	  
We	  next	  sought	  to	  determine	  whether	  this	  effect	  might	  be	  mediated	  by	  either	  
inhibition	  of	  S1PR1	  or	  S1PR3.	  We	  isolated	  MSCs	  from	  S1PR3	  knockout	  animals	  and	  
from	  age	  and	  gender	  matched	  wild	  type	  controls	  as	  shown	  in	  Figure	  29.	  	  Evaluation	  
of	  S1PR	  expression	  by	  quantitative	  real	  time	  analysis	  demonstrated	  a	  marked	  
absence	  in	  S1PR3	  in	  S1PR3	  KO	  mice	  with	  concurrent	  diminished	  transcriptional	  
expression	  of	  S1PR4	  and	  R5.	  S1PR1	  expression	  was	  maintained	  at	  comparable	  
levels.	  There	  was	  potentially	  a	  decline	  in	  S1PR2	  levels	  in	  S1PR2	  knockout	  animals.	  
Unlike	  what	  was	  seen	  in	  S1PR2	  knockout	  mice	  without	  receptor	  compensation,	  
changes	  in	  transcriptional	  expression	  of	  non-­‐targeted	  receptors	  were	  seen	  in	  S1P3	  
KO	  mice.	  However,	  the	  most	  dominantly	  expressed	  receptors	  shown	  comparable	  
expression	  levels.	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Figure	  27:	  qPCR	  analysis	  of	  S1P	  receptor	  expression	  in	  wild	  type	  and	  S1PR3	  KO	  MSCs.	  Fold	  change	  is	  
shown	  as	  relative	  to	  GAPDH	  expression.	  Blue	  bars	  indicate	  control	  cell	  and	  red	  bars	  indicate	  S1PR3	  KO	  
cells	  (b)	  Clonogenic	  evaluation	  of	  S1PR3	  KO	  and	  wild	  type	  cells.	  Increased	  cell	  clonogenicity	  is	  observed	  
in	  S1PR3	  KO	  cells	  as	  compared	  to	  wild	  type	  control	  cells.	  
	  
Clonogenic	  evaluation	  of	  these	  cells	  demonstrates	  that	  S1PR3	  knock	  out	  cells	  
display	  increased	  clonogenicity	  as	  compared	  to	  wild	  type	  controls	  as	  shown	  in	  
Figure	  29b.	  	  When	  migration	  was	  assessed	  using	  scratch	  assay	  analysis	  followed	  by	  
Image	  j	  quantification	  of	  initial	  scratch	  width	  and	  scratch	  width	  at	  16	  hours,	  
increased	  migration	  was	  observed	  in	  S1PR3	  knockout	  cells	  as	  compared	  to	  wild	  
type	  controls	  as	  shown	  in	  Figure	  29a.	  An	  additional	  control	  of	  VPC	  treatment	  in	  wild	  
type	  cells	  was	  included	  demonstrating	  no	  change	  in	  migration	  as	  previously	  
demonstrated	  by	  Essen	  analysis.	  	  	  Proliferation	  analysis	  by	  MTS	  assay	  was	  
consistent	  with	  VPC	  treatment	  with	  KO	  cells	  proliferating	  more	  rapidly	  than	  the	  
wild	  type	  controls	  suggesting	  that	  inhibition	  of	  S1PR3	  may	  contribute	  more	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Figure	  28:	  Evaluation	  of	  wild	  type,	  VPC	  treated,	  and	  S1PR3	  KO	  cells	  for	  migration	  using	  %	  closure	  to	  
evaluate	  .	  P<	  0.001	  for	  S1P3KO	  vs.	  vehicle	  control	  and	  no	  significant	  difference	  was	  observed	  for	  Vehicle	  
vs	  VPC	  treatment	  (a)	  and	  proliferation	  analysis	  of	  control	  and	  S1PR3	  KO	  cells	  	  with	  p<0.001	  for	  wild	  type	  
controls	  as	  compared	  to	  S1P3KO	  animals.	  Proliferation	  was	  assessed	  using	  MTS	  assay	  with	  fold	  change	  
calculated	  based	  on	  cells	  prior	  to	  initiation	  of	  treatment.	  
	  
Finally,	  we	  evaluated	  the	  effects	  of	  functional	  antagonism	  of	  all	  of	  the	  S1P	  receptors	  
to	  the	  exclusion	  of	  S1PR2	  with	  increasing	  doses	  of	  FTY720	  treatment	  as	  shown	  in	  
Figure	  30.	  No	  changes	  in	  proliferation	  were	  observed	  with	  a	  dose	  range	  of	  10	  nM	  to	  
1	  μM	  FTY720	  as	  assessed	  by	  MTS	  assay	  as	  shown	  in	  Figure	  30a.	  However,	  at	  this	  
same	  dose	  range,	  there	  were	  no	  increases	  in	  migration	  at	  all	  concentrations	  of	  
FTY720.	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Figure	  29:	  Proliferation	  analysis	  using	  MTS	  analysis	  following	  treatment	  with	  increasing	  doses	  of	  
FTY720	  from	  0	  to	  1	  μM	  (a)	  Proliferation	  analysis	  of	  FTY720	  using	  50	  nm-­3000	  nM	  treatment	  as	  assess	  by	  
crystal	  violet	  proliferation	  assay.	  	  Migration	  analysis	  following	  treatment	  with	  increasing	  doses	  of	  
FTY720	  	  using	  scratch	  assay(b)	  No	  significant	  differences	  in	  proliferation	  of	  migration	  were	  observed	  
with	  FTY720	  treatment	  in	  these	  dose	  ranges.	  
	  
Although	  we	  have	  characterized	  the	  role	  of	  S1PR2	  in	  impacting	  MSC	  differentiation,	  
proliferation,	  and	  migration	  in	  previous	  chapters,	  S1PR1	  and	  S1PR3	  have	  
documented	  roles	  in	  promoting	  MSC	  proliferation	  and	  migration	  often	  functioning	  
antagonistically	  to	  S1PR2.	  When	  S1PR1	  and	  R3	  were	  inhibited	  by	  treatment	  with	  
VPC	  in	  MSCs	  from	  C57Bl/6	  mice,	  no	  changes	  in	  migration	  were	  observed,	  but	  an	  
increase	  in	  proliferation	  was	  observed.	  The	  increased	  proliferation	  observed	  
following	  VPC	  treatment	  is	  likely	  the	  result	  of	  S1PR3	  as	  S1PR3	  KO	  cells	  have	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increased	  proliferation	  as	  compared	  to	  wild	  type	  counterparts.	  No	  changes	  in	  Erk	  
expression	  were	  observed	  following	  VPC	  treatment	  indicating	  that	  the	  mechanism	  
of	  these	  proliferative	  changes	  is	  not	  based	  on	  Erk	  activation	  as	  has	  been	  described	  
for	  S1PR2	  knockout	  cells.	  Based	  on	  this	  analysis,	  increased	  focus	  was	  placed	  on	  
S1PR2	  although	  increased	  research	  certainly	  needs	  to	  be	  conducted	  further	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Chapter	  6:	  Role	  of	  S1PR2	  in	  MSC	  adipogenic	  and	  
osteogenic	  differentiation	  
	  
Previous	  chapters	  have	  examined	  the	  role	  of	  S1PR2	  in	  migration	  and	  proliferation	  of	  
MSCs.	  However,	  critical	  to	  the	  function	  of	  a	  stem	  cell	  is	  its	  ability	  to	  differentiate	  into	  
its	  derivative	  lineages.	  For	  MSCs,	  differentiation	  into	  adipogenic	  and	  osteogenic	  
lineages	  is	  essential	  to	  the	  definition	  of	  an	  MSC.	  In	  the	  first	  chapter,	  we	  
demonstrated	  the	  capacity	  of	  MSCs	  to	  differentiate	  into	  adipocytes	  expressing	  
FABP4	  and	  mature	  osteoblasts	  expressing	  osteopontin.	  I	  followed	  up	  on	  this	  finding	  
in	  this	  chapter	  by	  addressing	  the	  capacity	  of	  MSCs	  to	  differentiate	  following	  
modulation	  of	  S1PR2.	  	  Due	  to	  experimental	  limitations	  chondrogenic	  lineage	  was	  
not	  addressed	  in	  this	  chapter.	  	  
	  
Differentiation	  into	  adipocytes	  is	  controlled	  by	  master	  regulator	  PPARΥ	  whereas	  
induction	  of	  osteogenesis	  is	  controlled	  by	  master	  regulator	  Runx2.	  In	  either	  case	  a	  
variety	  of	  factors	  impact	  the	  expression	  of	  these	  master	  regulators.	  	  Evaluation	  of	  
the	  role	  of	  MAPKs	  in	  this	  process	  has	  suggested	  that	  although	  JNK	  activation	  is	  
critical	  to	  extracellular	  matrix	  synthesis	  in	  the	  osteogenic	  process,	  Erk	  is	  
upregulated	  during	  days	  7-­‐11	  of	  induction	  by	  osteogenic	  differentiation	  media	  
during	  the	  critical	  differentiation	  time	  with	  a	  return	  to	  basal	  expression	  status	  
following	  differentiation	  (219).	  Overexpression	  of	  a	  dominant	  negative	  Mek1	  results	  
in	  the	  diminished	  osteogenic	  activation	  (219).	  In	  contrast,	  Erk	  is	  not	  required	  for	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MSC	  adipogenic	  differentiation	  and	  Erk	  phosphorylation	  of	  PPARγ	  diminishes	  its	  
transcriptional	  activity	  (220).	  	  
	  
Induction	  of	  osteogenesis	  in	  vitro	  has	  been	  achieved	  through	  a	  variety	  of	  protocols	  
and	  agents.	  Most	  commonly	  osteogenic	  differentiation	  media	  includes	  a	  
combination	  of	  dexamethasone,	  ascorbic	  acid,	  and	  B-­‐glycerophosphate	  (221).	  
Osteogenic	  differentiation	  can	  be	  evaluated	  by	  osteopontin	  staining,	  alkaline	  
phosphatase	  activity,	  or	  alizirin	  red	  staining	  (219,	  222).	  Adipogenic	  differentiation	  
media	  commonly	  contains	  isobutylmethylxanthine	  which	  increases	  PPARγ	  by	  acting	  
as	  a	  nonselective	  phosphodiesterase	  inhibitor	  and	  insulin	  which	  a	  promotes	  
proliferation	  and	  differentiation	  of	  MSCs	  (223).	  Adipogenic	  differentiation	  can	  be	  
evaluated	  by	  oil	  red	  O	  staining	  or	  FABP4	  expression	  (224).	  	  
	  
Differentiation	  of	  wild	  type	  and	  S1PR2	  knockout	  MSCs	  was	  evaluated	  following	  
induction	  into	  osteogenic	  and	  adipogenic	  differentiation	  lineages	  according	  to	  the	  
instructions	  provided	  by	  the	  manufacturer	  for	  the	  R&D	  systems	  murine	  MSC	  
functional	  identification	  kit.	  Adipogenic	  differentiation	  media	  contained	  
hydrocortisone,	  isobutylmethylxanthine,	  and	  indomethacin	  and	  osteogenic	  
supplementation	  media	  contained	  dexamethasone,	  ascobate-­‐phosphate,	  proline,	  
pyruvate	  and	  TGFβ.	  	  Exact	  concentrations	  of	  these	  agents	  are	  proprietary.	  Induction	  
media	  was	  changed	  every	  2-­‐3	  days	  for	  2-­‐3	  weeks	  and	  evaluated	  by	  osteopontin	  
immunofluorescent	  staining	  for	  osteogenesis	  and	  FABP4	  staining	  for	  adipogenesis.	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Cells	  were	  evaluated	  by	  confocal	  microscopy	  with	  cells	  counted	  in	  at	  least	  10	  fields	  
for	  positive	  or	  negative	  staining	  as	  shown	  in	  Figure	  31.	  Cells	  lacking	  expression	  of	  
S1PR2	  had	  decreased	  induction	  of	  differentiation	  for	  both	  adipogenic	  and	  
osteogenic	  lineages,	  suggesting	  a	  more	  central	  role	  for	  S1PR2	  in	  MSC	  differentiation	  
rather	  than	  a	  lineage	  specific	  role.	  However,	  these	  MSCs	  still	  demonstrated	  the	  
capacity	  to	  differentiate	  into	  both	  lineages.	  Representative	  images	  of	  the	  staining	  
are	  shown	  in	  Figure	  31c.	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Figure	  30:	  Evaluation	  of	  S1PR2	  KO	  cell	  differentiation.	  Osteogenic	  differentiation	  was	  assessed	  by	  the	  
number	  of	  cells	  expressing	  Osteopontin	  relative	  to	  the	  total	  number	  of	  cells	  per	  each	  high	  powered	  field	  
(A).	  	  	  Adipogenic	  differentiation	  was	  similarly	  assessed	  using	  FABP4	  as	  a	  marker	  (b)	  	  Represenative	  
images	  of	  	  wild	  type	  and	  KO	  cells	  are	  shown	  	  in	  (C).	  
	  
Following	  evaluation	  of	  differentiation	  of	  MSCs	  in	  knockout	  cells,	  we	  treated	  cells	  
with	  JTE013	  in	  standard	  culture	  media	  during	  each	  media	  change	  for	  MSCs.	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However,	  given	  concern	  for	  the	  strong	  capacity	  of	  the	  induction	  media	  to	  promote	  
differentiation,	  we	  sought	  to	  examine	  differentiation	  of	  MSCs	  following	  long-­‐term	  
culture	  in	  the	  absence	  of	  induction	  media	  and	  cultures	  in	  standard	  cell	  culture	  
media.	  Similar	  to	  the	  results	  seen	  with	  S1PR	  knockout	  cells	  following	  induction,	  
inhibition	  of	  S1PR2	  resulted	  in	  decreased	  MSC	  differentiation	  into	  both	  adipogenic	  
and	  osteogenic	  lineages	  as	  shown	  in	  Figure	  32.	  	  
	  
Figure	  31:	  MSC	  differentiation	  into	  osteocytes	  and	  adipocytes	  with	  S1PR2	  inhibition.	  Evaluation	  of	  
JTE013	  treated	  MSCs	  for	  differentiation	  into	  adipogenic	  lineages.	  Differentiation	  was	  calculated	  as	  the	  
number	  of	  cells	  expressing	  FABP4	  per	  high	  powered	  field	  (a).	  Similar	  analysis	  was	  conducted	  for	  
osteogenic	  differentiation	  	  (b)	  using	  Osteopontin	  as	  a	  marker	  for	  differentiation.	  *	  indicates	  p<0.05	  
based	  on	  a	  student	  t-­test.	  
	  
Following	  identification	  of	  decreased	  differentiation	  of	  MSCs	  following	  inhibition	  of	  
S1PR2	  we	  sought	  to	  determine	  the	  mechanism	  by	  which	  this	  decreased	  
differentiation	  was	  occurring.	  We	  evaluated	  this	  both	  on	  the	  pathway	  specific	  level	  
and	  at	  the	  level	  of	  MSC	  self-­‐renewal.	  MSCs	  were	  treated	  in	  100	  mm	  dishes	  with	  1	  μM	  
JTE	  in	  duplicate	  for	  30	  minutes.	  RNA	  was	  synthesized	  using	  Qiagen	  RNEASY	  and	  
quantified	  based	  on	  the	  Beckman	  spectrophotometer	  260	  nm	  absorbance	  values.	  
RNA	  was	  analyzed	  for	  RNA	  copy	  number	  using	  Nanostring	  analysis	  conducted	  by	  
	   107	  
murine	  code	  set	  -­‐1	  developed	  my	  the	  Medical	  University	  of	  South	  Carolina	  Center	  
for	  Oral	  Health	  Research.	  Data	  was	  normalized	  to	  positive	  controls	  using	  nSolver	  	  
Analysis	  software	  with	  background	  reduced	  to	  accurately	  depict	  RNA	  copy	  number.	  
Bone	  morphogenic	  protein	  (BMP4)	  promotes	  MSC	  differentiation	  into	  both	  
adipogenic	  and	  osteogenic	  lineages.	  Sox9	  is	  upregulated	  and	  dictates	  chondrogenic	  
differentiation	  whereas	  αSMA	  is	  upregulated	  in	  fibroblast	  differentiation	  pathways.	  
No	  changes	  in	  expression	  were	  observed	  in	  any	  of	  these	  pathway	  specific	  
differentiation	  genes	  following	  inhibition	  for	  S1PR2	  as	  shown	  in	  Figure	  33.	  
However,	  for	  a	  better	  analysis	  of	  these	  factors	  using	  a	  dose	  range	  and	  time	  course	  
including	  longer	  time	  points	  will	  need	  to	  be	  evaluated	  to	  properly	  evaluate	  changes	  
following	  the	  differentiation	  process.	  At	  a	  more	  central	  level,	  MSC	  differentiation	  is	  
controlled	  by	  pluripotency	  factors	  that	  promote	  MSC	  self-­‐renewal	  and	  inhibit	  MSC	  
differentiation.	  	  Figure	  33b	  shows	  that	  Nanog	  is	  prominently	  expressed	  both	  in	  
MSCs	  have	  not	  been	  passaged	  and	  MSCs	  at	  passage	  4.	  This	  conclusions	  supports	  the	  
conclusion	  that	  Nanog	  plays	  a	  critical	  function	  in	  MSC	  differentiation	  and	  is	  not	  an	  
artifact	  of	  cell	  culture	  processes.	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Figure	  32:	  Mechanism	  of	  S1PR2	  impact	  on	  MSC	  differentiation	  into	  adipogenic	  lineages	  (a)	  Nanostring	  
analysis	  of	  JTE013	  treated	  MSCs	  for	  number	  of	  transcripts	  of	  the	  indicated	  genes	  (b)	  qPCR	  evaluation	  of	  
Nanog	  expression	  in	  uncultured	  cells	  	  as	  compared	  to	  P4	  cultured	  cells	  after	  cell	  sorting	  (c)	  qPCR	  
expression	  of	  MSCs	  in	  wild	  type	  and	  KO	  cells	  for	  pluripotency	  factors	  (d)	  qPCR	  expression	  of	  JTE013	  
treated	  MSCS	  for	  pluripotency	  factors.	  
	  
In	  MSCs,	  there	  is	  variation	  in	  the	  pluripotency	  factors	  that	  are	  reported	  to	  be	  
expressed.	  However,	  reports	  consistently	  implicate	  Nanog,	  Oct4,	  Rex1,	  and	  Sox2	  as	  
being	  expressed	  and	  critical	  to	  MSC	  self-­‐renewal.	  Literature	  reports	  some	  
controversy	  as	  to	  whether	  Nanog	  is	  expressed	  in	  vivo	  or	  whether	  the	  culture	  
conditions	  of	  MSCs	  cause	  its	  upregulation.	  To	  evaluate	  whether	  Nanog	  was	  
expressed	  in	  MSCs	  in	  vivo	  we	  compared	  sorted	  passage	  4	  cells	  used	  for	  experiments	  
as	  compared	  to	  cells	  sorted	  directly	  from	  bone	  marrow	  and	  pelleted	  by	  
centrifugation	  without	  culturing	  as	  shown	  in	  Figure	  33C	  and	  D.	  These	  cells	  strongly	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expressed	  Nanog	  with	  a	  561-­‐fold	  increase	  in	  Nanog	  expression	  as	  compared	  to	  
passage	  4	  cultured	  cells.	  To	  evaluate	  pluripotency	  factors	  expressed	  in	  MSCs,	  qPCR	  
was	  conducted	  following	  S1P	  inhibition.	  RNA	  was	  isolated,	  cDNA	  was	  synthesized,	  
and	  quantitative	  real	  time	  PCR	  performed.	  	  	  
	  
Increases	  in	  the	  transcriptional	  activity	  of	  pluripotency	  factors	  were	  observed	  for	  all	  
pluripotency	  factors	  as	  evaluated	  in	  Figure	  33	  C	  and	  D.	  The	  diagrams	  shown	  
demonstrate	  fold	  change	  for	  representative	  quantitative	  realtime	  PCR	  expression	  of	  
one	  of	  three	  independent	  experiments.	  Consistent	  results	  were	  reported	  for	  both	  
inhibition	  of	  S1PR2	  using	  JTE013	  and	  in	  the	  knockout	  cells	  as	  compared	  to	  wild	  type	  
cells.	  	  The	  changes	  in	  pluripotency	  factors	  suggest	  a	  parallel	  increase	  consistent	  with	  
the	  changes	  in	  the	  differentiation	  of	  MSCs.	  Further	  evaluation	  of	  differentiation	  with	  
Nanog	  inhibition	  using	  siRNA	  or	  overexpression	  would	  elucidate	  the	  role	  of	  the	  
pluripotency	  factors	  in	  impacting	  the	  reduction	  of	  differentiation	  follow	  S1PR2	  
inhibition.	  	  
	  
The	  capacity	  of	  MSCs	  for	  differentiation	  is	  critical	  to	  MSC	  self-­‐renewal	  and	  the	  
maintenance	  of	  a	  pluripotent	  MSC	  population.	  Our	  results	  indicate	  that	  S1PR2	  is	  
critical	  to	  mediating	  MSC	  differentiation	  into	  adipogenic	  and	  osteogenic	  lineages.	  
Inhibition	  of	  S1PR2	  results	  in	  diminished	  MSC	  differentiation	  with	  associated	  
increases	  in	  MSC	  pluripotency	  factor	  qPCR	  expression.	  Differentiation	  of	  osteogenic	  
and	  adipogenic	  differentiation	  is	  mediated	  by	  a	  balance	  of	  factors	  expressed	  that	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either	  promote	  	  differentiation	  or	  maintenance	  of	  the	  undifferentiated	  state.	  If	  a	  
differentiated	  state	  is	  promoted	  the	  exact	  factors	  expressed	  will	  determine	  the	  
lineage	  of	  differentiation	  into	  the	  three	  classical	  pathways	  osteogenic,	  adipogenic,	  or	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Chapter	  7:	  Inhibition	  of	  S1PR2	  in	  prostate	  cancer	  
	  
S1PR2	  may	  have	  a	  critical	  function	  in	  the	  maintenance	  of	  other	  stem	  cell	  
populations	  not	  limited	  to	  MSCs.	  Cancer	  stem	  cells	  are	  tumors	  cells	  within	  the	  
malignant	  clonal	  population	  that	  can	  repopulate	  a	  cancer.	  Identification	  and	  
elimination	  or	  these	  cells	  is	  therefore	  necessary	  to	  consider	  in	  strategies	  designed	  
for	  tumor	  control	  and	  elimination.	  Serial	  transplantation	  assays	  and	  lineage	  tracing	  
assays	  have	  been	  conducted	  examine	  which	  cell	  populations	  might	  be	  considered	  a	  
tumor	  stem	  cell	  (225).	  In	  prostate	  cancer,	  stem	  cells	  have	  been	  identified	  and	  
characterized	  to	  have	  a	  number	  of	  different	  marker	  characterizations.	  Most	  
commonly	  prostate	  cancer	  stem	  cells	  have	  been	  shown	  to	  express	  CD44+,	  α2β1	  
integrin,	  and	  CD133+	  marker	  expression	  with	  enzymatic	  activity	  of	  aldehyde	  
dehydrogenase	  (93).	  	  Previous	  work	  has	  identified	  that	  S1P	  stimulated	  increases	  in	  
Erk	  phosphorylation	  result	  in	  increased	  CD44+	  expression	  in	  human	  colon	  cancer	  
cells	  (209,	  226).	  
	  
Aldehyde	  dehydrogenase	  (ALDH)	  can	  be	  evaluated	  by	  Aldefluor	  assays,	  which	  
provide	  aldefluor	  substrate	  that	  when	  metabolized	  results	  in	  fluorescent	  expression	  
that	  can	  be	  detected	  by	  standard	  Flow	  Cytometry.	  ALDH	  has	  been	  shown	  in	  prostate	  
cancer	  to	  be	  highly	  expressed	  in	  a	  small	  subset	  of	  the	  population	  with	  0.5	  to	  6%	  of	  
cells	  in	  human	  prostate	  cancer	  cell	  lines	  expressing	  ALDH	  and	  0.6	  to	  4%	  in	  tumor	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clinical	  samples	  (227).	  Cells	  expressing	  ALDH	  have	  been	  shown	  to	  have	  increased	  
clonogenicity,	  migration,	  sphere	  formation,	  metastatic	  in	  vivo,	  and	  invasion	  (228-­‐
230).	  These	  assays	  have	  suggested	  that	  ALDH	  may	  be	  able	  to	  be	  used	  to	  identify	  
tumor	  initiating	  or	  metastasis	  initiating	  tumor	  stem	  cells.	  	  
	  
CD133	  or	  prominin-­‐1	  is	  a	  peptaspan	  membrane	  glycoprotein	  associated	  with	  cells	  
having	  a	  high	  proliferative	  potential	  (231).	  In	  prostate	  cancer	  biopsies,	  CD133+,	  
when	  expressed,	  represented	  less	  than	  1%	  of	  cells.	  Expression	  was	  identified	  in	  
50%	  of	  prostate	  cancers	  with	  increases	  in	  CD133	  expression	  in	  matched	  metastatic	  
samples	  as	  compared	  to	  the	  primary	  tumor	  (231).	  When	  CD133+	  cells	  are	  
transplanted	  from	  primary	  xenografts,	  less	  than	  10	  cells	  are	  required	  for	  tumor	  
formation.	  Hypoxia,	  common	  in	  solid	  tumors,	  results	  in	  increased	  CD133+	  
expression	  through	  Oct4	  and	  Sox2	  upregulation	  (232).	  	  
	  
CD44	  is	  a	  homing	  adhesion	  molecule	  that	  acts	  as	  a	  transmembrane	  glycoprotein	  that	  
interacts	  primarily	  with	  hyaluronin	  and	  other	  extracellular	  matrix	  components	  
(233,	  234).	  These	  components	  are	  highly	  upregulated	  with	  the	  desmoplastic	  
environment	  of	  prostate	  cancer.	  Desmoplasia	  is	  the	  expansion	  of	  tumor	  stroma	  
within	  the	  inflammatory	  tumor	  microenvironment	  associated	  with	  increased	  ECM	  
deposition	  including	  collagens,	  fibronectin,	  proteoglycans,	  and	  hyaluronin	  (235,	  
236).	  The	  formation	  of	  this	  desmoplastic	  environment	  provides	  a	  significant	  barrier	  
to	  solid	  tumor	  treatment	  due	  to	  decreased	  drug	  delivery.	  Pellacani	  et	  al.	  have	  shown	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that	  CD44+,	  α2β1	  integrin,	  and	  CD133+	  prostate	  cancer	  cells	  have	  increased	  self-­‐
renewal	  capacity	  in	  addition	  to	  a	  tumor	  initiating	  capacity	  suggesting	  this	  
combination	  as	  a	  important	  cell	  marker	  combination	  for	  prostate	  cancer	  stem	  cell	  
identification(231).	  	  
	  
In	  this	  chapter,	  we	  evaluate	  the	  impact	  of	  S1PR2	  on	  prostate	  cancer	  stem	  cell	  
formation.	  The	  role	  of	  S1PR2	  in	  prostate	  cancer	  has	  only	  been	  characterized	  to	  a	  
limited	  capacity	  with	  Beckham	  et	  al.	  demonstrating	  that	  increased	  S1PR2	  
expression	  results	  from	  increases	  in	  acid	  ceramidase.	  This	  increase	  is	  associated	  
with	  an	  increased	  oncogenic	  phenotype	  as	  evaluated	  by	  soft	  agar	  colony	  formation	  
and	  by	  MTS	  proliferation	  analysis	  (237).	  S1PR2	  has	  been	  preliminarily	  
characterized	  as	  promoting	  prostate	  cancer	  progression	  in	  vitro.	  	  	  
	  
Following	  the	  work	  of	  Beckham	  et	  al.	  we	  examined	  the	  transcriptional	  expression	  of	  
acid	  ceramidase	  and	  the	  sphingosine	  kinases	  following	  treatment	  with	  3	  μM	  JTE013.	  
Overnight	  treatment	  with	  3	  μM	  JTE013	  was	  conducted	  in	  TRAMP-­‐C2	  murine	  
prostate	  cancer	  cells.	  	  RNA	  was	  isolated	  by	  trizol	  extraction	  and	  cDNA	  synthesized	  
according	  to	  manufacturer’s	  instruction	  using	  the	  Biorad	  iScript	  cDNA	  synthesis	  kit.	  
Quantitative	  realtime	  pcr	  was	  conducted	  as	  previously	  described.	  JTE013	  treatment	  
results	  in	  the	  transcriptional	  upregulation	  of	  acid	  ceramidase	  as	  well	  as	  a	  moderate	  
increase	  in	  sphingosine	  kinase	  1	  and	  2	  suggesting	  upregulation	  of	  the	  oncogenic	  
pathway	  characterized	  by	  Beckham	  et	  al.	  in	  prostate	  cancer	  as	  shown	  in	  Figure	  34.	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Further	  evaluation	  of	  the	  transcriptional	  expression	  of	  pluripotency	  factors	  
commonly	  expressed	  in	  prostate	  cancer	  tumor	  initiating	  stem	  cell	  populations	  
suggest	  an	  increase	  in	  Nanog	  expression	  consistent	  with	  a	  more	  stem	  cell	  line	  
population	  as	  shown	  in	  Figure	  34B.	  JTE013	  may	  promote	  increased	  oncogenesis	  and	  
an	  increased	  stem-­‐like	  population	  in	  Tramp-­‐C2	  prostate	  cancer	  cells.	  This	  discovery	  
prompted	  further	  evaluation	  of	  the	  stem-­‐like	  characteristics	  of	  this	  population.	  	  
	  
	  
	   115	  
	  
Figure	  33:	  Transcriptional	  analysis	  of	  TRAMP-­C2	  cells	  following	  JTE013	  treatment.	  qPCR	  analysis	  of	  S1P	  
generating	  enzymes	  in	  TRAMP-­C2	  cells	  normalized	  to	  actin	  controls	  (a)	  qPCR	  analysis	  of	  pluripotency	  
genes	  in	  TRAMP-­C2	  cells	  following	  JTE	  treatment	  (b).***	  indicate	  p<0.001,	  **	  indicates	  p<0.01	  and	  *	  
indicates	  p<0.05	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Based	  on	  these	  findings,	  and	  the	  suggestion	  of	  a	  more	  stem-­‐like	  population	  within	  
JTE013	  treated	  prostate	  cancer	  cells,	  we	  evaluated	  the	  marker	  expression	  of	  cell	  
surface	  markers	  of	  prostate	  cancer	  stem	  cells	  for	  CD44+,	  CD133+	  and	  the	  enzymatic	  
activity	  of	  ALDH.	  Cells	  were	  plated	  in	  cell	  culture	  dishes	  treated	  overnight	  with	  the	  
indicated	  doses	  of	  JTE013.	  Cells	  were	  lifted	  by	  trysinization,	  stained	  for	  20	  minutes	  
with	  the	  indicated	  antibody	  or	  staining	  kit	  according	  to	  manufacturers	  instructions	  
for	  the	  Aldefluor	  aldehyde	  dehydrogenase	  expression	  kit.	  CD44+	  cells	  composed	  
over	  99%	  of	  the	  TRAMP-­‐C2	  cell	  population	  and	  as	  such	  further	  evaluation	  of	  this	  
marker	  in	  differentiating	  tumor	  initiating	  cells	  was	  not	  used.	  Aldefluor	  analysis	  of	  
TRAMPC2	  cells	  yielded	  more	  informative	  results	  in	  the	  evaluation	  of	  JTE013	  
treatment	  and	  its	  impact	  on	  the	  stem	  cell	  population	  as	  shown	  in	  Figure	  35.	  For	  
aldefluor	  treatment,	  DEAB,	  an	  inhibitor	  of	  aldehyde	  dehydrogenase,	  was	  used	  as	  a	  
negative	  control.	  Vehicle	  treatment	  included	  an	  equivalent	  volume	  of	  DMSO.	  Both	  
ALDH	  and	  CD133+	  have	  increased	  expression	  following	  JTE013	  treatment.	  
Representative	  plots	  of	  flow	  Cytometry	  are	  shown	  in	  figure	  35a	  and	  35b	  with	  
quantitative	  evaluation	  shown	  in	  35c.	  Flow	  cytometry	  was	  conducted	  using	  a	  BD	  
FACS	  Calibur	  with	  subsequent	  analysis	  of	  cell	  populations	  evaluated	  by	  Flo	  Jo.	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Figure	  34:	  Flow	  Cytometry	  analysis	  of	  TRAMP-­C2	  cells	  for	  stem	  cell	  characteristics.	  Aldefluor	  expression	  
analysis	  of	  TRAMP-­C2	  following	  JTE013	  treatment.	  DEAB	  is	  an	  inhibitor	  of	  aldefluor	  dehydrogenase	  used	  
as	  a	  negative	  control	  (a)	  CD133+	  	  analysis	  of	  JTE013	  treated	  TRAMP-­C2	  cells.	  Cell	  population	  summary	  
for	  ALDH	  and	  CD133	  expressions	  summary	  (c).Representative	  images	  are	  shown	  for	  two	  independent	  
experiments.	  
	  
From	  this	  analysis,	  increased	  expression	  of	  PCa	  stem	  markers	  was	  observed	  
following	  JTE013	  treatment	  in	  TRAMP-­‐C2	  murine	  prostate	  cancer	  cells.	  Expression	  
levels	  of	  untreated	  ALDH	  were	  consistent	  with	  that	  of	  the	  previously	  published	  
results	  for	  prostate	  cancer	  cell	  lines.	  This	  data	  suggests	  that	  S1PR2	  inhibition	  results	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An	  interesting	  dichotomy	  proposed	  by	  the	  following	  analysis	  is	  in	  the	  dual	  and	  
somewhat	  antagonistic	  effect	  in	  which	  S1PR2	  inhibition	  promotes	  increased	  MSC	  
proliferation	  but	  inhibition	  in	  PCa	  promotes	  an	  increased	  prostate	  cancer	  cell	  
proliferation	  as	  shown	  by	  Beckham	  et	  al.	  	  S1PR2	  inhibition	  simultaneously	  
promotes	  an	  increased	  stem	  cell	  like	  phenotype	  in	  PCa.	  As	  stem	  cells	  are	  largely	  
thought	  to	  be	  quiescent,	  we	  sought	  to	  analyze	  whether	  the	  small	  subpopulation	  of	  
cells	  expressing	  CD133	  and	  Alde	  was	  itself	  demonstrating	  changes	  in	  proliferation	  
consistent	  with	  the	  remainder	  of	  the	  cell	  population.	  To	  evaluate	  this	  phenomenon,	  
cells	  were	  stained	  with	  cell	  trace	  violet	  for	  5	  minutes	  at	  37	  degrees	  Celsius.	  Baseline	  
fluorescence	  was	  assessed	  in	  this	  cell	  population	  using	  the	  FACS	  ARIA	  II	  flow	  
Cytometry	  and	  this	  analysis	  was	  considered	  the	  day	  0	  samples.	  The	  remainder	  of	  the	  
treatment	  groups	  were	  either	  plated	  with	  vehicle	  treatment	  or	  JTE013	  treatment	  as	  
indicated.	  Cells	  were	  trypsinized	  and	  analyzed	  48	  hours	  following	  treatment	  as	  
shown	  in	  Figure	  36.	  An	  increased	  left	  shift	  indicates	  further	  dilution	  of	  the	  dye	  and	  
therefore	  increased	  proliferation.	  In	  these	  cells,	  no	  increase	  in	  cell	  proliferation	  was	  
observed	  following	  7.5	  μM	  JTE013	  treatment.	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Figure	  35:	  Proliferation	  analysis	  of	  JTE013	  treated	  TRAMP-­C2	  prostate	  cancer	  cells	  by	  cell	  trace	  violet	  
expression.	  Red	  indicates	  staining	  at	  t=0,	  yellow	  indicates	  JTE013	  treatment	  at	  Day	  2,	  and	  green	  
indicates	  vehicle	  treated	  cells	  at	  Day	  2.	  
	  
To	  further	  evaluate	  whether	  subpopulations	  of	  JTE013	  might	  be	  proliferating	  at	  
different	  rates,	  prostate	  cancer	  cells	  were	  additionally	  stained	  at	  day	  2	  with	  
aldefluor	  as	  previously	  described	  with	  simultaneous	  proliferation	  analysis	  as	  shown	  
in	  Figure	  37.	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Figure	  36:	  Evaluation	  of	  cell	  trace	  violet	  expression	  of	  aldefluor	  expression	  in	  TRAMP-­C2	  aldefluor	  
positive	  prostate	  cancer	  cells.	  Cells	  were	  treated	  with	  JTEO13	  from	  1.5	  -­6	  μM	  JTE013	  with	  negative	  
Vehicle	  controls	  and	  DEAB,	  an	  inhibitor	  of	  Aldehyde	  dehydrogenase	  (a)	  Similar	  analysis	  of	  cell	  trace	  
violet	  staining	  was	  conducted	  in	  TRAMP-­C2	  aldefluor	  negative	  cells	  (b)	  Comparison	  between	  cell	  trace	  
violet	  staining	  of	  TRAMP-­C2	  cells	  treated	  with	  vehicle	  control	  for	  Aldefluor	  positive	  and	  negative	  cell	  
populations	  (c).	  	  
	  
Similar	  to	  the	  previous	  evaluation	  of	  JTE013	  on	  TRAMP-­‐C2	  prostate	  cancer	  cells,	  no	  
impact	  on	  proliferation	  overall	  was	  observed	  following	  JTE013	  treated	  protaste	  
cancer	  cells	  as	  shown	  in	  Figure	  37.	  JTE013	  treatment	  between	  1.5	  and	  6	  μM	  JTE013	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demonstrated	  no	  differences	  in	  proliferation	  as	  assessed	  by	  cell	  trace	  violet.	  This	  
same	  result	  was	  observed	  in	  the	  aldefluor	  positive	  TRAMP-­‐C2	  population,	  the	  
aldefluor	  negative	  population,	  and	  the	  total	  cell	  populations.	  While	  no	  differences	  
were	  observed	  between	  the	  non-­‐treated	  and	  treated	  cell	  populations,	  one	  
interesting	  observation	  was	  noted.	  There	  was	  a	  distinct	  difference	  in	  proliferation	  
between	  the	  aldefluor	  negative	  and	  the	  aldefluor	  positive	  cells.	  Aldefluor	  positive	  
cells	  have	  had	  decreased	  left-­‐ward	  shift	  and	  therefore	  decreased	  proliferation	  as	  
compared	  to	  aldefluor	  negative	  cells.	  We	  therefore	  conclude	  that	  JTE013	  promotes	  
an	  increased	  stem	  cell	  like	  phenotype	  in	  prostate	  cancer	  cells	  consistent	  with	  that	  of	  
previous	  reports	  for	  prostate	  cancer	  cells	  following	  S1PR2	  inhibition.	  	  
	  
To	  assess	  the	  role	  of	  S1PR2	  inhibition	  on	  TRAMP-­‐C2	  cells,	  in	  vivo	  analysis	  of	  this	  
system	  was	  conducted.	  TRAMP-­‐C2	  tumors	  were	  grown	  in	  C57BL/6	  mice.	  Following	  
tumor	  presentation	  in	  these	  mice,	  tumors	  were	  randomized	  to	  vehicle	  treatment	  or	  
JTE013	  treatment.	  No	  differences	  were	  observed	  in	  initial	  tumor	  volume	  between	  
vehicle	  and	  JTE013	  randomize	  group.	  Throughout	  the	  experiment,	  no	  change	  in	  
animal	  weight	  was	  observed	  following	  JTE013	  treatment.	  JTE013	  was	  delivered	  
intraperitoneally	  at	  a	  3	  mg/kg	  dose	  to	  mice	  as	  2	  doses	  72	  hours	  apart.	  Following	  
treatment	  with	  JTE013,	  no	  differences	  in	  tumor	  proliferation	  were	  observed	  as	  
shown	  in	  Figure	  38B.	  On	  flow	  cytometry	  analysis	  no	  differences	  were	  observed	  
between	  the	  mean	  fluorescence	  intensity	  of	  CD133+,	  Aldh+,	  or	  dual	  positive	  cell	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populations	  as	  shown	  in	  Figure	  38a,	  c,	  or	  d.	  This	  indicates	  that	  no	  differences	  in	  the	  
stem	  cell	  population	  were	  observed	  following	  JTE013	  treatment	  in	  these	  cells.	  	  
	   	  
This	  experiment	  demonstrated	  that	  the	  JTE013	  enhanced	  changes	  in	  the	  stem	  cell	  
population	  that	  were	  observed	  in	  vitro	  were	  not	  recapitulated	  in	  our	  in	  vivo	  
experiment.	  Limitations	  of	  this	  experiment	  were	  the	  lack	  of	  indicators	  of	  successful	  
S1PR2	  inhibition.	  	  Experimental	  difficulty	  in	  assessing
	  
Figure	  37:	  In	  vivo	  tumor	  analysis	  of	  JTE013	  treated	  TRAMP-­C2	  prostate	  cancer	  tumors	  in	  C57Bl/6	  mice.	  
Tumors	  were	  grown	  until	  the	  average	  tumor	  volume	  was	  greater	  than	  200	  mm3.	  Treatment	  was	  
initiation	  with	  JTE013	  as	  two	  3	  mg/kg	  doses	  of	  JTE013	  72	  hours	  apart.	  Tumor	  digestion	  was	  conducted	  
following	  tumor	  removal	  with	  analysis	  conducted	  for	  vehicle	  treated	  and	  JTE013	  treated	  tumors	  for	  
expression	  of	  	  ALDH+	  CD133+	  cells	  (a).	  	  Tumor	  volume	  was	  evaluated	  following	  JTE	  treatment	  as	  shown	  
(B).	  The	  MFI	  for	  CD133+	  cells	  (c)	  and	  Aldh+	  	  cells	  (c)	  for	  each	  treatment	  group	  is	  shown.	  N=4	  for	  each	  
treatment	  group.	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this	  function	  results	  from	  the	  lack	  of	  quality	  antibodies	  to	  S1PR2	  protein	  and	  
additionally	  lack	  of	  S1PR2	  activity	  assays.	  The	  timing	  of	  the	  delivery	  of	  the	  JTE	  may	  
be	  a	  critical	  factor	  in	  impacting	  the	  tumor	  response	  to	  JTE013	  treatment.	  	  	  
	  
Cancer	  stem	  cells	  have	  been	  described	  in	  a	  number	  of	  different	  solid	  cancer	  types	  
and	  represent	  a	  cell	  population	  critical	  for	  treatment	  approaches	  as	  the	  failure	  to	  
eradicate	  cancer	  stem	  cells	  allows	  for	  tumor	  recurrence	  and	  metastasis	  following	  
treatment	  of	  the	  primary	  tumor.	  It	  is	  therefore	  important	  to	  understand	  the	  
mechanisms	  by	  which	  these	  cancer	  stem	  cells	  are	  generated.	  S1P	  concentrations	  are	  
high	  within	  a	  tumor	  environment	  due	  to	  the	  high	  inflammation	  of	  the	  tumor	  and	  the	  
often	  hypoxic	  nature	  of	  solid	  tumors	  resulting	  from	  the	  poor	  vascular	  perfusion.	  
Although	  many	  of	  the	  contributions	  of	  this	  high	  S1P	  concentration	  have	  been	  
evaluated,	  further	  understanding	  of	  the	  functions	  of	  S1P	  in	  prostate	  cancer	  stem	  
cells	  is	  required.	  Inhibition	  of	  S1PR2	  in	  prostate	  cancer	  cells	  results	  in	  an	  increased	  
stem	  cell	  phenotype	  in	  this	  population	  as	  assessed	  by	  marker	  expression	  using	  
CD133+	  expression	  with	  further	  validation	  of	  expression	  of	  Nanog	  and	  aldehyde	  
dehydrogenase.	  	  Additional	  characterization	  of	  these	  cells	  reveals	  that	  the	  prostate	  
cancer	  cells	  expressing	  aldefluor	  have	  decreased	  proliferation	  as	  compared	  to	  their	  
aldefluor	  negative	  counterparts.	  This	  relative	  quiescence	  suggests	  that	  these	  cells	  
could	  represent	  a	  cancer	  stem	  cell	  population	  consistent	  with	  the	  marker	  
expression.	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Chapter	  8:	  MSC	  co-­culture	  with	  TRAMP-­C2	  prostate	  
cancer	  cells	  
	  
MSCs	  are	  actively	  recruited	  to	  prostate	  cancer	  tumors	  and	  once	  there	  increase	  the	  
invasive	  and	  metastatic	  potential	  of	  the	  tumor	  (86).	  This	  is	  accomplished	  through	  a	  
number	  of	  mechanisms	  including	  increasing	  the	  stem	  cell	  population	  of	  tumor	  cells	  
and	  through	  the	  action	  of	  secreted	  factors	  that	  increase	  the	  motility	  and	  the	  
epithelial	  to	  mesenchymal	  transition.	  One	  of	  the	  key	  secreted	  factors	  that	  mediates	  
these	  changes	  is	  SDF-­‐1,	  although	  a	  number	  of	  other	  contributing	  factors	  have	  also	  
been	  identified	  (238).	  Based	  on	  these	  findings	  we	  investigated	  the	  impact	  of	  S1PR2	  
inhibition	  on	  MSC	  co-­‐culture	  with	  Tramp	  C2	  cells.	  	  
	  
Evaluation	  of	  a	  number	  of	  proteins	  with	  expression	  changes	  that	  impact	  prostate	  
cancer	  cell	  progression	  was	  evaluated.	  Nanog,	  although	  originally	  identified	  as	  
critical	  to	  embryonic	  stem	  cell	  self-­‐renewal	  is	  expressed	  in	  prostate	  cancer	  tumors	  
and	  impacts	  the	  tumorigenicity	  of	  the	  cells	  (239).	  Increased	  Nanog	  expression	  
results	  in	  increased	  drug	  resistance	  and	  increased	  tumor	  regeneration	  whereas	  
knockdown	  of	  Nanog	  diminishes	  the	  tumorigenicity	  and	  clonogenic	  growth	  of	  the	  
cells	  (240-­‐242).	  B-­‐catenin	  is	  a	  protein	  mutated	  in	  5%	  of	  prostate	  cancers	  and	  that	  
demonstrates	  20-­‐30%	  increased	  nuclear	  and	  cytoplasmic	  staining	  in	  prostate	  
cancer	  as	  compared	  to	  normal	  prostatic	  epithelium	  (243,	  244).	  This	  increased	  B-­‐
catenin	  expression	  results	  in	  increased	  growth	  and	  tumor	  invasion.	  Overexpression	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of	  B-­‐catenin	  in	  mouse	  models	  has	  been	  shown	  to	  promote	  murine	  PCa	  progression	  
through	  increased	  invasive	  potential	  (245).	  Survivin	  in	  an	  inhibitor	  of	  apoptosis	  
with	  increased	  expression	  associated	  with	  cancer	  progression	  and	  drug	  resistance.	  
Prostate	  cancer	  cell	  lines	  highly	  express	  survivin	  (246).	  Finally,	  cyclin	  D1	  is	  a	  
regulatory	  of	  G1	  phase	  progression	  in	  the	  cell	  cycle	  and	  may	  contribute	  to	  androgen	  
receptor	  independence	  in	  prostate	  cancer	  (247).	  	  
	  
The	  genes	  mentioned	  above	  were	  evaluated	  following	  delivery	  of	  either	  conditioned	  
media	  generated	  from	  MSCs	  that	  were	  vehicle	  treated	  or	  MSCs	  that	  were	  treated	  
with	  JTE013	  overnight.	  This	  media	  was	  given	  for	  24	  hours	  to	  Tramp	  C2	  cells	  and	  
lysates	  collected	  for	  western	  analysis	  (244).	  Increased	  nanog,	  B-­‐catenin,	  CD44,	  and	  
cyclin	  D1	  were	  observed	  when	  cells	  were	  treated	  with	  JTE013	  conditioned	  MSC	  
medium	  as	  shown	  in	  Figure	  38.	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Figure	  38:	  Western	  blot	  evaluation	  of	  TRAMP-­C2	  cells	  treated	  with	  JTE013	  conditioned	  media	  on	  MSCs.	  
Conditioned	  media	  from	  MSCs	  with	  either	  vehicle	  treatment	  or	  JTE013	  treatment.	  Media	  was	  centrifuged	  
down	  and	  transferred	  to	  TC2	  cells	  for	  24	  hours	  prior	  to	  collection	  of	  the	  cells	  for	  western	  blot	  analysis.	  	  
	  
Having	  observed	  that	  conditioned	  media	  with	  decreased	  S1PR2	  expression	  
predisposes	  MSCs	  to	  express	  genes	  consistent	  with	  increased	  cancer	  cell	  
progression	  and	  proliferation,	  further	  investigation	  using	  a	  transwell	  cell	  culture	  
system	  was	  merited.	  Tramp	  C2	  cells	  were	  plated	  on	  the	  bottom	  well	  of	  trans-­‐well	  
plate	  with	  MSCs	  plated	  in	  the	  top	  well.	  Treatment	  with	  3	  μM	  JTE013	  was	  delivered	  
in	  the	  top	  well	  of	  the	  plate.	  Proliferation	  was	  assessed	  in	  aldefluor	  +	  cells	  as	  
previously	  described	  using	  cell	  trace	  violet	  staining	  as	  shown	  in	  Figure	  39.	  
Increased	  proliferation	  was	  observed	  in	  aldefluor	  positive	  prostate	  cancer	  cells	  but	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no	  change	  was	  observed	  in	  aldefluor	  negative	  cells.	  	  This	  change	  in	  proliferation	  was	  
reflected	  in	  the	  leftward	  shift	  in	  cell	  trace	  violet	  fluorescent	  expression.	  	  
	  
Figure	  39:	  Cell	  trace	  violet	  evaluation	  of	  co-­cultured	  MSC	  and	  TRAMP-­C2	  cells.	  Orange	  indicates	  no	  
treatment,	  teal	  indicates	  DEAB,	  Red	  indicates	  co-­culture	  and	  green	  co-­culture	  with	  JTE	  treatment.	  JTE	  
treatment	  was	  given	  to	  the	  well	  containing	  MSCs	  and	  analysis	  was	  separated	  by	  aldefluor	  expression	  as	  
shown	  with	  aldh+	  positive	  cells	  on	  the	  left	  and	  negative	  cells	  on	  the	  right	  for	  each	  condition.	  	  
	  
Transwell	  co-­‐culture	  system	  was	  also	  utilized	  to	  evaluate	  transcriptional	  expression	  
of	  genes	  associated	  with	  epithelial	  to	  mesenchymal	  transition	  and	  metastasis.	  
Increased	  JTE013	  expression	  is	  associated	  with	  decreases	  in	  EMT	  gene	  expression	  
following	  JTE	  treatment	  and	  JTE	  treatment	  of	  MSCs	  in	  co-­‐culture.	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Figure	  40:	  qPCR	  analysis	  TRAMP-­C2	  prostate	  cancer	  cells	  in	  a	  co-­culture	  system	  composed	  of	  TRAMP	  C2	  
cells	  and	  MSCs	  for	  genes	  associated	  with	  EMT	  and	  metastasis.	  	  JTE	  1	  indicates	  1μM	  JTE013	  treatment	  and	  
JTE3	  indicates	  3	  μM	  JTE013	  treatment.	  JTE013	  treatment	  was	  given	  to	  MSC	  containing	  wells.	  Co	  indicates	  
that	  a	  co-­culture	  system	  was	  employed	  either	  in	  the	  presence	  or	  absence	  of	  JTE013	  treatment.	  	  
	  
Protein	  analysis	  of	  these	  factors	  is	  shown	  in	  figure	  41	  below.	  Consistent	  with	  the	  
qPCR	  results	  Snail,	  Vimentin,	  αSMA,	  and	  E-­‐Cadherin	  are	  all	  down-­‐regulated	  with	  co-­‐
culture	  and	  further	  downregulated	  following	  JTE013	  treatment	  in	  a	  co-­‐culture	  
setting.	  This	  provides	  a	  further	  confirmatory	  step	  to	  our	  transcriptional	  analysis.	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Figure	  41:	  Western	  blot	  analysis	  of	  EMT	  genes.	  TRAMP-­C2	  cells	  were	  analyzed	  following	  co-­culture	  with	  
MSCs	  given	  either	  vehicle	  treatment	  or	  JTE013	  treatment.	  Collection	  of	  protein	  lysates	  was	  conducted	  24	  
hours	  after	  JTE013	  treatment	  and	  48	  hours	  following	  cell	  plating.	  	  
	  
Based	  on	  these	  transwell	  co-­‐culture	  conditions	  co-­‐culture	  of	  the	  two	  cell	  types	  at	  a	  
10:1	  ratio	  of	  MSCs:TRAMP-­‐C2	  resulted	  in	  the	  formation	  of	  MSCs	  forming	  a	  capsule	  
like	  structure	  surrounding	  the	  prostate	  cancer	  cells	  with	  invasive	  lammellipodia	  
type	  projections	  on	  the	  exterior.	  	  MSCs	  for	  this	  experiment	  express	  GFP	  based	  on	  
isolation	  from	  transgenic	  GFP	  mice.	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Figure	  42:	  Images	  of	  in	  vitro	  co-­culture	  of	  MSCs	  (GFP)	  and	  TRAMP-­C2	  cells.	  The	  leftmost	  panel	  shows	  	  the	  
light	  microscopy	  view	  of	  the	  co-­culure	  with	  the	  right	  panels	  showing	  two	  views	  of	  the	  co-­culture	  
environment.	  
	  
MSCs	  co-­‐cultured	  with	  prostate	  cancer	  cells	  require	  S1PR2	  expression	  for	  the	  
maintenance	  of	  the	  expression	  of	  genes	  affiliated	  with	  EMT	  and	  metastasis.	  
Although	  further	  work	  will	  need	  to	  be	  conducted	  evaluating	  the	  protein	  expression	  
and	  activation	  status	  of	  these	  markers,	  initial	  evaluation	  suggests	  that	  consistent	  
with	  previous	  reports,	  S1PR2	  expression	  in	  MSCs	  is	  important	  in	  mitigating	  their	  
oncogenic	  function.	  Follow	  up	  on	  this	  finding	  using	  an	  in	  vivo	  co-­‐culture	  system	  will	  
be	  important	  in	  further	  investigating	  this	  phenomenon	  in	  a	  setting	  that	  better	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MSCS are gaining increasing importance both in our understanding of their physiologic 
function in immunomodulation and injury repair and in a clinical setting where these 
properties can be harnessed to help improve injury repair and to modulate immune 
responses in conditions of autoimmunity (20). Research on MSCs has steadily increased 
following their initial isolation and characterization with an acceleration in interest and 
increased work following the definition of MSCs by the 2006 International Society for 
Cell Therapy. The capacity of MSCs to be easily isolated from bone marrow and their 
capacity for adherence in culture in vitro makes them ideally situated for use in adult 
stem cell therapy (108). This interest has been reflected in the multiplicity of clinical 
trials for which MSC therapy, both allogeneic and autologous, has been conducted. 
Although still predominantly Phase I/II clinical trials, an increasing number of Phase III 
trials has shown promise for MSCs in Graft vs. Host Disease, following cardiac 
infarction, and in bone and cartilage diseases (248). The method of the delivery of the 
cells, capacity for ex vivo expansion, and limited engraftment remain issues of further 
investigation as the clinical potential of MSCs evolves.  
 
Ongoing clinical interest in the MSCs has made further understanding of MSC renewal, 
differentiation status, and physiologic function in different tissue microenvironments 
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critically important to both understanding the function and modulation thereof of MSCs 
and in further assessing the potential clinical use of the cells. Although some self-renewal 
factors have been identified including environmental factors and pluripotency factors 
including Nanog, Oct-4, Sox2, and Rex-1, further evaluation as to what additional factors 
might contribute to self-renewal or what factors modulate expression of these is required. 
Furthermore, additional understanding of the mechanism of differentiation of MSCs into 
the classical pathways of osteogenesis, adipogenesis, and chondrogenic signaling is 
critical as well as the auxillliary pathways of differentiation that are gaining increased 
interest.  
 
In this dissertation, we purport that S1P has a critical function in stem cells and more 
specifically in MSCs. This conclusion is based on previously published data and the new 
data presented here in this dissertation. S1P has been shown to promote increased MSC 
migration, mobilization, and differentiation into cardiomyocytes and smooth muscle cells 
(154, 158, 159, 161, 164). At the start of the project, I was particularly interested in 
further investigating the effect of S1P and more specifically the S1P receptors on MSC 
function. Increasing our understand of how MSCs self renew in their reservoir areas 
including the bone marrow will expand our knowledge on the physiologic function and 
maintenance as well as providing information on improved ex vivo culture to improve 
their clinical utility. 
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Preliminary evaluation was conducted using human hTert immortalized MSCs due to 
their ease of expansion which express many of the characteristics of the primary MSCs 
but are somewhat limited due to their immortalization. We observed decreased Erk 
phosphorylation with increasing doses of S1P treatment following a two hour exposure 
with increased transcriptional expression of S1PR1, R2, and R3 in this same time frame. 
With continuous bid treatment with S1P transcriptional expression of S1PR1 and S1PR3 
was decreased. Treatment with JTE013, a chemical antagonist of S1PR2 resulted in 
increased MSC clonogenicity and cell migration.  Based on these experiments, it was 
concluded that S1P was critical to both MSC signaling and basic cell functioning. Due to 
the limitations of the hTERT MSCs, primary murine MSCs were used for future analysis. 
Primary questions addressed included understanding what the role of the S1P receptors 
was in the maintenance of a multipotent MSC population and what impact S1P receptors 
had in prostate cancer progression.  
 
Examination of the impact of S1PR2 inhibition of primary murine MSCs both by 
chemical and genetic mechanisms revealed that inhibition of S1PR2 promotes increased 
cell clonogenicity, proliferation, and migration. The increased MSC proliferation and 
migration in response to S1P treatment can be inhibited by inhibition of Erk 
phosphorylation. S1P stimulation canonically results in an enhancement of Erk 
phosphorylation through the Ras and Erk signaling pathway downstream of Gi, a target g 
protein of S1PR1-3(142, 249, 250). Inhibition of S1PR2 in MSCs, a cell type we have 
shown to have high S1PR2 expression relative to S1P1, results in increased Erk1 
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phosphorylation. The mechanism behind this increased phosphorylation could be the 
reduction of decreased inhibitory signaling through G12/G13 or through changes in the 
MAPK regulation as MKP-1 can also be upregulated following S1P stimulation(105) 
Receptor compensation through increased Gi signaling in S1PR1 could also account for 
the increased Erk signaling in the condition of S1PR2 inhibition.  Erk inhibition results in 
abrogation of the increases in proliferation and migration mediated by inhibition of 
S1PR2. Changes in protein expression and activation in the other common downstream 
signaling pathways downstream of S1PR2 are not impacted by genetic or chemical 
inhibition of S1PR2. S1PR1 and S1PR3 do not appear to be involved in regulation of 
MSC proliferation or migration, as inhibition of these receptors does not impact these 
parameters.  
 
Evaluation of differentiation reveals that S1PR2 promotes osteogenic and adipogenic 
differentiation and inhibition of this receptor results in decreased differentiation into 
these lineages. This is likely the result of changes in pluripotency factors as MSCs that 
have inhibited or absent S1PR2 function demonstrate higher transcriptional expression of 
pluripotency factors critical central mechanisms of MSC differentiation including Nanog, 
Oct4, and Rex1 without significant impact of pathway specific gene expression including 
Runx2, Bmp4, PPARλ, or MMP9.  
 
 We therefore in the first section of this project identify S1PR2 as a receptor that 
promotes cell differentiation and inhibits cell proliferation therefore acting 
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antagonistically to the culture conditions required for ex vivo cell culture expansion of 
MSCS. Inhibition of S1PR2 promotes self-renewal of MSCs and enhances MSC 
proliferation. S1P is a critical lipid signaling molecule that promotes to cell proliferation 
and migration in a variety of cell types. Current research is starting to address receptor 
specific responses to S1P stimulation in cells of different origin. We have shown that 
inhibition of S1PR2 in bone marrow derived murine MSCs using genetic and 
pharmacological means results in increased MSC clonogenicity, proliferation, 
pluripotency and migration.  
 
MSCs enable tissue repair and regeneration though a combination of factors including 
their immunomodulatory role, cytokine secretion and differentiation into cells required 
for the location (10, 11, 37). MSC can differentiate into osteocytes, adipocytes, smooth 
muscle cells, cardiomyocytes, fibroblasts, chondrocytes, neuronal cells, and many other 
cell types(251). In this dissertation, we have shown that S1P is critical to MSC 
differentiation into osteocytes and adipocytes. In the absence of S1PR2 signaling MSCs, 
there is a significant reduction in MSC differentiation.  
 
Previously published work has examined some of the signaling pathways and factors 
maintaining MSCs in an undifferentiated state (17). In MSCs, increases in transcriptional 
and protein expression of Nanog, Oct4, Sox2, and Rex1 direct a downstream signaling 
network promoting maintenance of a pluripotent state although there remains some 
controversy over which pluripotency factors are involved (17, 44, 45, 252). Furthermore, 
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increased CD44 expression has been demonstrated in MSCs in a less differentiated state 
(6). The increases in these pluripotency factors following S1PR2 inhibition parallels the 
changes in differentiation observed in MSCs. The impact of S1PR2 inhibition on 
differentiation in both adipogenesis and osteogenesis combined with the impact on 
critical universal self-renewal markers places S1PR2 at a central role in MSC 
differentiation that would likely impact other cells types. These changes in differentiation 
may have significant implications in the capacity of MSCs to migrate to promote wound 
recovery at sites of injury and suggest an involvement of S1P and the S1P gradient in 
controlling MSC differentiation status. S1PR2 promotes proliferation while 
simultaneously promoting an increased stem cell phenotype. Although this may initially 
seem contradictory, it is likely that the complexity of S1P signaling and receptor 
compensation or local signaling from growth factors may contribute to this dual effect. In 
this paper we have identified S1PR2 as a critical promoter of MSC differentiation 
through alteration transcriptional pluripotency factors and propose a modification in cell 
culture conditions for expanding ex vivo pluripotent murine MSCs.    
 
In the second part of this work, we evaluate the oncogenic function of MSCs within 
prostate cancer cells.  Due to the high incidence of prostate cancer in the general 
population and the difficulty in predicting the aggressiveness of prostate cancer tumors, 
ongoing prostate cancer research is critical to improving patient care by both preventing 
the overtreatment of prostate cancer and identifying effective ways to control the 
progression of malignant cancers. One differentiating factor that has been explained to 
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classify tumors based on their malignant potential has been the stem cell content of the 
tumor. Using the TRAMP-C2 prostate cancer model we demonstrate that there is an 
increased stem cell population of prostate cancer cells following treatment with JTE013 
in vitro as assessed by Aldehyde dehydrogenase expression and CD133 expression. 
These cell populations transcriptionally express increased factors associated with a stem 
cell population and that have been previously described for prostate cancer stem cells 
including Nanog, Sox2, and Rex1. JTE treatment in vivo on TRAMP-C2 tumors grown 
in vivo resulted in no changes in tumor growth or stem cell population as compared to 
vehicle controls. The discrepancy between this result and the results obtained in vitro 
could result from poor coordination of the timing, concentration, or mechanism of the 
drug delivery in vivo based on the more complex nature of the system. Additionally 
analysis on the success of S1PR2 inhibition and transcriptional and translation expression 
of proteins associated with prostate cancer stem cells will be necessary to further evaluate 
which mechanism might explain the different results observed in vitro as compared to in 
vivo.  
 
In the final part of this dissertation, the impact of co-culturing MSCs with modified 
S1PR2 expression with prostate cancer is evaluated. The rationale for this examination is 
based on the recruitment of MSCs to prostate cancer tumors in vivo and their promotion 
of increased invasion, metastasis, and stem cell population of the tumor following their 
recruitment to the tumor microenvironment.  
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Inhibition of S1PR2 inhibition results in an increased stem cell population as assessed by 
CD133 expression, aldefluor expression, and increased Nanog transcription. Co-culture 
of MSCs with JTE013 inhibition results in a decrease in gene expression associated with 
EMT and metastasis. This suggests that S1PR2 expression in MSCs in the tumor 
environment is critical to the invasiveness and metastatic ability of the tumor. Better 
understanding the factors involved in this pathway is critical to our understanding of the 
tumor microenvironment and the role that accessory non-cancerous cells provide within 
this environment. Inhibition of S1PR2 using JTE013 in MSCs co-cultured with TRAMP-
C2 cells resulted in decreased gene expression both transcriptionally and translationally 
associated with the epithelial-mesenchymal transition and with metastasis. Genes 
demonstrated to be downregulated following co-culture and S1PR2 inhibition include 
Snail, Vimentin, alpha-sma, and E-cadherin. Therefore S1PR2 provides critical 
stimulation to the tumor cells enabling the increased invasion and metastasis observed 
following MSC and prostate cancer cell co-culture. This observation requires further 
follow up onto what impact this might have on cell migration in a co-culture situation and 
other functional assays both in vivo and in vitro to follow up on this observation. This 
represents a promising avenue for ongoing research in this process as the mechanism by 
which MSCs increase tumor cell invasion, metastasis, and stem-like characteristics of 
adjacent prostate cancer cells is largely unknown. A summary of the findings presented in 
this dissertation is provided below. 
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Figure	  43:	  Summary	  diagram	  of	  dissertation	  including	  part	  I	  addressing	  the	  role	  of	  the	  S1PRs	  in	  MSC	  
function,	  part	  II	  addressing	  the	  role	  of	  the	  S1PR2	  in	  prostate	  cancer	  cells,	  and	  part	  III	  addressing	  MSCs	  
and	  prostate	  cancer	  cells	  in	  co-­culture	  with	  inhibition	  of	  S1PR3.	  Images	  purchased	  from	  canstock	  
photos.com. 
 
From this dissertation, four novel and central conclusions can be drawn that further the 
field of MSC research as it relates to sphingolipids and cancer. The first conclusion that 
can be reaches is that inhibition of S1PR2 increases proliferation of undifferentiated 
MSCs. This observation is critical to providing a new approach for ex vivo expansion of 
MSCS for clinical trial production of cells that has been a long-standing limitation of 
MSC cell therapy. Secondly, we identify S1PR2 as a novel factor in MSC differentiation 
likely impacting multiple pathways rather than the osteogenic and adipogenic pathways 
analyzed in this work. In the realm of cancer research, this work supports the role for 
S1PR2 in promoting an increased prostate cancer stem cell population. Finally, within 
MSCs co-cultured with prostate cancer cells S1PR2 expression on MSCs promotes 
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increased invasion and metastasis. It is these four conclusions that can best guide the 
future work conducted on this project to have a maximum impact current MSC 




Although this research has evaluated a number of pathways involved in S1PR2 signaling 
within MSCs, it also opens many questions and avenues for future research to better 
understand and contextualize the conclusions presented from this research. This 
highlights the broad applicability of the research and its potential to have greater impact 
than has been presented currently. The future direction addressed here address the four 
main novel findings of the project. With regard to the role of S1PR2 on MSC 
proliferation, additional analysis of MSC markers is required to fully characterize the 
cells both following manipulation and JTE013 treatment. Additional proliferation 
analysis with modification of the oxygen levels and serum conditions to reflect different 
bone marrow and tissue microenvironments may further reveal the differing function of 
MSCs within different physiologic environments.  
 
Further investigation on the role of S1PR2 on differentiation can further develop our 
observations regarding its role in differentiation and how it might both impact MSCs and 
other stem cell pathways. Additional characterization of alternate differentiation 
pathways including that of fibroblast lineages impacted by S1PR2 inhibition is critical in 
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better characterizing this differentiation ability of MSCs. Further characterization of the 
mRNA and protein expression characteristic of adipogenic and osteogenic lineages will 
better cement our understanding of the impact of S1PR2 on this pathway. JTE013 
treatment in S1PR2 knockout cells will further clarify the specificity of this receptor in 
impacting these functions. Additional rescue experiments using S1PR2 rescue in the 
context of S1PR2 inhibition would also further support the conclusions presented by the 
differentiation studies conducted in the research presented here.  
 
The role of S1PR2 in prostate cancer stem cell function requires further follow up to the 
pathways that might be involved in this effect. Further evaluation of α2β1 integrin 
marker expression of JTE013 treated prostate cancer cells will further contribute to the 
stem cell identity of S1PR2 treated MSCs. Beyond evaluation of the individual marker, 
co-staining for CD133, CD44 and Aldefluor will more effectively identify a stem cell 
population than individual evaluation of expression. Evaluation of the pathway 
involvement based on the work by Beckham et al. might highlight some of the 
mechanisms by which this occurs focusing on inhibition of the sphingosine kinases and 
acid ceramidase using previously published inhibitors and siRNA. Serial transplantation 
assays conducted with these proposed stem cell populations for tumor initiation capacity 
will further evaluate the progenitor cell function of this population as compared to cells 
lacking this expression.  
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Finally the role of MSCs in a co-culture setting requires further investigation into the 
pathways that might be involved. Although we have examined the transcriptional 
involvement of genes association and EMT and metastasis, western blotting examination 
of proteins expression involved will further elucidate the EMT and metastatic potential of 
these cells. Co-culture of S1PR2 knockout cells within an in vivo tumor as compared to 
vehicle treated cells will further examine the potential for metastasis and would greatly 
contribute to the impact of this work. The	  further	  experiments	  proposed	  for	  the	  
project	  derived	  from	  the	  four	  main	  novel	  findings	  presented	  in	  this	  dissertation	  
reflect	  both	  on	  the	  exciting	  nature	  of	  these	  findings	  and	  their	  potential	  clinical	  and	  
scientific	  implications.	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